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Abbreviations and acronyms 
 
ACC/AHA American College of Cardiology/American 
Heart Association 
ACCF/AHA American College of Cardiology Foundation/ 
American Heart Association 
ACE angiotensin-converting enzyme 
ACEI angiotensin-converting enzyme inhibitor 
ACS acute coronary syndrome 
AF atrial  fibrillation 
AHF acute heart failure 
AHI apnoea/hypopnoea index 
AIDS acquired immunodeficiency syndrome 
AKI acute kidney injury 
Aldo-DHF aldosterone receptor blockade in diastolic 
heart failure 
AL amyloid light chain 
ALT alanine  aminotransferase 
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AMI acute myocardial infarction 
AMICA Atrial fibrillation Management In Congestive 
heart failure with Ablation 
ANP A-type natriuretic peptide 
ANS autonomic nervous system 
ARB angiotensin receptor blocker 
ARNI angiotensin receptor neprilysin inhibitor 
ARVC arrhythmogenic right ventricular 
cardiomyopathy 
AST aspartate  aminotransferase 
ASV assisted servo-ventilation 
ATLAS Assessment of Treatment with Lisinopril And 
Survival 
ATTR transthyretin-mediated amyloidosis 
AV atrio-ventricular 
AVP arginine vasopressin 
b.i.d. bis in die (twice daily) 
BioPACE Biventricular  Pacing  for  Atrio-ventricular 
Block to Prevent Cardiac Desynchronization 
BiPAP bilevel positive airway pressure 
BiVAD biventricular assist device 
BLOCK-HF Biventricular versus Right Ventricular Pacing in 
Heart Failure Patients with Atrio-ventricular 
Block 
BMI body mass index 
BNP B-type natriuretic peptide 
BP blood pressure 
bpm beats per minute 
BSA body surface area 
BTB bridge to bridge 
BTC bridge to candidacy 
BTD bridge to decision 
BTR bridge to recovery 
BTT bridge to transplantation 
BUN blood urea nitrogen 
CABANA Catheter ABlation versus ANtiarrhythmic 
drug therapy for Atrial fibrillation 
CABG coronary artery bypass graft/grafting 
CAD coronary artery disease 
CARE-HF CArdiac REsynchronization in Heart Failure 
CASTLE-AF Catheter Ablation versus Standard conven- 
tional Treatment in patients with LEft ven- 
tricular dysfunction and Atrial Fibrillation 
CCB calcium-channel blocker 
CCM cardiac contractility modulation 
CCS Canadian Cardiovascular Society 
CCU coronary care unit 
CHA2DS2-VASc Congestive heart failure or left ventricular dys- 
function, Hypertension, Age ≥75 (doubled), 
Diabetes, Stroke (doubled)-Vascular disease, 
Age 65–74, Sex category (female) 
CHARM-Alternative  Candesartan in heart failure assessment of 
reduction in mortality and morbidity 
CHARM-Added Candesartan Cilexetil in Heart Failure Assess- 
ment of Reduction in Mortality and Morbidity 
CHARM-Preserved    Candesartan Cilexetil in Heart Failure Assess- 
ment of Reduction in Mortality and Morbidity 
CI cardiac index 
CI-AKI contrast-induced acute kidney injury 
CIBIS II Cardiac Insufficiency Bisoprolol Study II 
CK creatine kinase 
CKD chronic kidney disease 
CK-MB creatine kinase MB 
CMP cardiomyopathy 
CMR cardiac magnetic resonance 
COMPANION Comparison of Medical Therapy, Pacing, and 
Defibrillation in Heart Failure 
CONFIRM-HF Ferric CarboxymaltOse evaluatioN on per- 
Formance in patients with IRon deficiency 
in coMbination with chronic Heart Failure 
CONSENSUS Cooperative North Scandinavian Enalapril 
Survival Study 
COPD chronic obstructive pulmonary disease 
COPERNICUS Carvedilol Prospective Randomized Cumula- 
tive Survival 
COX-2 inhibitor cyclooxygenase-2 inhibitor 
CPAP continuous positive airway pressure 
CPG Committee for Practice Guidelines 
CRT cardiac resynchronization therapy 
CRT-D defibrillator with cardiac resynchronization 
therapy 
CRT-P pacemaker with cardiac resynchronization 
therapy 
CSA central sleep apnoea 
CSR Cheyne-Stokes respiration 
CT computed tomography 
CYP3A4 cytochrome P450 3A4 
DCM dilated cardiomyopathy 
DES desmin 
DHA docosahexaenoic acid 
DIG-PEF ancillary Digitalis Investigation Group trial 
DNA deoxyribonucleic acid 
DOSE Diuretic Optimization Strategies Evaluation 
DPD 3,3-diphosphono-1,2-propanodicarboxylic 
acid 
DPP4i dipeptidyl peptidase-4 inhibitor 
DT destination therapy 
e′ early diastolic tissue velocity 
ECG electrocardiogram 
Echo-CRT Echocardiography Guided Cardiac Resyn- 
chronization Therapy 
ECLS extracorporeal life support 
ECMO extracorporeal membrane oxygenation 
ED emergency department 
EF ejection   fraction 
eGFR estimated glomerular filtration rate 
EHRA European Heart Rhythm Association 
EMA European Medicines Agency 
EMB endomyocardial biopsy 
EMF endomyocardial fibrosis 
Page 5 of 85 ESC Guidelines  
 
 
 
EMPHASIS-HF 
 
EPA 
EPHESUS 
 
ESC 
EU 
EULAR 
Ex-DHF 
FACIT-Pal 
FAIR-HF 
FCM 
FiO2 
Eplerenone in Mild Patients Hospitalization 
and Survival Study in Heart Failure 
eicosapentaenoic  acid 
Eplerenone Post-Acute Myocardial Infarction 
Heart Failure Efficacy and Survival Study 
European Society of Cardiology 
European Union 
European League Against Rheumatism 
Exercise training in Diastolic Heart Failure 
Functional Assessment of Chronic Illness 
Therapy - Palliative Care 
Ferinject Assessment in Patients with Iron 
Deficiency and Chronic Heart Failure 
ferric carboxymaltose 
fraction of inspired oxygen 
IVRT 
KCCQ 
LA 
LAE 
LAVI 
LBBB 
LGE 
LMNA 
LMWH 
LV 
LVAD 
LVEDP 
LVEDV 
LVEF 
LVESV 
isovolumetric relaxation time 
Kansas City Cardiomyopathy Questionnaire 
left atrial/atrium 
left atrial enlargement 
left atrial volume index 
left bundle branch block 
late gadolinium enhancement 
lamin A/C 
low-molecular-weight  heparin 
left ventricular/left ventricle 
left ventricular assist device 
left ventricular end diastolic pressure 
left ventricular end diastolic volume 
left ventricular ejection fraction 
left ventricular end systolic volume 
GFR glomerular filtration rate LVID left ventricular internal dimension 
GGTP gamma-glutamyl  transpeptidase LVMI left ventricular mass index 
GH growth hormone LVSD left ventricular systolic dysfunction 
GLS global longitudinal strain MADIT-CRT Multicenter Automatic Defibrillator Implant- 
GLP-1 glucagon-like peptide 1  ation Trial with Cardiac Resynchronization 
HAS-BLED Hypertension, Abnormal renal/liver function  Therapy 
 (1 point each), Stroke, Bleeding history or MCS mechanical circulatory support 
 predisposition, Labile international normal- MERIT-HF Metoprolol CR/XL Randomised Intervention 
 ized ratio, Elderly (.65 years), Drugs/alcohol  Trial in Congestive Heart Failure 
 concomitantly (1 point each) MR mineralocorticoid  receptor/magnetic 
HbA1c glycated haemoglobin  resonance 
HCM hypertrophic  cardiomyopathy MRA mineralocorticoid receptor antagonist 
HES hypereosinophilic syndrome MR-proANP mid-regional pro A-type natriuretic peptide 
HF heart failure MV mitral valve 
HFA Heart Failure Association MV A-Wave mitral valve late diastolic flow 
HFmrEF heart failure with mid-range ejection fraction MV E-Wave mitral valve early diastolic flow 
HFpEF heart failure with preserved ejection fraction MYBPC3 cardiac myosin binding protein C 
HFrEF heart failure with reduced ejection fraction MYH7 cardiac b-myosin heavy chain 
H-ISDN hydralazine and isosorbide dinitrate n-3 PUFA n-3 polyunsaturated fatty acid 
HIV/AIDS human  immunodeficiency  virus/acquired NEP neprilysin 
 immune deficiency syndrome NOAC non-vitamin K antagonist oral anticoagulant 
HR heart rate NP natriuretic peptide 
Hs troponin high sensitivity troponin NPPV non-invasive positive pressure ventilation 
IABP intra-aortic balloon pump NSAID non-steroidal anti-inflammatory drug 
IABP-SHOCK IntraAortic Balloon Pump in Cardiogenic Shock NSTE-ACS non-ST elevation acute coronary syndrome 
IABP-SHOCK  II IntraAortic  Balloon  Pump  in  Cardiogenic NT-proBNP N-terminal pro-B type natriuretic peptide 
 Shock II NYHA New York Heart Association 
ICD implantable  cardioverter-defibrillator o.d. omne in die (once daily) 
ICU intensive care unit OMT optimal medical therapy 
IHD ischaemic heart disease OSA obstructive sleep apnoea 
IL 
INH 
interleukin 
Interdisciplinary Network for Heart Failure 
PaCO2 partial pressure of carbon dioxide in arterial 
blood 
INTERMACS Interagency Registry for Mechanically PAH pulmonary arterial hypertension 
 
IN-TIME 
Assisted Circulatory Support 
Implant-based  multiparameter  telemonitor- 
PaO2 
PARADIGM-HF 
partial pressure of oxygen in arterial blood 
Prospective Comparison of ARNI with ACEI 
 ing of patients with heart failure  to Determine Impact on Global Mortality and 
IPD individual patient data  Morbidity in Heart Failure Trial 
I-PRESERVE Irbesartan in Heart Failure with Preserved PARAMOUNT LCZ696 Compared to Valsartan in Patients 
 Ejection Fraction Study  With Chronic Heart Failure and Preserved 
i.v. intravenous  Left-ventricular Ejection Fraction 
IVC inferior vena cava PCI percutaneous coronary intervention 
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PCWP 
PDE5I 
pulmonary capillary wedge pressure 
phosphodiesterase 5 inhibitor 
SpO2 
SPPB 
transcutaneous oxygen saturation 
Short Physical Performance Battery 
Peak VO2 
PEP-CHF 
peak oxygen uptake 
Perindopril in Elderly People with Chronic 
SPRINT Systolic Blood Pressure Intervention 
Trial 
 Heart Failure STEMI ST segment elevation myocardial 
PET positron emission tomography  infarction 
PLN phospholamban STICH Surgical Treatment for Ischemic Heart 
PPV positive pressure ventilation  Failure 
PRISMA 7 seven-item, self-completion questionnaire to STS structured telephone support 
 identify older adults with moderate to severe TAPSE tricuspid annular plane systolic excursion 
 disabilities TAVI transaortic valve implantation 
PROTECT  II Prospective,    Multi-center,    Randomized TDI tissue Doppler imaging 
 Controlled Trial of the IMPELLA RECOVER TECOS Trial Evaluating Cardiovascular Outcomes 
 LP 2.5 System Versus Intra Aortic Balloon  with Sitagliptin 
 Pump (IABP) in Patients Undergoing Non TEHAF Telemonitoring in Patients with Heart 
 Emergent High Risk PCI  Failure 
PS-PEEP pressure-support  positive  end-expiratory Tele-HF Telemonitoring to Improve Heart 
 pressure  Failure Outcomes 
PV pulmonary vein TIA transient ischaemic attack 
PVR pulmonary vascular resistance TIBC total iron-binding capacity 
QALY quality-adjusted life year t.i.d. ter in die (three times a day) 
QRS Q, R, and S waves (combination of three of TIM-HF Telemedical  Interventional  Monitoring  in 
 the graphical deflections)  Heart Failure 
RA right atrium/atrial TOE transoesophageal   echocardiography 
RAAS renin – angiotensin – aldosterone system TOPCAT Treatment of Preserved Cardiac Function 
RAFT Resynchronization-Defibrillation  for  Ambu-  Heart Failure with an Aldosterone 
 latory Heart Failure Trial  Antagonist 
RALES Randomized Aldactone Evaluation Study TR tricuspid regurgitation 
RCT randomized controlled trial TRV tricuspid regurgitation velocity 
RELAX Phosphodiesterase-5 Inhibition to Improve TSAT transferrin saturation 
 Clinical Status and Exercise Capacity in TSH thyroid-stimulating  hormone 
 Diastolic Heart Failure TTE transthoracic echocardiography 
REVERSE REsynchronization reVErses Remodeling in TTN titin 
 Systolic left vEntricular dysfunction ULT urate lowering therapy 
RV right  ventricular/ventricle VAD ventricular assist device 
RVAD right ventricular assist device Val-HeFT Valsartan Heart Failure Trial 
SADHART Sertraline   Antidepressant   Heart   Attack 
Randomized Trial 
VE-VCO2 ventilatory equivalent ratio for carbon 
dioxide 
SAVE Survival After Veno-arterial ECMO VT ventricular tachycardia 
SBP systolic blood pressure VV interval interventricular pacing interval 
SCD-HeFT Sudden Cardiac Death in Heart Failure Trial WBC white blood cells 
SDB sleep-disordered breathing WISH Weight Monitoring in Patients with Severe 
SENIORS Study of the Effects of Nebivolol Intervention  Heart Failure 
 on  Outcomes  and  Rehospitalisations  in WRF worsening renal function 
Seniors with Heart Failure 
SERVE-HF Treatment  of  sleep-disordered  breathing 
with predominant central sleep apnoea with 
adaptive Servo-ventilation in patients with 
chronic heart failure 
SHIFT Systolic Heart failure treatment with the If 
inhibitor ivabradine Trial 
SIGNIFY Study Assessing the Morbidity – Mortality 
Benefits of the If Inhibitor Ivabradine in 
Patients with Coronary Artery Disease 
SOLVD Studies of Left Ventricular Dysfunction 
SPECT single-photon emission computed 
tomography 
 
1. Preamble 
 
Guidelines summarize and evaluate all available evidence on a par- 
ticular issue at the time of the writing process, with the aim of assist- 
ing health professionals in selecting the best management strategies 
for an individual patient with a given condition, taking into account 
the impact on outcome, as well as the riskbenefit ratio of particular 
diagnostic or therapeutic means. Guidelines and recommendations 
should help health professionals to make decisions in their daily 
practice. However, the final decisions concerning an individual pa- 
tient must be made by the responsible health professional(s) in con- 
sultation with the patient and caregiver as appropriate. 
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T  able 1.2   Level of evidence  
   
   
   
 
 
A great number of Guidelines have been issued in recent years by 
the European Society of Cardiology (ESC) as well as by other soci- 
eties and organisations. Because of the impact on clinical practice, 
quality criteria for the development of guidelines have been estab- 
lished in order to make all decisions transparent to the user. The re- 
commendations for formulating and issuing ESC Guidelines can be 
found on the ESC website (http://www.escardio.org/Guidelines- 
&-Education/Clinical-Practice-Guidelines/Guidelines-development/ 
Writing-ESC-Guidelines). ESC Guidelines represent the official pos- 
ition of the ESC on a given topic and are regularly updated. 
Members of this Task Force were selected by the ESC to re- 
present professionals involved with the medical care of patients 
with this pathology. Selected experts in the field undertook a com- 
prehensive review of the published evidence for management (in- 
cluding diagnosis, treatment, prevention and rehabilitation) of a 
given condition according to ESC Committee for Practice Guide- 
lines (CPG) policy. A critical evaluation of diagnostic and therapeutic 
procedures was performed, including assessment of the risk-benefit 
ratio. Estimates of expected health outcomes for larger populations 
were included, where data exist. The level of evidence and the 
strength of the recommendation of particular management options 
were weighed and graded according to predefined scales, as out- 
lined in Tables 1.1 and 1.2. 
The experts of the writing and reviewing panels provided declara- 
tions of interest forms for all relationships that might be perceived as 
real or potential sources of conflicts of interest. These forms were 
compiled into one file and can be found on the ESC website (http:// 
www.escardio.org/guidelines). Any changes in declarations of interest 
that arise during the writing period must be notified to the ESC and 
updated. The Task Force received its entire financial support from the 
ESC without any involvement from the healthcare industry. 
The ESC CPG supervises and coordinates the preparation of new 
Guidelines produced by task forces, expert groups or consensus 
panels. The Committee is also responsible for the endorsement pro- 
cess of these Guidelines. The ESC Guidelines undergo extensive re- 
view by the CPG and external experts. After appropriate revisions 
the Guidelines are approved by all the experts involved in the Task 
Force. The finalized document is approved by the CPG for publica- 
tion in the European Heart Journal. The Guidelines were developed 
after careful consideration of the scientific and medical knowledge 
and the evidence available at the time of their dating. 
The task of developing ESC Guidelines covers not only integration 
of the most recent research, but also the creation of educational tools 
and implementation programmes for the recommendations. To im- 
plement the guidelines, condensed pocket guidelines versions, sum- 
mary slides, booklets with essential messages, summary cards for 
non-specialists, and an electronic version for digital applications 
(smartphones, etc.) are produced. These versions are abridged and 
thus, if needed, one should always refer to the full text version, which 
is freely available on the ESC website. The National Cardiac Societies 
of the ESC are encouraged to endorse, translate and implement all 
ESC Guidelines. Implementation programmes are needed because 
 
 
T  able 1.1  Classes of recommendations  
   
   
   
Page 8 of 85 ESC Guidelines  
 
 
 
it has been shown that the outcome of disease may be favourably in- 
fluenced by the thorough application of clinical recommendations. 
Surveys and registries are needed to verify that real-life daily prac- 
tice is in keeping with what is recommended in the guidelines, thus 
completing the loop between clinical research, writing of guidelines, 
disseminating them and implementing them into clinical practice. 
Health professionals are encouraged to take the ESC Guidelines 
fully into account when exercising their clinical judgment, as well as 
in the determination and the implementation of preventive, diagnos- 
tic or therapeutic medical strategies. However, the ESC Guidelines 
do not override in any way whatsoever the individual responsibility 
of health professionals to make appropriate and accurate decisions 
in consideration of each patient’s health condition and in consult- 
ation with that patient and the patient’s caregiver where appropriate 
and/or necessary. It is also the health professional’s responsibility to 
verify the rules and regulations applicable to drugs and devices at the 
time of prescription. 
 
 
 
2. Introduction 
 
The aim of all the ESC Guidelines is to help health professionals to 
make decisions in their everyday life based on the best available evi- 
dence. We will soon be celebrating the 30th anniversary of clinical 
trials that for the first time incontrovertibly demonstrated that the 
miserable outcome of patients with heart failure (HF) can be mark- 
edly improved.2 Since then, in the area of HF management we have 
witnessed and celebrated numerous highs, which have definitely 
outnumbered several lows, all of which have allowed us to unravel 
the pathophysiology of this clinical syndrome, but more importantly 
has led to better care of our patients.3  In the year 2016, no one 
would any longer dispute that, by applying all evidence-based dis- 
coveries, HF is now becoming a preventable and treatable disease. 
The aim of this document is to provide practical, evidence-based 
guidelines for the diagnosis and treatment of HF. The principal 
changes from the 2012 guidelines relate to: 
 
(i) a new term for patients with HF and a left ventricular ejection 
fraction (LVEF) that ranges from 40 to 49% — ‘HF with mid- 
range EF (HFmrEF)’; we believe that identifying HFmrEF as a 
separate group will stimulate research into the underlying char- 
acteristics, pathophysiology and treatment of this population; 
(ii) clear recommendations on the diagnostic criteria for HF with re- 
duced EF (HFrEF), HFmrEF and HF with preserved EF (HFpEF); 
(iii) a new algorithm for the diagnosis of HF in the non-acute set- 
ting based on the evaluation of HF probability; 
(iv) recommendations aimed at prevention or delay of the devel- 
opment of overt HF or the prevention of death before the on- 
set of symptoms; 
(v) indications for the use of the new compound sacubitril/ 
valsartan, the first in the class of angiotensin receptor neprily- 
sin inhibitors (ARNIs); 
(vi) modified indications for cardiac resynchronization therapy 
(CRT); 
(vii) the concept of an early initiation of appropriate therapy going 
along with relevant investigations in acute HF that follows the 
‘time to therapy’ approach already well established in acute 
coronary syndrome (ACS); 
(viii) a new algorithm for a combined diagnosis and treatment ap- 
proach of acute HF based on the presence/absence of conges- 
tion/hypoperfusion. 
 
We followed the format of the previous ESC 2012 HF Guidelines. 
Therapeutic recommendations state the treatment effect supported 
by the class and level of recommendation in tabular format; in the 
case of chronic HF due to left ventricular systolic dysfunction 
(LVSD) the recommendations focus on mortality and morbidity 
outcomes. Detailed summaries of the key evidence supporting gen- 
erally recommended treatments have been provided. For diagnostic 
recommendations a level of evidence C has been typically decided 
upon, because for the majority of diagnostic tests there are no data 
from randomized controlled trials (RCTs) showing that they will 
lead to reductions in morbidity and/or mortality. Practical guidance 
is provided for the use of the important disease-modifying drugs and 
diuretics. When possible, other relevant guidelines, consensus 
statements and position papers have been cited to avoid unduly 
lengthy text. All tables should be read in conjunction with their ac- 
companying text and not read in isolation. 
This document is the result of extensive interactions between the 
Task Force, the review team and the ESC Committee for Practice 
Guidelines. It represents a consensus of opinion of all of the experts 
involved in its development. Concurrently to the development of 
the 2016 ESC Guidelines on HF, the group writing the “2016 
ACC/AHA/HFSA Focused Update on New Pharmacological Ther- 
apy for Heart Failure” independently developed its recommenda- 
tions on new pharmacotherapy for Heart Failure. Both working 
groups/Task Force independently surveyed the evidence, arrived 
at similar conclusions, and constructed similar, but not identical, re- 
commendations. Given the concordance, the respective organiza- 
tions simultaneously issued aligned recommendations on the use 
of these new treatments to minimize confusion and improve the 
care of patients with HF. 
 
 
3. Definition, epidemiology and 
prognosis 
 
3.1 Definition of heart failure 
HF  is  a clinical  syndrome  characterized  by  typical  symptoms 
(e.g. breathlessness, ankle swelling and fatigue) that may be accom- 
panied by signs (e.g. elevated jugular venous pressure, pulmonary 
crackles and peripheral oedema) caused by a structural and/or func- 
tional cardiac abnormality, resulting in a reduced cardiac output and/ 
or elevated intracardiac pressures at rest or during stress. 
The current definition of HF restricts itself to stages at which clinical 
symptoms are apparent. Before clinical symptoms become apparent, 
patients can present with asymptomatic structural or functional cardiac 
abnormalities [systolic or diastolic left ventricular (LV) dysfunction], 
which are precursors of HF. Recognition of these precursors is import- 
ant because they are related to poor outcomes, and starting treatment 
at the precursor stage may reduce mortality in patients with asymp- 
tomatic systolic LV dysfunction4,5 (for details see Section 6). 
Demonstration of an underlying cardiac cause is central to the 
diagnosis of HF. This is usually a myocardial abnormality causing sys- 
tolic and/or diastolic ventricular dysfunction. However, abnormal- 
ities of the valves, pericardium, endocardium, heart rhythm and 
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conduction can also cause HF (and more than one abnormality is of- 
ten present). Identification of the underlying cardiac problem is cru- 
cial for therapeutic reasons, as the precise pathology determines the 
specific treatment used (e.g. valve repair or replacement for valvular 
disease, specific pharmacological therapy for HF with reduced EF, 
reduction of heart rate in tachycardiomyopathy, etc). 
 
3.2 Terminology 
3.2.1 Heart failure with preserved, mid-range and reduced 
ejection fraction 
The main terminology used to describe HF is historical and is based 
on measurement of the LVEF. HF comprises a wide range of pa- 
tients, from those with normal LVEF [typically considered as 
≥50%; HF with preserved EF (HFpEF)] to those with reduced 
LVEF [typically considered as ,40%; HF with reduced EF (HFrEF)] 
(Table 3.1). Patients with an LVEF in the range of 40 – 49% represent 
a ‘grey area’, which we now define as HFmrEF (Table 3.1). Differen- 
tiation of patients with HF based on LVEF is important due to 
different underlying aetiologies, demographics, co-morbidities and 
response to therapies.6 Most clinical trials published after 1990 se- 
lected patients based on LVEF [usually measured using echocardiog- 
raphy, a radionuclide technique or cardiac magnetic resonance 
(CMR)], and it is only in patients with HFrEF that therapies have 
been shown to reduce both morbidity and mortality. 
The diagnosis of HFpEF is more challenging than the diagnosis of 
HFrEF. Patients with HFpEF generally do not have a dilated LV, but 
instead often have an increase in LV wall thickness and/or increased 
left atrial (LA) size as a sign of increased filling pressures. Most have 
additional ‘evidence’ of impaired LV filling or suction capacity, also 
classified as diastolic dysfunction, which is generally accepted as 
the likely cause of HF in these patients (hence the term ‘diastolic 
HF’). However, most patients with HFrEF (previously referred to 
as ‘systolic HF’) also have diastolic dysfunction, and subtle abnormal- 
ities of systolic function have been shown in patients with HFpEF. 
Hence the preference for stating preserved or reduced LVEF over 
preserved or reduced ‘systolic function’. 
In previous guidelines it was acknowledged that a grey area exists 
between HFrEF and HFpEF.7 These patients have an LVEF that 
ranges from 40 to 49%, hence the term HFmrEF. Identifying HFmrEF 
as a separate group will stimulate research into the underlying 
characteristics, pathophysiology and treatment of this group of pa- 
tients. Patients with HFmrEF most probably have primarily mild sys- 
tolic dysfunction, but with features of diastolic dysfunction 
(Table 3.1). 
Patients without detectable LV myocardial disease may have 
other cardiovascular causes for HF (e.g. pulmonary hypertension, 
valvular heart disease, etc.). Patients with non-cardiovascular path- 
ologies (e.g. anaemia, pulmonary, renal or hepatic disease) may have 
symptoms similar or identical to those of HF and each may compli- 
cate or exacerbate the HF syndrome. 
 
 
3.2.2 Terminology related to the time course of heart 
failure 
In these guidelines, the term HF is used to describe the symptomatic 
syndrome, graded according to the New York Heart Association 
(NYHA) functional classification (see Section 3.2.3 and Web 
Table 3.2), although a patient can be rendered asymptomatic by 
treatment. In these guidelines, a patient who has never exhibited 
the typical symptoms and/or signs of HF and with a reduced LVEF 
is described as having asymptomatic LV systolic dysfunction. Patients 
who have had HF for some time are often said to have ‘chronic HF’. 
A treated patient with symptoms and signs that have remained gen- 
erally unchanged for at least 1 month is said to be ‘stable’. If chronic 
stable HF deteriorates, the patient may be described as ‘decompen- 
sated’ and this may happen suddenly or slowly, often leading to hos- 
pital admission, an event of considerable prognostic importance. 
New-onset (‘de novo’) HF may also present acutely, for example, 
as a consequence of acute myocardial infarction (AMI), or in a sub- 
acute (gradual) fashion, for example, in patients with a dilated cardio- 
myopathy (DCM), who often have symptoms for weeks or months 
before the diagnosis becomes clear. Although symptoms and signs 
of HF may resolve, the underlying cardiac dysfunction may not, and 
patients remain at the risk of recurrent ‘decompensation’. 
Occasionally, however, a patient may have HF due to a problem 
that resolves completely (e.g. acute viral myocarditis, takotsubo car- 
diomyopathy or tachycardiomyopathy). Other patients, particularly 
those with ‘idiopathic’ DCM, may also show substantial or even 
complete recovery of LV systolic function with modern disease- 
modifying therapy [including angiotensin-converting enzyme inhibi- 
tor (ACEI), beta-blocker, mineralocorticoid receptor antagonist 
 
 
T 
( 
able 3.1   Definition of heart failure with preserved (HFpEF), mid-range (HFmrEF) and reduced ejection fraction 
HFrEF) 
 
   
   
      B 
h 
p 
a 
b 
NP ¼ B-type natriuretic peptide; HF ¼ heart failure; HFmrEF ¼ heart failure with mid-range ejection fraction; HFpEF ¼ heart failure with preserved ejection fraction; HFrEF 
eart failure with reduced ejection fraction; LAE ¼ left atrial enlargement; LVEF ¼ left ventricular ejection fraction; LVH ¼ left ventricular hypertrophy; NT-proBNP ¼ N-termina 
ro-B type natriuretic peptide. 
Signs may not be present in the early stages of HF (especially in HFpEF) and in patients treated with diuretics. 
BNP.35  pg/ml  and/or  NT-proBNP .125  pg/mL. 
¼ 
l 
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(MRA), ivabradine and/or CRT]. ‘Congestive HF’ is a term that is 
sometimes used, and may describe acute or chronic HF with evi- 
dence of volume overload. Many or all of these terms may be accur- 
ately applied to the same patient at different times, depending upon 
their stage of illness. 
 
 
3.2.3 Terminology related to the symptomatic severity 
of heart failure 
The NYHA functional classification (Web Table 3.2) has been used 
to describe the severity of symptoms and exercise intolerance. 
However, symptom severity correlates poorly with many measures 
of LV function; although there is a clear relationship between the se- 
verity of symptoms and survival, patients with mild symptoms may 
still have an increased risk of hospitalization and death.8 – 10 
Sometimes the term ‘advanced HF’ is used to characterize pa- 
tients with severe symptoms, recurrent decompensation and severe 
cardiac dysfunction.11 The American College of Cardiology Founda- 
tion/American Heart Association (ACCF/AHA) classification de- 
scribes stages of HF development based on structural changes and 
symptoms (Web Table 3.3).12 The Killip classification may be used to 
describe the severity of the patient’s condition in the acute setting 
after myocardial infarction (see Section 12).13 
 
 
3.3 Epidemiology, aetiology and natural 
history of heart failure 
The prevalence of HF depends on the definition applied, but is ap- 
proximately 1 – 2% of the adult population in developed countries, 
rising to ≥10% among people .70 years of age.14 – 17 Among peo- 
ple .65 years of age presenting to primary care with breathlessness 
on exertion, one in six will have unrecognized HF (mainly 
HFpEF).18,19 The lifetime risk of HF at age 55 years is 33% for 
men and 28% for women.16 The proportion of patients with HFpEF 
ranges from 22 to 73%, depending on the definition applied, the clin- 
ical setting (primary care, hospital clinic, hospital admission), age and 
In clinical practice, a clear distinction between acquired and inher- 
ited cardiomyopathies remains challenging. In most patients with a 
definite clinical diagnosis of HF, there is no confirmatory role for 
routine genetic testing, but genetic counselling is recommended in 
patients with hypertrophic cardiomyopathy (HCM), ‘idiopathic’ 
DCM or arrhythmogenic right ventricular cardiomyopathy 
(ARVC) (see Section 5.10.1), since the outcomes of these tests 
may have clinical implications. 
Over the last 30 years, improvements in treatments and their im- 
plementation have improved survival and reduced the hospitalization 
rate in patients with HFrEF, although the outcome often remains un- 
satisfactory. The most recent European data (ESC-HF pilot study) 
demonstrate that 12-month all-cause mortality rates for hospitalized 
and stable/ambulatory HF patients were 17% and 7%, respectively, 
and the 12-month hospitalization rates were 44% and 32%, respect- 
ively.35 In patients with HF (both hospitalized and ambulatory), most 
deaths are due to cardiovascular causes, mainly sudden death and 
worsening HF. All-cause mortality is generally higher in HFrEF than 
HFpEF.35,36 Hospitalizations are often due to non-cardiovascular 
causes, particularly in patients with HFpEF. Hospitalization for cardio- 
vascular causes did not change from 2000 to 2010, whereas those 
with non-cardiovascular causes increased.31 
3.4 Prognosis 
Estimation of prognosis for morbidity, disability and death helps pa- 
tients, their families and clinicians decide on the appropriate type 
and timing of therapies (in particular, decisions about a rapid transi- 
tion to advanced therapies) and assists with planning of health and 
social services and resources. 
Numerous prognostic markers of death and/or HF hospitalization 
have been identified in patients with HF (Web Table 3.5). However, 
their clinical applicability is limited and precise risk stratification in 
HF remains challenging. 
In recent decades, several multivariable prognostic risk scores 
have been developed for different populations of patients with 
36 – 41 
sex of the studied population, previous myocardial infarction and HF, and some are available as interactive online applications. 
the year of publication.17,18,20 – 30 
Data on temporal trends based on hospitalized patients suggest 
Multivariable risk scores may help predict death in patients with 
HF, but remain less useful for the prediction of subsequent HF hos- 
37,38 
that the incidence of HF may be decreasing, more for HFrEF than pitalizations. 37 A systematic review examining 64 prognostic 
for HFpEF.31,32 HFpEF and HFrEF seem to have different epidemio- models along with a meta-analysis and meta-regression study of 38 
logical and aetiological profiles. Compared with HFrEF, patients 117 prognostic models revealed only a moderate accuracy of 
with HFpEF are older, more often women and more commonly 
have a history of hypertension and atrial fibrillation (AF), while a his- 
tory of myocardial infarction is less common.32,33 The characteristics 
of patients with HFmrEF are between those with HFrEF and HFpEF,34 
but further studies are needed to better characterize this population. 
The aetiology of HF is diverse within and among world regions. 
There is no agreed single classification system for the causes of 
HF, with much overlap between potential categories (Table 3.4). 
Many patients will have several different pathologies—cardiovascu- 
lar and non-cardiovascular—that conspire to cause HF. Identifica- 
tion of these diverse pathologies should be part of the diagnostic 
workup, as they may offer specific therapeutic opportunities. 
Many patients with HF and ischaemic heart disease (IHD) have a 
history of myocardial infarction or revascularization. However, a 
normal coronary angiogram does not exclude myocardial scar 
(e.g. by CMR imaging) or impaired coronary microcirculation as al- 
ternative evidence for IHD. 
models predicting mortality, whereas models designed to predict 
the combined endpoint of death or hospitalization, or only hospital- 
ization, had an even poorer discriminative ability. 
 
4. Diagnosis 
 
4.1 Symptoms and signs 
Symptoms are often non-specific and do not, therefore, help discrim- 
inate between HF and other problems (Table 4.1).42 – 46 Symptoms and 
signs of HF due to fluid retention may resolve quickly with diuretic 
therapy. Signs, such as elevated jugular venous pressure and displace- 
ment of the apical impulse, may be more specific, but are harder to 
detect and have poor reproducibility.18,46,47 Symptoms and signs 
may be particularly difficult to identify and interpret in obese indivi- 
duals, in the elderly and in patients with chronic lung disease.48 – 50 
Younger patients with HF often have a different aetiology, clinical pres- 
entation and outcome compared with older patients.51,52 
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DISEASED MYOCARDIUM 
Ischaemic heart 
disease 
Myocardial scar  
Myocardial stunning/hibernation  
Epicardial coronary artery disease  
Abnormal coronary microcirculation  
Endothelial dysfunction  
Toxic damage Recreational substance abuse Alcohol, cocaine, amphetamine, anabolic steroids. 
Heavy metals Copper, iron, lead, cobalt. 
Medications Cytostatic drugs (e.g. anthracyclines), immunomodulating drugs (e.g. interferons monoclonal 
antibodies such as trastuzumab, cetuximab), antidepressant drugs, antiarrhythmics, non-steroidal 
Radiation  
Immune-mediated 
damage 
Related to infection Bacteria, spirochaetes, fungi, protozoa, parasites (Chagas disease), rickettsiae, viruses (HIV/AIDS). 
Not related to infection Lymphocytic/giant cell myocarditis, autoimmune diseases (e.g. Graves’ disease, rheumatoid 
arthritis, connective tissue disorders, mainly systemic lupus erythematosus), hypersensitivity and 
eosinophilic myocarditis (Churg–Strauss). 
 Related to malignancy  
Not related to malignancy Amyloidosis, sarcoidosis, haemochromatosis (iron), glycogen storage diseases (e.g. Pompe disease), 
lysosomal storage diseases (e.g. Fabry disease). 
Metabolic 
derangements 
Hormonal  
disease,Addison disease, diabetes, metabolic syndrome, phaeochromocytoma, pathologies related 
to pregnancy and peripartum. 
Nutritional  
(e.g. malignancy,AIDS, anorexia nervosa), obesity. 
Genetic abnormalities Diverse forms HCM, DCM, LV non-compaction,ARVC, restrictive cardiomyopathy (for details see respective 
expert documents), muscular dystrophies and laminopathies. 
ABNORMAL LOADING CONDITIONS 
Hypertension   
Valve and 
myocardium 
structural defects 
Acquired Mitral, aortic, tricuspid and pulmonary valve diseases. 
Congenital Atrial and ventricular septum defects and others (for details see a respective expert document). 
Pericardial and 
endomyocardial 
pathologies 
Pericardial Constrictive pericarditis 
Pericardial effusion 
Endomyocardial  
High output states   
Volume overload   
ARRHYTHMIAS 
Tachyarrhythmias  Atrial, ventricular arrhythmias. 
Bradyarrhythmias  Sinus node dysfunctions, conduction disorders. 
 
 
 
 
Table 3.4    Aetiologies of heart failure 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; DCM ¼ dilated cardiomyopathy; EMF ¼ endomyocardial fibrosis; GH ¼ growth hormone; HCM ¼ hypertrophic cardiomyopathy; HES ¼ hypereosinophilic syndrome; HIV/AIDS ¼ human immunodeficiency virus/acquired immune deficiency syndrome; LV ¼ left ventricular.  
 
A detailed history should always be obtained. HF is unusual in an 
individual with no relevant medical history (e.g. a potential cause of 
cardiac damage), whereas certain features, particularly previous 
myocardial infarction, greatly increase the likelihood of HF in a pa- 
tient with appropriate symptoms and signs.42 – 45 
At each visit, symptoms and signs of HF need to be assessed, with 
particular attention to evidence of congestion. Symptoms and signs 
are important in monitoring a patient’s response to treatment and 
stability over time. Persistence of symptoms despite treatment usu- 
ally indicates the need for additional therapy, and worsening of 
symptoms is a serious development (placing the patient at risk of ur- 
gent hospital admission and death) and merits prompt medical 
attention. 
4.2 Essential initial investigations: 
natriuretic peptides, electrocardiogram 
and echocardiography 
The plasma concentration of natriuretic peptides (NPs) can be used 
as an initial diagnostic test, especially in the non-acute setting when 
echocardiography is not immediately available. Elevated NPs help 
establish an initial working diagnosis, identifying those who require 
further cardiac investigation; patients with values below the cut- 
point for the exclusion of important cardiac dysfunction do not 
require echocardiography (see also Section 4.3 and Section 12). 
Patients with normal plasma NP concentrations are unlikely to 
have HF. The upper limit of normal in the non-acute setting for 
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Table 4.1   Symptoms and signs typical of heart failure 
 
Symptoms Signs 
Typical  
Breathlessness 
Orthopnoea 
Paroxysmal nocturnal dyspnoea 
Reduced exercise tolerance 
Fatigue, tiredness, increased time 
to recover after exercise 
Ankle swelling 
Elevated jugular venous pressure 
 
Third heart sound (gallop rhythm) 
Laterally displaced apical impulse 
Less typical  
Nocturnal cough 
Wheezing 
Bloated feeling 
Loss of appetite 
Confusion (especially in the 
elderly) 
Depression 
Palpitations 
Dizziness 
Syncope 
Bendopnea53 
Weight gain (>2 kg/week) 
Weight loss (in advanced HF) 
Tissue wasting (cachexia) 
Cardiac murmur 
Peripheral oedema (ankle, sacral, 
scrotal) 
Pulmonary crepitations 
Reduced air entry and dullness to 
percussion at lung bases (pleural 
effusion) 
Tachycardia 
Irregular pulse 
Tachypnoea 
Cheyne Stokes respiration 
Hepatomegaly 
Ascites 
Cold extremities 
Oliguria 
Narrow pulse pressure 
 
HF ¼ heart failure. 
 
 
B- type natriuretic peptide (BNP) is 35 pg/mL and for N-
terminal pro-BNP (NT-proBNP) it is 125 pg/mL; in the acute 
setting, higher values should be used [BNP , 100 pg/mL, NT-
proBNP , 300 pg/ mL and mid-regional pro A-type natriuretic 
peptide (MR-proANP) 
, 120 pmol/L]. Diagnostic values apply similarly to HFrEF and 
HFpEF; on average, values are lower for HFpEF than for HFrEF.54,55 
At the mentioned exclusionary cut-points, the negative predictive 
values are very similar and high (0.94 – 0.98) in both the non-acute 
and acute setting, but the positive predictive values are lower 
both in the non-acute setting (0.44 – 0.57) and in the acute setting 
(0.66 – 0.67).54,56 – 61  Therefore, the use of NPs is recommended 
for ruling-out HF, but not to establish the diagnosis. 
There are numerous cardiovascular and non-cardiovascular 
causes of elevated NPs that may weaken their diagnostic utility in 
HF. Among them, AF, age and renal failure are the most important 
factors impeding the interpretation of NP measurements.55 On the 
other hand, NP levels may be disproportionally low in obese pa- 
tients62 (see also Section 12.2 and Table 12.3). 
An abnormal electrocardiogram (ECG) increases the likelihood 
of the diagnosis of HF, but has low specificity.18,46,63,64 Some abnor- 
malities on the ECG provide information on aetiology (e.g. myocar- 
dial infarction), and findings on the ECG might provide indications 
for therapy (e.g. anticoagulation for AF, pacing for bradycardia, 
CRT if broadened QRS complex) (see Sections 8 and 10). HF is un- 
likely in patients presenting with a completely normal ECG (sensitiv- 
ity 89%).43 Therefore, the routine use of an ECG is mainly 
recommended to rule out HF. 
 
tients with suspected HF to establish the diagnosis. It provides im- 
mediate information on chamber volumes, ventricular systolic and 
diastolic function, wall thickness, valve function and pulmonary 
hypertension.65 – 74 This information is crucial in establishing the 
diagnosis and in determining appropriate treatment (see Sections 
5.2 – 5.4 for details on echocardiography). 
The information provided by careful clinical evaluation and the 
above mentioned tests will permit an initial working diagnosis and 
treatment plan in most patients. Other tests are generally required 
only if the diagnosis remains uncertain (e.g. if echocardiographic 
images are suboptimal or an unusual cause of HF is suspected) 
(for details see Sections 5.5 – 5.10). 
 
 
4.3 Algorithm for the diagnosis of heart 
failure 
4.3.1 Algorithm for the diagnosis of heart failure in the 
non-acute setting 
An algorithm for the diagnosis of HF in the non-acute setting is 
shown in Figure 4.1. The diagnosis of HF in the acute setting is 
discussed in Section 12. 
For patients presenting with symptoms or signs for the first time, 
non-urgently in primary care or in a hospital outpatient clinic 
(Table 4.1), the probability of HF should first be evaluated based 
on the patient’s prior clinical history [e.g. coronary artery disease 
(CAD), arterial hypertension, diuretic use], presenting symptoms 
(e.g. orthopnoea), physical examination (e.g. bilateral oedema, in- 
 
ECG. If all elements are normal, HF is highly unlikely and other diag- 
noses need to be considered. If at least one element is abnormal, 
plasma NPs should be measured, if available, to identify those 
who need echocardiography (an echocardiogram is indicated if 
the NP level is above the exclusion threshold or if circulating NP 
levels cannot be assessed).55 – 60,75 – 78 
 
 
4.3.2 Diagnosis of heart failure with preserved ejection 
fraction 
The diagnosis of HFpEF remains challenging. LVEF is normal and 
signs and symptoms for HF (Table 4.1) are often non-specific and 
do not discriminate well between HF and other clinical conditions. 
This section summarizes practical recommendations necessary for 
proper diagnosis of this clinical entity in clinical practice. 
The diagnosis of chronic HFpEF, especially in the typical elderly 
patient with co-morbidities and no obvious signs of central fluid 
overload, is cumbersome and a validated gold standard is missing. 
To improve the specificity of diagnosing HFpEF, the clinical diagnosis 
needs to be supported by objective measures of cardiac dysfunction 
at rest or during exercise. The diagnosis of HFpEF requires the fol- 
lowing conditions to be fulfilled (see Table 3.1): 
 
• The presence of symptoms and/or signs of HF (see Table 4.1) 
• A ‘preserved’ EF (defined as LVEF  ≥50% or  40 – 49%  for 
HFmrEF) 
• Elevated levels of NPs (BNP .35 pg/mL and/or NT-proBNP 
.125 pg/mL) 
• Objective evidence of other cardiac functional and structural al- 
terations underlying HF (for details, see below) 
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Figure 4.1  Diagnostic algorithm for a diagnosis of heart failure of non-acute onset 
BNP ¼ B-type natriuretic peptide; CAD ¼ coronary artery disease; HF ¼ heart failure; MI ¼ myocardial infarction; NT-proBNP ¼ N-terminal 
pro-B type natriuretic peptide. 
aPatient reporting symptoms typical of HF (see Table 4.1). 
bNormal ventricular and atrial volumes and function. 
cConsider other causes of elevated natriuretic peptides (Table 12.3). 
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• In case of uncertainty, a stress test or invasively measured ele- 
vated LV filling pressure may be needed to confirm the diagnosis 
(for details, see below). 
 
The initial assessment consists of a clinical diagnosis compatible with 
the algorithm presented above and the assessment of LVEF by echo- 
cardiography. The cut-off of 50% for a diagnosis of HFpEF is arbi- 
trary; patients with an LVEF between 40 and 49% are often 
classified as HFpEF in clinical trials.79 However, in the present guide- 
lines, we define HFpEF as an LVEF ≥50% and consider patients with 
an LVEF between 40 and 49% as a grey area, which could be indi- 
cated as HFmrEF. Clinical signs and symptoms are similar for pa- 
tients with HFrEF, HFmrEF and HFpEF. Typical demographics and 
co-morbidities are provided in Web Table 4.2. The resting ECG 
may reveal abnormalities such as AF, LV hypertrophy and repolari- 
sation abnormalities. A normal ECG and/or plasma concentrations 
of BNP ,35 pg/mL and/or NT-proBNP ,125 pg/mL make a diag- 
nosis of HFpEF, HFmrEF or HFrEF unlikely. 
The next step comprises an advanced workup in case of initial evi- 
dence of HFpEF/HFmrEF and consists of objective demonstration of 
structural and/or functional alterations of the heart as the underlying 
cause for the clinical presentation. Key structural alterations are a 
left atrial volume index (LAVI) .34 mL/m2 or a left ventricular 
mass index (LVMI) ≥115 g/m2 for males and ≥ 95 g/m2 for fe- 
males.65,67,72 Key functional alterations are an E/e′ ≥13 and a 
mean e’ septal and lateral wall ,9 cm/s.65,67,70,72,80 – 84 Other (indir- 
ect) echocardiographically derived measurements are longitudinal 
strain or tricuspid regurgitation velocity (TRV).72,82 An overview 
of normal and abnormal values for echocardiographic parameters 
related to diastolic function is presented in Web Table 4.3. Not all 
of the recommended values are identical to those published in pre- 
vious guidelines, because of the inclusion of new data published in 
recent reports, in particular by Cabarello et al.70 
A diastolic stress test can be performed with echocardiography, 
typically using a semi-supine bicycle ergometer exercise protocol 
with assessment of LV (E/e′) and pulmonary artery pressures 
(TRV), systolic dysfunction (longitudinal strain), stroke volume and 
cardiac output changes with exercise.85,86 Different dynamic exercise 
protocols are available, with semi-supine bicycle ergometry and echo- 
cardiography at rest and submaximal exercise being used most of- 
ten.85 Exercise-induced increases in E/e′ beyond diagnostic cut-offs 
(i.e. .13), but also other indirect measures of systolic and diastolic 
function, such as longitudinal strain or TRV, are used. Alternatively, in- 
vasive haemodynamics at rest with assessment of filling pressures 
[pulmonary capillary wedge pressure (PCWP) ≥15 mmHg or left 
ventricular end diastolic pressure (LVEDP) ≥16 mmHg] followed 
by exercise haemodynamics if below these thresholds, with assess- 
ment of changes in filling pressures, pulmonary artery systolic pres- 
sure, stroke volume and cardiac output, can be performed.87 
The diagnosis of HFpEF in patients with AF is difficult. Since AF is 
associated with higher NP levels, the use of NT-proBNP or BNP for 
diagnosing HFpEF probably needs to be stratified by the presence of 
sinus rhythm (with lower cut-offs) vs. AF (higher cut-offs). LAVI is 
increased by AF, and functional parameters of diastolic dysfunction 
are less well established in AF, and other cut-off values probably ap- 
ply. On the other hand, AF might be a sign of the presence of HFpEF, 
and patients with AF and HFpEF often have similar patient character- 
istics. In addition, patients with HFpEF and AF might have more ad- 
vanced HF compared with patients with HFpEF and sinus rhythm. 
Patients with HFpEF are a heterogeneous group with various 
underlying aetiologies and pathophysiological abnormalities. Based 
on specific suspected causes, additional tests can be performed 
(Web Table 4.4).71,88 – 94 However, they can only be recommended 
if the results might affect management. 
 
 
5. Cardiac imaging and other 
diagnostic tests 
 
Cardiac imaging plays a central role in the diagnosis of HF and in guiding 
treatment. Of several imaging modalities available, echocardiography is 
the method of choice in patients with suspected HF, for reasons of ac- 
curacy, availability (including portability), safety and cost.68,69,72 Echocar- 
diography may be complemented by other modalities, chosen 
according to their ability to answer specific clinical questions and taking 
account of contraindications to and risks of specific tests.71,73 
In general, imaging tests should only be performed when they 
have a meaningful clinical consequence. The reliability of the out- 
comes is highly dependent on the imaging modality, the operator 
and centre experience  and imaging quality. Normal  values may 
vary with age, sex and imaging modality. 
 
5.1 Chest X-ray 
A chest X-ray is of limited use in the diagnostic work-up of patients 
with suspected HF. It is probably most useful in identifying an alter- 
native, pulmonary explanation for a patient’s symptoms and signs, 
i.e. pulmonary malignancy and interstitial pulmonary disease, al- 
though computed tomography (CT) of the chest is currently the 
standard of care. For the diagnosis of asthma or chronic obstructive 
pulmonary disease (COPD), pulmonary function testing with spir- 
ometry is needed. The chest X-ray may, however, show pulmonary 
venous congestion or oedema in a patient with HF, and is more 
helpful in the acute setting than in the non-acute setting.49,64 It is im- 
portant to note that significant LV dysfunction may be present with- 
out cardiomegaly on the chest X-ray.49,64 
 
5.2 Transthoracic         echocardiography 
Echocardiography is a term used here to refer to all cardiac ultra- 
sound  imaging  techniques,  including  two-dimensional/three- 
dimensional echocardiography, pulsed and continuous wave Dop- 
pler, colour flow Doppler, tissue Doppler imaging (TDI) contrast 
echocardiography and deformation imaging (strain and strain rate). 
Transthoracic echocardiography (TTE) is the method of choice 
for assessment of myocardial systolic and diastolic function of 
both left and right ventricles. 
 
5.2.1 Assessment of left ventricular systolic function 
For measurement of LVEF, the modified biplane Simpson’s rule is re- 
commended. LV end diastolic volume (LVEDV) and LV end systolic 
volume (LVESV) are obtained from apical four- and two-chamber 
views. This method relies on accurate tracing of endocardial bor- 
ders. In case of poor image quality, contrast agents should be 
used to improve endocardial delineation.72 Measurement of region- 
al wall motion abnormalities might be particularly relevant for pa- 
tients suspected of CAD or myocarditis. 
The Teichholz and Quinones methods of calculating LVEF from 
linear dimensions, as well as a measurement of fractional shortening, 
are  not  recommended,  as  they  may  result  in  inaccuracies, 
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particularly in patients with regional LV dysfunction and/or LV re- 
modelling. Three-dimensional echocardiography of adequate quality 
improves the quantification of LV volumes and LVEF and has the 
best accuracy compared with values obtained through CMR.95 
5.4  Stress echocardiography 
Exercise or pharmacological stress echocardiography may be used 
for the assessment of inducible ischaemia and/or myocardium viabil- 
99 
ity and in some clinical scenarios of patients with valve disease (e.g. 
Doppler techniques allow the calculation of haemodynamic vari- 
ables, such as stroke volume index and cardiac output, based on the 
velocity time integral at the LV outflow tract area. 
In recent years, tissue Doppler parameters (S wave) and deform- 
ation imaging techniques (strain and strain rate) have been shown to 
be reproducible and feasible for clinical use, especially in detecting sub- 
tle abnormalities in systolic function in the preclinical stage; however, 
measurements may vary among vendors and software versions.74 
 
5.2.2 Assessment of left ventricular diastolic function 
LV diastolic dysfunction is thought to be the underlying pathophysio- 
logical abnormality in patients with HFpEF and perhaps HFmrEF, and 
thus its assessment plays an important role in diagnosis. Although 
echocardiography is at present the only imaging technique that can 
allow for the diagnosis of diastolic dysfunction, no single echocardiog- 
raphy variable is sufficiently accurate to be used in isolation to make a 
diagnosis of LV diastolic dysfunction. Therefore, a comprehensive 
echocardiography examination incorporating all relevant two- 
dimensional and Doppler data is recommended (see Section 4.3.2). 
 
5.2.3 Assessment of right ventricular function and 
pulmonary arterial pressure 
An obligatory element of echocardiography examination is the as- 
sessment of right ventricle (RV) structure and function, including 
RV and right atrial (RA) dimensions, an estimation of RV systolic 
function and pulmonary arterial pressure. Among parameters re- 
flecting RV systolic function, the following measures are of particular 
importance: tricuspid annular plane systolic excursion (TAPSE; ab- 
normal TAPSE ,17 mm indicates RV systolic dysfunction) and 
tissue Doppler-derived tricuspid lateral annular systolic velocity 
(s′) (s′ velocity ,9.5 cm/s indicates RV systolic dysfunction).72,96 
Systolic pulmonary artery pressure is derived from an optimal 
recording of maximal tricuspid regurgitant jet and the tricuspid 
systolic gradient, together with an estimate of RA pressure on the 
basis of inferior vena cava (IVC) size and its breathing-related col- 
lapse.97 RV size should be routinely assessed by conventional two- 
dimensional echocardiography using multiple acoustic windows, and 
the report should include both qualitative and quantitative para- 
meters. In laboratories with experience in three-dimensional echo- 
cardiography, when knowledge of RV volumes may be clinically 
important, three-dimensional measurement of RV volumes is re- 
commended.95  Three-dimensional speckle tracking echocardio- 
dynamic mitral regurgitation, low-flow – low-gradient aortic sten- 
osis).99,100 There are also suggestions that stress echocardiography 
may allow the detection of diastolic dysfunction related to exercise 
exposure in patients with exertional dyspnoea, preserved LVEF and 
inconclusive diastolic parameters at rest.85,86 
 
5.5 Cardiac magnetic resonance 
CMR is acknowledged as the gold standard for the measurements of 
volumes, mass and EF of both the left and right ventricles. It is the 
best alternative cardiac imaging modality for patients with non- 
diagnostic echocardiographic studies (particularly for imaging of 
the right heart) and is the method of choice in patients with complex 
congenital heart diseases.91,101,102 
CMR is the preferred imaging method to assess myocardial fibrosis 
using late gadolinium enhancement (LGE) along with T1 mapping and 
can be useful for establishing HF aetiology.91,103 For example, CMR 
with LGE allows differentiation between ischaemic and non-ischaemic 
origins of HF and myocardial fibrosis/scars can be visualized. In addition, 
CMR allows the characterization of myocardial tissue of myocarditis, 
amyloidosis, sarcoidosis, Chagas disease, Fabry disease non-compaction 
cardiomyopathy and haemochromatosis.91,101,103,104 
CMR may also be used for the assessment of myocardial ischae- 
mia and viability in patients with HF and CAD (considered suitable 
for coronary revascularization). However, limited evidence from 
RCTs has failed to show that viability assessed by CMR or other 
means identified patients who obtained clinical benefit from revas- 
cularization.105 – 107 
Clinical limitations of CMR include local expertise, lower availability 
and higher costs compared with echocardiography, uncertainty about 
safety in patients with metallic implants (including cardiac devices) and 
less reliable measurements in patients with tachyarrhythmias. Claus- 
trophobia is an important limitation for CMR. Linear gadolinium- 
based contrast agents are contraindicated in individuals with a glom- 
erular filtration rate (GFR) ,30 mL/min/1.73m2, because they may 
trigger nephrogenic systemic fibrosis (this may be less of a concern 
with newer cyclic gadolinium-based contrast agents).108 
 
5.6 Single-photon emission computed 
tomography and radionuclide 
ventriculography 
Single-photon emission CT (SPECT) may be useful in assessing is- 
109 
graphy may be an additional quantitative method to assess RV chaemia and myocardial viability. Gated SPECT can also yield in- 
function in specialised centres.98 
 
 
5.3       Transoesophageal    echocardiography 
Transoesophageal echocardiography (TOE) is not needed in the 
routine diagnostic assessment of HF; however, it may be valuable 
in some clinical scenarios of patients with valve disease, suspected 
aortic dissection, suspected endocarditis or congenital heart disease 
and for ruling out intracavitary thrombi in AF patients requiring car- 
dioversion. When the severity of mitral or aortic valve disease does 
not match the patient’s symptoms using TTE alone, a TOE examin- 
ation should be performed. 
formation on ventricular volumes and function, but exposes the 
patient to ionizing radiation. 3,3-diphosphono-1,2-propanodicar- 
boxylic acid (DPD) scintigraphy may be useful for the detection of 
transthyretin cardiac amyloidosis.110 
 
5.7 Positron emission tomography 
Positron emission tomography (PET) (alone or with CT) may be 
used to assess ischaemia and viability, but the flow tracers (N-13 
ammonia or O-15 water) require an on-site cyclotron.92,111 Rubid- 
ium is an alternative tracer for ischaemia testing with PET, which can 
be produced locally at relatively low cost. Limited availability, radi- 
ation exposure and cost are the main limitations. 
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5.8 Coronary angiography 
Indications for coronary angiography in patients with HF are in con- 
cordance with the recommendations of other relevant ESC guide- 
lines.112 – 114 Coronary angiography is recommended in patients 
with HF who suffer from angina pectoris recalcitrant to medical 
therapy,115 provided the patient is otherwise suitable for coronary 
revascularization. Coronary angiography is also recommended in 
patients with a history of symptomatic ventricular arrhythmia or 
aborted cardiac arrest. Coronary angiography should be considered 
in patients with HF and intermediate to high pre-test probability of 
CAD and the presence of ischaemia in non-invasive stress tests in 
order to establish the ischaemic aetiology and CAD severity. 
5.9 Cardiac computed tomography 
The main use of cardiac CT in patients with HF is as a non-invasive 
means to visualize the coronary anatomy in patients with HF with 
low intermediate pre-test probability of CAD or those with equivo- 
cal non-invasive stress tests in order to exclude the diagnosis of 
CAD, in the absence of relative contraindications. However, the 
test is only required when its results might affect a therapeutic 
decision. 
The most important clinical indications for the applicability of cer- 
tain imaging methods in patients with suspected or confirmed HF 
are shown in the recommendations table. 
 
Recommendations for cardiac imaging in patients with suspected or established heart failure 
 
Recommendations Class a Level b Ref c 
TTE is recommended for the assessment of myocardial structure and function in subjects with suspected HF in order to establish 
a diagnosis of either HFrEF, HFmrEF or HFpEF. 
 
I 
 
C  
TTE is recommended to assess LVEF in order to identify patients with HF who would be suitable for evidence-based 
pharmacological and device (ICD, CRT) treatment recommended for HFrEF. 
 
I 
 
C  
TTE is recommended for the assessment of valve disease, right ventricular function and pulmonary arterial pressure in patients with 
an already established diagnosis of either HFrEF, HFmrEF or HFpEF in order to identify those suitable for correction of valve disease. 
 
I 
 
C  
TTE is recommended for the assessment of myocardial structure and function in subjects to be exposed to treatment which 
potentially can damage myocardium (e.g. chemotherapy). 
 
I 
 
C  
Other techniques (including systolic tissue Doppler velocities and deformation indices, i.e. strain and strain rate), should be 
considered in a TTE protocol in subjects at risk of developing HF in order to identify myocardial dysfunction at the preclinical stage. 
 
IIa 
 
C  
CMR is recommended for the assessment of myocardial structure and function (including right heart) in subjects with poor 
acoustic window and patients with complex congenital heart diseases (taking account of cautions/contra-indications to CMR). 
 
I 
 
C  
CMR with LGE should be considered in patients with dilated cardiomyopathy in order to distinguish between ischaemic and non- 
ischaemic myocardial damage in case of equivocal clinical and other imaging data (taking account of cautions/contra-indications to CMR). 
 
IIa 
 
C  
CMR is recommended for the characterization of myocardial tissue in case of suspected myocarditis, amyloidosis, sarcoidosis, 
Chagas disease, Fabry disease non-compaction cardiomyopathy, and haemochromatosis (taking account of cautions/contra- 
indications to CMR). 
 
I 
 
C 
 
Non-invasive stress imaging (CMR, stress echocardiography, SPECT, PET) may be considered for the assessment of myocardial 
ischaemia and viability in patients with HF and CAD (considered suitable for coronary revascularization) before the decision on 
revascularization. 
 
IIb 
 
B 
 
116–118 
Invasive coronary angiography is recommended in patients with HF and angina pectoris recalcitrant to pharmacological   
therapy or symptomatic ventricular arrhythmias or aborted cardiac arrest (who are considered suitable for potential coronary 
revascularization) in order to establish the diagnosis of CAD and its severity. 
 
I 
 
C 
 
Invasive coronary angiography should be considered in patients with HF and intermediate to high pre-test probability of CAD and 
the presence of ischaemia in non-invasive stress tests (who are considered suitable for potential coronary revascularization) in 
order to establish the diagnosis of CAD and its severity. 
 
IIa 
 
C 
 
Cardiac CT may be considered in patients with HF and low to intermediate pre-test probability of CAD or those with equivocal 
non-invasive stress tests in order to rule out coronary artery stenosis. 
 
IIb 
 
C  
Reassessment of myocardial structure and function is recommended using non-invasive imaging: 
- in patients presenting with worsening HF symptoms (including episodes of AHF) or experiencing any other 
important cardiovascular event; 
- in patients with HF who have received evidence-based pharmacotherapy in maximal tolerated doses, before the decision on 
device implantation (ICD, CRT); 
- in patients exposed to therapies which may damage the myocardium (e.g. chemotherapy) (serial assessments). 
 
 
 
I 
 
 
 
C 
 
 
AHF ¼ acute heart failure; CAD ¼ coronary artery disease; CMR ¼ cardiac magnetic resonance; CRT ¼ cardiac resynchronization therapy; CT ¼ computed tomography; HF ¼ 
heart failure; HFpEF ¼ heart failure with preserved ejection fraction; HFmrEF ¼ heart failure with mid-range ejection fraction; HFrEF ¼ heart failure with reduced ejection fraction; 
ICD ¼ implantable cardioverter-defibrillator; LGE ¼ late gadolinium enhancement; LVEF ¼ left ventricular ejection fraction; PET ¼ positron emission tomography; SPECT ¼ 
single-photon emission computed tomography; TTE ¼ transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
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The following diagnostic tests are recommended/should be considered for initial assessment of a patient with newly diagnosed 
HF in order to evaluate the patient’s suitability for particular therapies, to detect reversible/treatable causes of HF and co- 
morbidities interfering with HF: 
- haemoglobin and WBC 
- sodium, potassium, urea, creatinine (with estimated GFR) 
- liver function tests (bilirubin,AST,ALT, GGTP) 
- glucose, HbA1c 
 
- TSH 
- ferritin,TSAT = TIBC 
- natriuretic peptides 
   
 
 
 
I 
 
 
 
C 
IIa C 
Additional diagnostic tests aiming to identify other HF aetiologies and comorbidities should be considered in individual 
patients with HF when there is a clinical suspicion of a particular pathology (see Table 3.4 on HF aetiologies). 
 
IIa 
 
C  
A 12-lead ECG is recommended in all patients with HF in order to determine heart rhythm, heart rate, QRS morphology, and 
QRS duration, and to detect other relevant abnormalities.This information is needed to plan and monitor treatment. 
 
I 
 
C  
Exercise testing in patients with HF: 
- is recommended as a part of the evaluation for heart transplantation and/or mechanical circulatory support 
(cardiopulmonary exercise testing); 
- should be considered to optimize prescription of exercise training (preferably cardiopulmonary exercise testing); 
- should be considered to identify the cause of unexplained dyspnoea (cardiopulmonary exercise testing). 
- may be considered to detect reversible myocardial ischaemia. 
   
 
119, 120  I C 
C 
C 
C 
IIa 
IIa 
IIb 
Chest radiography (X-ray) is recommended in patients with HF to detect/exclude alternative pulmonary or other diseases, 
which may contribute to dyspnoea. It may also identify pulmonary congestion/oedema and is more useful in patients with 
suspected HF in the acute setting. 
 
I 
 
C 
 
Right heart catheterization with a pulmonary artery catheter: 
- is recommended in patients with severe HF being evaluated for heart transplantation or mechanical circulatory support; 
 
pulmonary hypertension and its reversibility before the correction of valve/structural heart disease; 
- may be considered in order to adjust therapy in patients with HF who remain severely symptomatic despite initial 
standard therapies and whose haemodynamic status is unclear. 
   
I C 
C 
C 
 
IIa 
 
IIb 
EMB should be considered in patients with rapidly progressive HF despite standard therapy when there is a probability of a  IIa 
 
C 
 
93 
 IIb C 121 
Ultrasound measurement of inferior vena cava diameter may be considered for the assessment of volaemia status in patients with HF. IIb C  
 
 
5.10 Other diagnostic tests 
Comprehensive assessment of patients with HF comprises, besides 
medical history and physical examination, including adequate imaging 
techniques, a set of additional diagnostic tests, i.e. laboratory vari- 
ables, ECG, chest X-ray, exercise testing, invasive haemodynamic as- 
sessments and endomyocardial biopsy. The major typical indications 
are summarized in the recommendations table for diagnostic tests in 
patients with HF. Although there is extensive research on biomarkers 
in HF (e.g. ST2, galectin 3, copeptin, adrenomedullin), there is no def- 
inite evidence to recommend them for clinical practice. 
 
 
  Recommendations for diagnostic tests in patients with heart failure  
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       AHF ¼ acute heart failure; ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BNP ¼ B-type natriuretic peptide; ECG ¼ electrocardiogram; eGFR ¼ estimate glomerular filtration rate; EMB ¼ endomyocardial biopsy; GFR ¼ glomerular filtration rate; GGTP ¼ gamma-glutamyl transpeptidase; HbA1c ¼ glycated haemoglobin; HF ¼ 
heart failure; HFrEF ¼ heart failure with reduced ejection fraction; QRS ¼ Q, R, and S waves (combination of three of the graphical deflections); TIBC ¼ total iron-binding capacit 
TSAT ¼ transferrin saturation; TSH ¼ thyroid-stimulating hormone; WBC ¼ white blood cell. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
d 
 
y; 
 
 
5.10.1 Genetic testing in heart failure 
Molecular genetic analysis in patients with cardiomyopathies is re- 
commended when the prevalence of detectable mutations is 
sufficiently high and consistent to justify routine targeted genetic 
screening. Recommendations for genetic testing in patients with 
HF are based on the position statement of the European Society 
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of Cardiology Working Group on Myocardial and Pericardial Dis- 
eases.94 In most patients with a definite clinical diagnosis of HF, there 
is no confirmatory role for routine genetic testing to establish the 
diagnosis. Genetic counselling is recommended in patients with 
HCM, idiopathic DCM and ARVC. Restrictive cardiomyopathy 
and isolated non-compaction cardiomyopathies are of a possible 
genetic origin and should also be considered for genetic testing. 
HCM is mostly inherited as an autosomal dominant disease with 
variable expressivity and age-related penetrance. Currently, more 
than 20 genes and 1400 mutations have been identified, most of which 
are located in the sarcomere genes encoding cardiac b-myosin heavy 
chain (MYH7) and cardiac myosin binding protein C (MYBPC3).88,122 
DCM is idiopathic in 50% of cases, about one-third of which are her- 
editary. There are already more than 50 genes identified that are asso- 
ciated with DCM. Many genes are related to the cytoskeleton. The most 
frequent ones are titin (TTN), lamin (LMNA) and desmin (DES).88,123 
ARVC is hereditary in most cases and is caused by gene mutations 
that encode elements of the desmosome. Desmosomal gene muta- 
tions explain 50% of cases and 10 genes are currently associated 
with the disease.124 
Counselling should be performed by someone with sufficient 
knowledge of the specific psychological, social and medical implica- 
tions of a diagnosis. Determination of the genotype is important, 
since some forms [e.g. mutations in LMNA and phospholamban 
(PLN)] are related to a poorer prognosis. DNA analysis could also 
be of help to establish the diagnosis of rare forms, such as mitochon- 
drial cardiomyopathies. Screening of first-degree relatives for early 
detection is recommended from early adolescence onwards, al- 
though earlier screening may be considered depending on the age 
of disease onset in other family members. 
Recently, the MOGE(S) classification of inherited cardiomyopathies 
has been proposed, which includes the morphofunctional phenotype 
(M), organ(s) involvement (O), genetic inheritance pattern (G), aetio- 
logical annotation (E), including genetic defect or underlying disease/ 
substrate, and the functional status (S) of the disease.125 
 
 
6. Delaying or preventing the 
development of overt heart failure 
or preventing death before the 
onset of symptoms 
 
There is considerable evidence that the onset of HF may be delayed 
or prevented through interventions aimed at modifying risk factors 
for HF or treating asymptomatic LV systolic dysfunction (see recom- 
mendations table). Many trials show that control of hypertension 
will delay the onset of HF and some also show that it will prolong 
life.126 – 129 Different antihypertensive drugs [diuretics, ACEIs, angio- 
tensin receptor blockers (ARBs), beta-blockers] have been shown 
to be effective, especially in older people, both in patients with 
and without a history of myocardial infarction.126 – 128 Along with 
the ongoing discussion on optimal target blood pressure values in 
hypertensive non-diabetic subjects, the recent SPRINT study has 
already demonstrated that treating hypertension to a lower goal 
[systolic blood pressure (SBP) ,120 mmHg vs. ,140 mmHg] in 
older hypertensive subjects (≥75 years of age) or high-risk 
hypertensive patients reduces the risk of cardiovascular disease, 
death and hospitalization for HF.129 
Recently, empaglifozin (an inhibitor of sodium-glucose cotran- 
sporter 2), has been shown to improve outcomes (including the re- 
duction of mortality and HF hospitalizations) in patients with type 2 
diabetes.130 Other hypoglycaemic agents have not been shown con- 
vincingly to reduce the risk of cardiovascular events and may in- 
crease the risk of HF. Intensification of hypoglycaemic therapy to 
drive down glycated haemoglobin (HbA1c) with agents other than 
empagliflozin does not reduce the risk of developing HF (for details 
see Section 11.6 on diabetes). 
Although smoking cessation has not been shown to reduce the 
risk of developing HF, the epidemiological associations with the de- 
velopment of cardiovascular disease131 suggest that such advice, if 
followed, would be beneficial. 
The association between alcohol intake and the risk of developing 
de novo HF is U-shaped, with the lowest risk with modest alcohol 
consumption (up to 7 drinks/week).132 – 134 Greater alcohol intake 
may trigger the development of toxic cardiomyopathy, and when 
present, complete abstention from alcohol is recommended. 
An inverse relationship between physical activity and the risk of 
HF has been reported. A recent meta-analysis found that doses 
of physical activity in excess of the guideline recommended 
minimal levels may be required for more substantial reductions in 
HF risk.135 
It has been shown that among subjects ≥40 years of age with ei- 
ther cardiovascular risk factors or cardiovascular disease (but nei- 
ther asymptomatic LV dysfunction nor overt HF), BNP-driven 
collaborative care between the primary care physician and the spe- 
cialist cardiovascular centre may reduce the combined rates of LV 
systolic dysfunction and overt HF.136 
Statins reduce the rate of cardiovascular events and mortality; 
there is also reasonable evidence that they prevent or delay the on- 
set of HF.137 – 140 Neither aspirin nor other antiplatelet agents, nor 
revascularization, have been shown to reduce the risk of developing 
HF or mortality in patients with stable CAD. Obesity is also a risk 
factor for HF,141 but the impact of treatments of obesity on the de- 
velopment of HF is unknown. 
In patients with CAD, without LV systolic dysfunction or HF, ACEIs 
prevent or delay the onset of HF and reduce cardiovascular and all- 
cause mortality, although the benefit may be small in the 
contemporary setting, especially in patients receiving aspirin.142 
Up-titration of renin–angiotensin system antagonists and beta-blockers 
to maximum tolerated dosages may improve outcomes, including HF, in 
patients with increased plasma concentrations of NPs.136,143 
A primary percutaneous coronary intervention (PCI) at the earli- 
est phase of an ST segment elevation myocardial infarction (STEMI) 
to reduce infarct size decreases the risk of developing a substantial 
reduction in LVEF and subsequent development of HFrEF.112 Initi- 
ation of an ACEI, a beta-blocker and an MRA immediately after a 
myocardial infarction, especially when it is associated with LV 
systolic dysfunction, reduces the rate of hospitalization for HF and 
mortality,144 – 148  as do statins.137 – 139 
In asymptomatic patients with chronically reduced LVEF, regard- 
less of its aetiology, an ACEI can reduce the risk of HF requiring hos- 
pitalization.5,144,145 This has not yet been shown for beta-blockers 
or MRAs. 
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Recommendations Class a Level b Ref c 
 
Treatment of hypertension is recommended to prevent or delay the onset of HF and prolong life. 
 
I 
 
A 126, 129, 150, 151 
Treatment with statins is recommended in patients with or at high-risk of CAD whether or not they have LV systolic 
dysfunction, in order to prevent or delay the onset of HF and prolong life. 
 
I 
 
A 137–140, 152 
Counselling and treatment for smoking cessation and alcohol intake reduction is recommended for people who smoke or who 
consume excess alcohol in order to prevent or delay the onset of HF. 
 
I 
 
C 
 
131–134 
 
Treating other risk factors of HF (e.g. obesity, dysglycaemia) should be considered in order to prevent or delay the onset of HF. 
 
IIa 
 
C 130, 141, 153–155 
 IIa B 130 
ACE-I is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction in order to 
prevent or delay the onset of HF and prolong life. 
 
I 
 
A 5, 144, 145 
ACE-I is recommended in patients with asymptomatic LV systolic dysfunction without a history of myocardial infarction, in order 
to prevent or delay the onset of HF. 
 
I 
 
B 
 
5 
ACE-I should be considered in patients with stable CAD even if they do not have LV systolic dysfunction, in order to prevent 
or delay the onset of HF. 
 
IIa 
 
A 
 
142 
Beta-blocker is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction, in 
order to prevent or delay the onset of HF or prolong life. 
 
I 
 
B 
 
146 
ICD is recommended in patients: 
a) with asymptomatic LV systolic dysfunction (LVEF ≤30%) of ischaemic origin, who are at least 40 days after acute 
myocardial infarction, 
b) with asymptomatic non-ischaemic dilated cardiomyopathy (LVEF ≤30%), who receive OMT therapy, 
 
in order to prevent sudden death and prolong life. 
 
 
 
I 
 
 
 
B 
 
 
149, 
156–158 
 
 
In patients with asymptomatic LV systolic dysfunction (LVEF 
,30%) of ischaemic origin who are ≥40 days after an AMI, an im- 
plantable cardioverter-defibrillator (ICD) is recommended to 
prolong life.149 
 
 Recommendations to prevent or delay the development of overt heart failure or prevent death before the onset of 
symptoms 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       ACEI ¼ angiotensin-converting enzyme inhibitor; CAD ¼ coronary artery disease; HF ¼ heart failure; ICD ¼ implantable cardioverter-defibrillator; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; OMT ¼ optimal medical therapy 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
 
 
 
7. Pharmacological treatment of 
heart failure with reduced ejection 
fraction 
 
7.1 Objectives in the management of 
heart failure 
The goals of treatment in patients with HF are to improve their clin- 
ical status, functional capacity and quality of life, prevent hospital ad- 
mission and reduce mortality. The fact that several drugs for HF 
have shown detrimental effects on long-term outcomes, despite 
Figure 7.1 shows a treatment strategy for the use of drugs (and de- 
vices) in patients with HFrEF. The recommendations for each treat- 
ment are summarized below. 
Neuro-hormonal antagonists (ACEIs, MRAs and beta-blockers) 
have been shown to improve survival in patients with HFrEF and 
are recommended for the treatment of every patient with HFrEF, 
unless contraindicated or not tolerated. A new compound 
(LCZ696) that combines the moieties of an ARB (valsartan) and a 
neprilysin (NEP) inhibitor (sacubitril) has recently been shown to 
be superior to an ACEI (enalapril) in reducing the risk of death 
and of hospitalization for HF in a single trial with strict inclusion/ex- 
162 
showing beneficial effects on shorter-term surrogate markers, has clusion criteria. Sacubitril/valsartan is therefore recommended to 
led regulatory bodies and clinical practice guidelines to seek mortal- 
ity/morbidity data for approving/recommending therapeutic inter- 
ventions for HF. However, it is now recognized that preventing 
HF hospitalization and improving functional capacity are important 
benefits to be considered if a mortality excess is ruled out.159 – 161 
replace ACEIs in ambulatory HFrEF patients who remain symptom- 
atic despite optimal therapy and who fit these trial criteria. ARBs 
have not been consistently proven to reduce mortality in patients 
with HFrEF and their use should be restricted to patients intolerant 
of an ACEI or those who take an ACEI but are unable to tolerate an 
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MRA. Ivabradine reduces the elevated heart rate often seen in 
HFrEF and has also been shown to improve outcomes, and should 
be considered when appropriate. 
The above medications should be used in conjunction with diure- 
tics in patients with symptoms and/or signs of congestion. The use of 
diuretics should be modulated according to the patient’s clinical 
status. 
The key evidence supporting the recommendations in this 
section is given in Web Table 7.1. The recommended doses of these 
disease-modifying medications are given in Table 7.2. The 
recommendations given in Sections 7.5 and 7.6 summarize drugs 
that should be avoided or used with caution in patients with HFrEF. 
 
7.2 Treatments recommended in 
all symptomatic patients with heart 
failure with reduced ejection 
fraction 
7.2.1 Angiotensin-converting enzyme inhibitors 
ACEIs have been shown to reduce mortality and morbidity in pa- 
tients with HFrEF2,5,163 – 165 and are recommended unless contrain- 
dicated or not tolerated in all symptomatic patients. ACEIs should 
be up-titrated to the maximum tolerated dose in order to achieve 
adequate inhibition of the renin – angiotensin – aldosterone system 
(RAAS). There is evidence that in clinical practice the majority of pa- 
tients receive suboptimal doses of ACEI.166 ACEIs are also recom- 
mended in patients with asymptomatic LV systolic dysfunction to 
reduce the risk of HF development, HF hospitalization and death 
(see Section 6). 
 
 
Pharmacological treatments indicated in patients with 
symptomatic (NYHA Class II-IV) heart failure with 
reduced ejection fraction 
 
Recommendations Class a Level b Ref c 
An ACE-Id  is recommended, 
in addition to a beta-blocker, 
for symptomatic patients with 
HFrEF to reduce the risk of HF 
hospitalization and death. 
 
 
I 
 
 
A 
 
2, 
163 
–165 
A beta-blocker is recommended, 
in addition an ACE-Id, for  
patients with stable, symptomatic 
HFrEF to reduce the risk of HF 
hospitalization and death. 
 
 
I 
 
 
A 
 
 
167– 
173 
An MRA is recommended for 
patients with HFrEF, who remain 
symptomatic despite treatment 
with an ACE-Id and a 
beta-blocker, to reduce the risk of 
HF hospitalization and death. 
 
 
 
I 
 
 
 
A 
 
 
 
174, 175 
 
ACEI ¼ angiotensin-converting enzyme inhibitor; HF ¼ heart failure; HFrEF ¼ 
heart failure with reduced ejection fraction; MRA ¼ mineralocorticoid receptor 
antagonist; NYHA ¼ New York Heart Association. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
dOr ARB if ACEI is not tolerated/contraindicated 
Practical guidance on how to use ACE inhibitors is given in Web 
Table 7.4. 
 
 
7.2.2 Beta-blockers 
Beta-blockers reduce mortality  and morbidity in symptomatic 
patients with HFrEF, despite treatment with an ACEI and, in 
most cases, a diuretic,167,168,170,172,173 but have not been tested 
in congested or decompensated patients. There is consensus 
that beta-blockers and ACEIs are complementary, and can be 
started together as soon as the diagnosis of HFrEF is made. 
There is no evidence favouring the  initiation  of  treatment 
with a beta-blocker before an ACEI has been started.176 Beta- 
blockers should be initiated in clinically stable patients at a low 
dose and gradually up-titrated to the maximum tolerated dose. 
In patients admitted due to acute HF (AHF) beta-blockers 
should be cautiously initiated in hospital, once the patient is 
stabilized. 
An individual patient data meta-analysis of all the major beta- 
blocker trials in HFrEF has shown no benefit on hospital admis- 
sions and mortality in the subgroup of patients with HFrEF who 
are in AF.177 However, since this is a retrospective subgroup 
analysis, and because beta-blockers did not increase the risk, 
the guideline committee decided not to make a separate recom- 
mendation according to heart rhythm. Beta-blockers should be 
considered for rate control in patients with HFrEF and AF, es- 
pecially in those with high  heart rate  (see Section  10.1 for 
details). 
Beta-blockers are recommended in patients with a history of 
myocardial infarction and asymptomatic LV systolic dysfunction to 
reduce the risk of death (see Section 6). 
Practical guidance on how to use beta-blockers is given in Web 
Table 7.5. 
 
 
7.2.3 Mineralocorticoid/aldosterone   receptor    antagonists 
MRAs (spironolactone and eplerenone) block receptors that 
bind aldosterone and, with different degrees of affinity, other ster- 
oid hormone (e.g. corticosteroids, androgens) receptors. Spirono- 
lactone or eplerenone are recommended in all symptomatic 
patients (despite treatment with an ACEI and a beta-blocker) 
with HFrEF and LVEF ≤35%, to reduce mortality and HF 
hospitalization.174,175 
Caution should be exercised when MRAs are used in patients 
with impaired renal function and in those with serum potassium 
levels .5.0 mmol/L. Regular checks of serum potassium levels 
and renal function should be performed according to clinical 
status. 
Practical guidance on how to use MRAs is  given  in  Web 
Table 7.6. 
 
 
7.3 Other treatments recommended in 
selected symptomatic patients with heart 
failure with reduced ejection fraction 
7.3.1 Diuretics 
Diuretics are recommended to reduce the signs and symptoms 
of  congestion  in  patients  with  HFrEF,  but  their  effects  on 
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Figure 7.1 Therapeutic algorithm for a patient with symptomatic heart failure with reduced ejection fraction. Green indicates a class I recom- 
mendation; yellow indicates a class IIa recommendation. ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; 
ARNI ¼ angiotensin receptor neprilysin inhibitor; BNP ¼ B-type natriuretic peptide; CRT ¼ cardiac resynchronization therapy; HF ¼ heart fail- 
ure; HFrEF ¼ heart failure with reduced ejection fraction; H-ISDN ¼ hydralazine and isosorbide dinitrate; HR ¼ heart rate; ICD ¼ implantable 
cardioverter defibrillator; LBBB ¼ left bundle branch block; LVAD ¼ left ventricular assist device; LVEF ¼ left ventricular ejection fraction; MR ¼ 
mineralocorticoid receptor; NT-proBNP ¼ N-terminal pro-B type natriuretic peptide; NYHA ¼ New York Heart Association; OMT ¼ optimal 
medical therapy; VF ¼ ventricular fibrillation; VT ¼ ventricular tachycardia. aSymptomatic ¼ NYHA Class II-IV. bHFrEF ¼ LVEF ,40%. cIf ACE 
inhibitor not tolerated/contra-indicated, use ARB. dIf MR antagonist not tolerated/contra-indicated, use ARB. eWith a hospital admission for 
HF within the last 6 months or with elevated natriuretic peptides (BNP . 250 pg/ml or NTproBNP . 500 pg/ml in men and 750 pg/ml in women). 
fWith an elevated plasma natriuretic peptide level (BNP ≥ 150 pg/mL or plasma NT-proBNP ≥ 600 pg/mL, or if HF hospitalization within recent 
12 months plasma BNP ≥ 100 pg/mL or plasma NT-proBNP ≥ 400 pg/mL). gIn doses equivalent to enalapril 10 mg b.i.d. hWith a hospital admis- 
sion for HF within the previous year. iCRT is recommended if QRS ≥ 130 msec and LBBB (in sinus rhythm). jCRT should/may be considered if 
QRS ≥ 130 msec with non-LBBB (in a sinus rhythm) or for patients in AF provided a strategy to ensure bi-ventricular capture in place (individua- 
lized decision). For further details, see Sections 7 and 8 and corresponding web pages. 
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mortality and morbidity have not been studied in RCTs. A Co- 
chrane meta-analysis has shown that in patients with chronic HF, 
loop and thiazide diuretics appear to reduce the risk of death 
and worsening HF compared with placebo,  and  compared 
with an active control, diuretics appear to improve exercise 
capacity.178,179 
 
 
 
 
 
Table 7.2 Evidence-based doses of disease-modifying 
drugs in key randomized trials in heart failure with 
reduced ejection fraction (or after myocardial 
infarction) 
 
 Starting dose (mg) Target dose (mg) 
ACE-I 
Captoprila 6.25 t.i.d. 50 t.i.d. 
Enalapril 2.5 b.i.d. 20 b.i.d. 
Lisinoprilb 2.5–5.0 o.d. 20–35 o.d. 
Ramipril 2.5 o.d. 10 o.d. 
Trandolaprila 0.5 o.d. 4 o.d. 
Beta-blockers 
Bisoprolol 1.25 o.d. 10 o.d. 
Carvedilol 3.125 b.i.d. 25 b.i.d.d 
Metoprolol succinate (CR/XL) 12.5–25 o.d. 200 o.d. 
Nebivololc 1.25 o.d. 10 o.d. 
ARBs 
Candesartan 4–8 o.d. 32 o.d. 
Valsartan 40 b.i.d. 160 b.i.d. 
Losartanb,c 50 o.d. 150 o.d. 
MRAs 
Eplerenone 25 o.d. 50 o.d. 
Spironolactone 25 o.d. 50 o.d. 
ARNI 
Sacubitril/valsartan 49/51 b.i.d. 97/103 b.i.d. 
If -channel blocker 
Ivabradine 5 b.i.d. 7.5 b.i.d. 
 
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; 
ARNI ¼ angiotensin receptor neprilysin inhibitor; b.i.d. ¼ bis in die (twice daily); 
MRA ¼ mineralocorticoid receptor antagonist; o.d. ¼ omne in die (once daily); 
t.i.d. ¼ ter in die (three times a day). 
aIndicates an ACE-I where the dosing target is derived from post-myocardial 
infarction trials. 
bIndicates drugs where a higher dose has been shown to reduce morbidity/ 
mortality compared with a lower dose of the same drug, but there is no substantive 
randomized, placebo-controlled trial and the optimum dose is uncertain. 
cIndicates a treatment not shown to reduce cardiovascular or all-cause mortality in 
patients with heart failure (or shown to be non-inferior to a treatment that does). 
dA maximum dose of 50 mg twice daily can be administered to patients weighing 
over 85 kg. 
Loop diuretics produce a more intense and shorter diuresis 
than thiazides, although they act synergistically and the combin- 
ation may be used to treat resistant oedema. However, adverse 
effects are more likely and these combinations should only be 
used with care. The aim of diuretic therapy is to achieve and main- 
tain euvolaemia with the lowest achievable dose. The dose of the 
diuretic must be adjusted according to the individual needs over 
time. In selected asymptomatic euvolaemic/hypovolaemic patients, 
the use of a diuretic drug might be (temporarily) discontinued. Pa- 
tients can be trained to self-adjust their diuretic dose based on 
monitoring of symptoms/signs of congestion and daily weight 
measurements. 
Doses of diuretics commonly used to treat HF are provided in 
Table 7.3. Practical guidance on how to use diuretics is given in 
Web Table 7.7. 
 
 
 
 
 
 
 
 
 
 
Table 7.3   Doses of diuretics commonly used in 
patients with heart failure 
 
Diuretics Initial dose (mg) Usual daily dose 
(mg) 
Loop diuretics a 
Furosemide 20–40 40–240 
Bumetanide 0.5–1.0 1–5 
Torasemide 5–10 10–20 
Thiazidesb 
 2.5 2.5–10 
Hydrochlorothiazide 25 12.5–100 
Metolazone 2.5 2.5–10 
lndapamidec 2.5 2.5–5 
Potassium-sparing diureticsd 
 +ACE-I/ 
ARB 
-ACE-I/ 
ARB 
+ACE-I/ 
ARB 
-ACE-I/ 
ARB 
Spironolactone/ 
eplerenone 
12.5–25 50 50 100– 
200 
Amiloride 2.5 5 5–10 10–20 
Triamterene 25 50 100 200 
 
ACE-I ¼ angiontensin-converting enzyme inhibitor, ARB ¼ angiotensin receptor 
blocker. 
aOral or intravenous; dose might need to be adjusted according to volume status/ 
weight; excessive doses may cause renal impairment and ototoxicity. 
bDo not use thiazides if estimated glomerular filtration rate ,30 mL/min/1.73 m2 , 
except when prescribed synergistically with loop diuretics. 
clndapamide is a non-thiazide sulfonamide. 
dA mineralocorticoid antagonist (MRA) i.e. spironolactone/eplerenone is always 
preferred. Amiloride and triamterene should not be combined with an MRA. 
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Recommendations Class a Level b Ref c 
Diuretics 
Diuretics are recommended in order to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion. I B 178, 179 
Diuretics should be considered to reduce the risk of HF hospitalization in patients with signs and/or symptoms of congestion. IIa B 178, 179 
Angiotensin receptor neprilysin inhibitor 
Sacubitril/valsartan is recommended as a replacement for an ACE-I to further reduce the risk of HF hospitalization and death in 
ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE-I, a beta-blocker and an MRAd 
 
I 
 
B 
 
162 
If -channel inhibitor 
Ivabradine should be considered to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients 
with LVEF ≤35%, in sinus rhythm and a resting heart rate ≥70 bpm despite treatment with an evidence-based dose of beta- 
blocker (or maximum tolerated dose below that),ACE-I (or ARB), and an MRA (or ARB). 
 
IIa 
 
B 
 
180 
Ivabradine should be considered to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients with 
LVEF ≤35%, in sinus rhythm and a resting heart rate ≥70 bpm who are unable to tolerate or have contra-indications for a 
beta-blocker. Patients should also receive an ACE-I (or ARB) and an MRA (or ARB). 
 
IIa 
 
C 
 
181 
ARB 
An ARB is recommended to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients unable to 
tolerate an ACE-I (patients should also receive a beta-blocker and an MRA). 
 
I  B  182 
An ARB may be considered to reduce the risk of HF hospitalization and death in patients who are symptomatic despite treatment 
with a beta-blocker who are unable to tolerate an MRA. 
 
IIb  C  - 
Hydralazine and isosorbide dinitrate 
≤35% or with an 
LVEF <45% combined with a dilated LV in NYHA Class III–IV despite treatment with an ACE-I a beta-blocker and an MRA 
to reduce the risk of HF hospitalization and death. 
 
IIa 
 
B 
 
183 
Hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who can tolerate neither an ACE-I 
nor an ARB (or they are contra-indicated) to reduce the risk of death. 
 
IIb  B  184 
 
Digoxin 
Digoxin may be considered in symptomatic patients in sinus rhythm despite treatment with an ACE-I (or ARB), a beta-blocker 
and an MRA, to reduce the risk of hospitalization (both all-cause and HF-hospitalizations). 
 
IIb  B  185 
N-3 PUFA 
An n-3 PUFAe preparation may be considered in symptomatic HF patients to reduce the risk of cardiovascular hospitalization 
and cardiovascular death. 
 
IIb 
 
B 
 
186 
 
 
 
Other pharmacological treatments recommended in selected patients with symptomatic (NYHA Class II-IV) heart 
failure with reduced ejection fraction 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BNP ¼ B-type natriuretic peptide; bpm ¼ beats per minute; HF ¼ heart failure; HFrEF heart failure with reduced ejection fraction; LVEF ¼ left ventricular ejection fraction; MRA ¼ mineralocorticoid receptor antagonist; NT-proBNP ¼ N-terminal pro-B type 
natriuretic peptide; NYHA ¼ New York Heart Association; PUFA ¼ polyunsaturated fatty acid. OMT ¼ optimal medical therapy (for HFrEF this mostly comprises an ACEI o 
sacubitril/valsartan, a beta-blocker and an MRA). 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
dPatient should have elevated natriuretic peptides (plasma BNP ≥150 pg/mL or plasma NT-proBNP ≥600 pg/mL, or if HF hospitalization within the last 12 months, plasma BN 
≥100 pg/mL or plasma NT-proBNP ≥400 pg/mL) and able to tolerate enalapril 10 mg b.i.d. 
eApplies only to preparation studied in cited trial. 
¼ 
 
r 
 
 
 
 
P 
 
 
 
 
7.3.2 Angiotensin receptor neprilysin inhibitor 
A new therapeutic class of agents acting on the RAAS and the neu- 
tral endopeptidase system has been developed [angiotensin recep- 
tor neprilysin inhibitor (ARNI)]. The first in class is LCZ696, which is 
a molecule that combines the moieties of valsartan and sacubitril 
(neprilysin inhibitor) in a single substance. By inhibiting neprilysin, 
the degradation of NPs, bradykinin and other peptides is slowed. 
High circulating A-type natriuretic peptide (ANP) and BNP exert 
physiologic effects through binding to NP receptors and the aug- 
mented generation of cGMP, thereby enhancing diuresis, natriuresis 
and myocardial relaxation and anti-remodelling. ANP and BNP also 
inhibit renin and aldosterone secretion. Selective AT1-receptor 
blockade reduces vasoconstriction, sodium and water retention 
and myocardial hypertrophy.187,188 
A recent trial investigated the long-term effects of sacubi- 
tril/valsartan compared with an ACEI (enalapril) on morbidity 
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and mortality in patients with ambulatory, symptomatic HFrEF 
with LVEF ≤40% (this was changed to ≤35% during the 
study), elevated plasma NP levels (BNP ≥150 pg/mL or NT-
proBNP ≥600 pg/mL or, if  they  had  been  hospitalized for 
HF within the previous 12 months, BNP ≥100 pg/mL or NT-
proBNP  ≥400 pg/mL),  and  an  estimated  GFR  (eGFR) 
≥30  mL/min/1.73  m2   of  body surface  area,  who were  able 
to   tolerate   separate   treatments   periods   with   enalapril 
(10 mg b.i.d.) and sacubitril/valsartan (97/103 mg b.i.d.) during 
a run-in period.162  In this population, sacubitril/valsartan (97/ 
103 mg b.i.d.) was superior to ACEI (enalapril 10 mg b.i.d.) in 
reducing hospitalizations for worsening HF, cardiovascular 
mortality and overall mortality.162  Sacubitril/valsartan is there- 
fore recommended in patients with HFrEF who fit this profile. 
Despite the superiority of sacubitril/valsartan over enalapril in 
the PARADIGM-HF trial, some relevant safety issues remain 
when initiating therapy with this drug in clinical practice. Symp- 
tomatic hypotension was more often present in the sacubitril/ 
valsartan group (in those ≥75 years of age, it affected 18% in 
the sacubitril/valsartan group vs. 12% in the enalapril group), al- 
though there was no increase in the rate of discontinuation.162 
The risk of angioedema in the trial was reduced by recruiting 
only those who tolerated therapy with enalapril 10 mg b.i.d. 
and an sacubitril/valsartan during an active run-in phase of 5 – 9 
weeks (it resulted in a 0.4% rate of angioedema in sacubitril/val- 
sartan group vs. 0.2% in an enalapril group). Also, the number of 
African American patients, who are at a higher risk of angioede- 
ma, was relatively small in this study. To minimize the risk of an- 
gioedema caused by overlapping ACE and neprilysin inhibition, 
the ACEI should be withheld for at least 36 h before initiating 
sacubitril/valsartan. Combined treatment with an ACEI (or 
ARB) and sacubitril/valsartan is contraindicated. There are add- 
itional concerns about its effects on the degradation of 
beta-amyloid peptide in the brain, which could theoretically ac- 
celerate amyloid deposition.189 – 191 However, a recent small 
14-day study with healthy subjects showed elevation of the 
beta-amyloid protein in the soluble rather than the aggregable 
form, which if confirmed over longer time periods in patients 
with HFrEF may indicate the cerebral safety of sacubitril/valsar- 
tan.192  Long-term safety needs to be addressed. 
 
 
7.3.3 If-channel 
inhibitor 
Ivabradine slows the heart rate through inhibition of the If 
channel in the sinus node and therefore should only be used 
for patients in sinus rhythm. Ivabradine reduced the combined 
endpoint of mortality and hospitalization for HF  in  patients 
with symptomatic HFrEF and LVEF ≤35%, in sinus rhythm 
and with a heart rate ≥70 beats per minute (bpm) who had 
been hospitalized for HF within the previous 12 months, re- 
ceiving treatment with an evidence-based dose of beta-blocker 
(or maximum tolerated dose), an ACEI (or ARB) and an 
MRA.180 The European Medicines Agency (EMA) approved 
ivabradine for use in Europe in patients with HFrEF  with 
LVEF  ≤35%  and  in  sinus  rhythm  with  a  resting  heart  rate 
≥75 bpm, because in this group ivabradine conferred a survival 
benefit193 based on a retrospective subgroup analysis re- 
quested by the EMA. 
Practical guidance on how to use ivabradine is given in Web 
Table 7.8. 
 
7.3.4 Angiotensin II type I receptor 
blockers 
ARBs are recommended only as an alternative in patients intolerant 
of an ACEI.182 Candesartan has been shown to reduce cardiovascu- 
lar mortality.182 Valsartan showed an effect on hospitalization for HF 
(but not on all-cause hospitalizations) in patients with HFrEF receiv- 
ing background ACEIs.194 
The combination of ACEI/ARB for HFrEF was reviewed by the 
EMA, which suggested that benefits are thought to outweigh risks 
only in a select group of patients with HFrEF in whom other treat- 
ments are unsuitable. Therefore, ARBs are indicated for the treat- 
ment of HFrEF only in patients who cannot tolerate an ACEI 
because of serious side effects. The combination of ACEI/ARB 
should be restricted to symptomatic HFrEF patients receiving a 
beta-blocker who are unable to tolerate an MRA, and must be 
used under strict supervision. 
 
7.3.5 Combination of  hydralazine  and  isosorbide  dinitrate 
There is no clear evidence to suggest the use of this fixed-dose 
combination therapy in all patients with HFrEF. Evidence on the 
clinical utility of this combination is scanty and comes from one 
relatively small RCT conducted exclusively in men and before 
ACEIs or beta-blockers were used to treat HF.184 A subsequent 
RCT conducted in self-identified black patients (defined as being 
of African descent) showed that addition of the combination of hy- 
dralazine and isosorbide dinitrate to conventional therapy (ACEI, 
beta-blocker and MRA) reduced mortality and HF hospitalizations 
in patients with HFrEF and NYHA Classes III – IV.183 The results of 
this study are difficult to translate to patients of other racial or eth- 
nic origins. 
Additionally, a combination of hydralazine and isosorbide dini- 
trate may be considered in symptomatic patients with HFrEF who 
can tolerate neither ACEI nor ARB (or they are contraindicated) 
to reduce mortality. However, this recommendation is based on 
the results of the Veterans Administration Cooperative Study, 
which recruited symptomatic HFrEF patients who received only di- 
goxin and diuretics.184 
 
7.4 Other treatments with less certain 
benefits in symptomatic patients with 
heart failure with reduced ejection 
fraction 
This section describes treatments that have shown benefits in 
terms of symptomatic improvement, reduction in HF hospitaliza- 
tions or both, and are useful additional treatments in patients 
with HFrEF. 
 
7.4.1 Digoxin and other digitalis glycosides 
Digoxin may be considered in patients in sinus rhythm with symp- 
tomatic HFrEF to reduce the risk of hospitalization (both all-cause 
and HF hospitalizations),185 although its effect on top of beta- 
blockers has never been tested. The effects of digoxin in patients 
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with HFrEF and AF have not been studied in RCTs, and recent stud- 
ies have suggested potentially higher risk of events (mortality and HF 
hospitalization) in patients with AF receiving digoxin.195,196 How- 
ever, this remains controversial, as another recent meta-analysis 
concluded on the basis of non-RCTs that digoxin has no deleterious 
effect on mortality in patients with AF and concomitant HF, most of 
whom had HFrEF.197 
In patients with symptomatic HF and AF, digoxin may be use- 
ful to slow a rapid ventricular rate, but it is only recommended 
for the treatment of patients with HFrEF and AF with rapid ven- 
tricular rate when other therapeutic options cannot be pur- 
sued.196,198 – 201 Of note, the optimal ventricular  rate  for 
patients with HF and AF has not been well established, but 
the prevailing evidence suggests that strict rate control might 
be deleterious. A resting ventricular rate in the range of 70 – 
90 bpm is recommended based on current opinion, although 
one trial suggested that a resting ventricular rate of up to 110 
bpm might still be acceptable.202 This should be tested and re- 
fined by further research. 
Digitalis should always be prescribed under specialist supervi- 
sion. Given its distribution and clearance, caution should be ex- 
erted in females, in the elderly and in patients with reduced 
renal function. In the latter patients, digitoxin should be 
preferred. 
 
7.4.2 n-3 polyunsaturated fatty acids 
n-3 polyunsaturated fatty acids (n-3 PUFAs) have shown a small 
treatment effect in a large RCT.186 n-3 PUFA preparations dif- 
fer in composition and dose. Only preparations with eicosa- 
pentaenoic acid (EPA) and docosahexaenoic acid (DHA) as 
ethyl esters of at least 85% (850 mg/g) have shown an effect 
on the cumulative endpoint of cardiovascular death and hospi- 
talization.  No  effect  of  n-3  PUFA  preparations  containing 
,850 mg/g has been shown in either HFrEF or post-myocardial 
infarction.203 n-3 PUFA preparations containing 850 – 882 mg of 
EPA and DHA as ethyl esters in the average ratio of 1 : 1.2 may 
be considered as an adjunctive therapy in patients with symp- 
tomatic HFrEF who are already receiving optimized recom- 
mended therapy with an ACEI (or ARB),  a beta-blocker and 
an MRA. 
 
7.5 Treatments not recommended 
(unproven benefit) in symptomatic 
patients with heart failure with reduced 
ejection fraction 
7.5.1 3-Hydroxy-3-methylglutaryl-coenzyme A reductase 
inhibitors (‘statins’) 
Although statins reduce mortality and morbidity in patients with 
atherosclerotic disease, statins are not effective in improving the 
prognosis in patients with HFrEF. Most statin trials excluded pa- 
tients with HF (because it was uncertain that they would bene- 
fit).204   The  two  major  trials  that  studied  the  effect  of  statin 
 
evidence of benefit.205 Therefore, evidence does not support 
the  initiation  of  statins  in  most  patients  with  chronic  HF. 
However, in patients who already receive a statin because of 
underlying CAD or/and hyperlipidaemia, a continuation of this 
therapy should be considered. 
 
 
7.5.2 Oral anticoagulants and antiplatelet therapy 
Other than in patients with AF (both HFrEF and HFpEF), there is no 
evidence that an oral anticoagulant reduces mortality/morbidity 
compared with placebo or aspirin.206,207 Studies testing the non- 
vitamin K antagonist oral anticoagulants (NOACs) in patients with 
HFrEF are currently ongoing. Patients with HFrEF receiving oral an- 
ticoagulation because of concurrent AF or risk of venous thrombo- 
embolism should continue anticoagulation. Detailed information is 
provided in Section 10.1. 
Similarly, there is no evidence on the benefits of antiplatelet 
drugs (including acetylsalicylic acid) in patients with HF without ac- 
companying CAD, whereas there is a substantial risk of gastro- 
intestinal bleeding, particularly in elderly subjects, related with 
this treatment. 
 
 
7.5.3 Renin inhibitors 
Aliskiren (direct renin inhibitor) failed to improve outcomes for pa- 
tients hospitalized for HF at 6 months or 12 months in one study208 
and is not presently recommended as an alternative to an ACEI or 
ARB. 
 
 
Treatments (or combinations of treatments) that may 
cause harm in patients with symptomatic (NYHA Class 
II – IV) heart failure with reduced ejection fraction 
 
Recommendations Class a Level b Ref c 
Thiazolidinediones (glitazones) are 
not recommended in patients with 
HF, as they increase the risk of HF 
worsening and HF hospitalization. 
 
 
III 
 
 
A 
 
 
209, 210 
NSAIDs or COX-2 inhibitors are 
not recommended in patients with 
HF, as they increase the risk of HF 
worsening and HF hospitalization. 
 
 
III 
 
 
B 
 
211– 
213 
Diltiazem or verapamil are not 
recommended in patients with 
HFrEF, as they increase the 
risk of HF worsening and HF 
hospitalization. 
 
 
III 
 
 
C 
 
 
214 
The addition of an ARB (or renin 
inhibitor) to the combination 
of an ACE-I and an MRA is not 
recommended in patients with 
HF, because of the increased 
risk of renal dysfunction and 
hyperkalaemia. 
 
 
 
III 
 
 
 
C 
 
 
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor 
blocker; COX-2 inhibitor ¼ cyclooxygenase-2 inhibitor; HF ¼ heart failure; 
HFrEF ¼ heart failure with reduced ejection fraction; MRA ¼ mineralocorticoid 
receptor antagonist; NSAIDs ¼ non-steroidal anti-inflammatory drugs. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations 
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Recommendations Class a Level b Ref c 
Secondary prevention 
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a 
ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status. 
 
I 
 
A 
 
223–226 
Primary prevention     
 
 
 
149, 156, 
227 
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA 
Class II–III), and an LVEF ≤35% despite ≥3 months of OMT, provided they are expected to survive substantially longer than one 
year with good functional status, and they have: 
 
• IHD (unless they have had an MI in the prior 40 days – see below). 
 
I 
 
I 
 
A 
 
• DCM. 
 
B 156, 157, 227 
ICD implantation is not recommended within 40 days of an MI as implantation at this time does not improve prognosis. III A 158, 228 
ICD therapy is not recommended in patients in NYHA Class IV with severe symptoms refractory to pharmacological therapy 
unless they are candidates for CRT, a ventricular assist device, or cardiac transplantation. 
 
III 
 
C 
 
229–233 
Patients should be carefully evaluated by an experienced cardiologist before generator replacement, because management goals 
and the patient’s needs and clinical status may have changed. 
 
IIa 
 
B 
 
234–238 
A wearable ICD may be considered for patients with HF who are at risk of sudden cardiac death for a limited period or as a 
bridge to an implanted device. 
 
IIb  C  239–241 
 
 
7.6 Treatments not 
recommended 
specific guideline recommendations for other therapeutic technolo- 
(believed to cause harm) in symptomatic gies, including baroreflex activation therapy,217 219,220 vagal stimulation,
218 
patients with heart failure with reduced diaphragmatic   pacing and  cardiac  contractility  modula- 
 
ejection fraction 
7.6.1 Calcium-channel blockers 
Non-dihydropyridine calcium-channel blockers (CCBs) are not in- 
dicated for the treatment of patients with HFrEF. Diltiazem and ver- 
apamil have been shown to be unsafe in patients with HFrEF.214 
There is a variety of dihydropyridine CCBs; some are known to 
increase sympathetic tone and they may have a negative safety pro- 
file in HFrEF. There is only evidence on safety for amlodipine215 and 
felodipine216 in patients with HFrEF, and they can be used only if 
there is a compelling indication in patients with HFrEF. 
 
8. Non-surgical device treatment 
of heart failure with reduced 
ejection fraction 
 
This section provides recommendations on the use of ICDs and 
CRT. Currently, the evidence is considered insufficient to support 
tion;221,222  further research is required. Implantable devices to 
monitor arrhythmias or haemodynamics are discussed elsewhere 
in these guidelines. 
 
8.1 Implantable           cardioverter-defibrillator 
A high proportion of deaths among patients with HF, especially 
those with milder symptoms, occur suddenly and unexpectedly. 
Many of these are due to electrical disturbances, including ven- 
tricular arrhythmias, bradycardia and asystole, although some are 
due to coronary, cerebral or aortic vascular events. Treatments 
that improve or delay the progression of cardiovascular disease 
will reduce the annual rate of sudden death, but they may have lit- 
tle effect on lifetime risk and will not treat arrhythmic events when 
they occur. ICDs are effective in preventing bradycardia and cor- 
recting potentially lethal ventricular arrhythmias. Some antiar- 
rhythmic drugs might reduce the rate of tachyarrhythmias and 
sudden death, but they do not reduce overall mortality and may 
increase it. 
 
R  ecommendations for implantable cardioverter-defibrillator in patients with heart failure  
   
   
      C 
I 
a 
b 
c 
AD ¼ coronary artery disease; CRT ¼ cardiac resynchronization therapy; DCM ¼ dilated cardiomyopathy; HF ¼ heart failure; ICD ¼ implantable cardioverter-defibrillator; 
HD ¼ ischaemic heart disease; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; NYHA ¼ New York Heart Association, OMT ¼ optimal medical therapy 
Class of recommendation. 
Level of evidence. 
Reference(s) supporting recommendations. 
 
. 
 
 
 
8.1.1 Secondary   prevention   of   sudden   cardiac  death 
Compared  with  amiodarone  treatment,  ICDs  reduce  mortality 
in survivors of cardiac arrest and in patients who have experi- 
enced  sustained  symptomatic ventricular arrhythmias. An ICD 
is recommended in such patients when the intent is to increase 
survival; the decision  to implant should  take into  account the 
patient’s view and their quality of life, the LVEF (survival bene- 
fit is uncertain when the LVEF is .35%) and the absence of 
other diseases likely to cause death within the following 
year.223 – 225 
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8.1.2 Primary  prevention  of  sudden  cardiac  death 
Although amiodarone may have reduced mortality in older trials of 
HF,242,243 contemporary studies conducted since the widespread 
introduction of beta-blockers suggest that it does not reduce mor- 
tality in patients with HFrEF.227,244,245 Dronedarone246,247 and class 
I antiarrhythmic agents246,248 should not be used for prevention of 
arrhythmias in this population. 
Some guideline-recommended therapies, including beta- 
blockers, MRAs, sacubitril/valsartan and pacemakers with CRT 
(CRT-Ps), reduce the risk of sudden death (see Section 7). 
An ICD reduces the rate of sudden arrhythmic death in patients 
with HFrEF.249,250 In patients with moderate or severe HF, a reduc- 
tion in sudden death may be partially or wholly offset by an increase 
in death due to worsening HF.227 In patients with mild HF (NYHA II), 
an ICD will prevent about two deaths per year for every 100 devices 
implanted.227 On average, patients with IHD are at greater risk of 
sudden death than patients with DCM and therefore, although the 
relative benefits are similar, the absolute benefit is greater in pa- 
tients with IHD.249 Patients with longer QRS durations may also re- 
ceive greater benefit from an ICD, but these patients should often 
receive a CRT device.227,251 
Two RCTs showed no benefit in patients who had an ICD im- 
planted within 40 days after a myocardial infarction.158,228 Al- 
though sudden arrhythmic deaths were reduced, this was 
balanced by an increase in non-arrhythmic deaths. Accordingly, 
an ICD is contraindicated in this time period. A wearable defibril- 
lator may be considered if the patient is deemed to be at high risk 
of ventricular fibrillation, although evidence from randomized 
trials is lacking.239 – 241 
ICD implantation is recommended only after a sufficient trial 
(minimum 3 months) of optimal medical therapy (OMT) has failed 
to increase the LVEF to .35%. However, one of the two landmark 
papers on which these recommendations are based included pa- 
tients with an LVEF .30%. Fewer than 400 patients with an LVEF 
of 30 – 35% were included in the landmark studies, and although 
there was no statistical interaction between treatment effect and 
LVEF, the evidence of benefit is less robust in this group of patients. 
Conservative programming with long delays252  between detec- 
tion and the ICD delivering therapy dramatically reduces the risk 
of both inappropriate (due to artefacts or AF) and appropriate 
but unnecessary [due to self-terminating ventricular tachycardia 
(VT)] shocks.252 – 254 
Patients with a QRS duration ≥130 ms should be considered for 
a defibrillator with CRT (CRT-D) rather than ICD. See the guideline 
on CRT for further details (Section 8.2). 
ICD therapy is not recommended in patients in NYHA Class IV 
with severe symptoms refractory to pharmacological therapy who 
are not candidates for CRT, a ventricular assist device or cardiac 
transplantation, because such patients have a very limited life ex- 
pectancy and are likely to die from pump failure. 
Patients with serious co-morbidities who are unlikely to survive 
substantially more than 1 year are unlikely to obtain substantial 
benefit from an ICD.229 – 233 
Patients should be counselled as to the purpose of an ICD, com- 
plications related to implantation and device activation (predomin- 
antly inappropriate shocks) and under what circumstances it might 
be deactivated (terminal disease) or explanted (infection, recovery 
of LV function).255 
If HF deteriorates, deactivation of a patient’s ICD may be consid- 
ered after appropriate discussion with the patient and caregiver(s). 
If the ICD generator reaches its end of life or requires explant- 
ation, it should not automatically be replaced.234 – 238 Patients should 
be carefully evaluated by an experienced cardiologist before gener- 
ator replacement. Treatment goals may have changed and the risk of 
fatal arrhythmia may be lower or the risk of non-arrhythmic death 
higher. It is a matter of some controversy whether patients whose 
LVEF has greatly improved and who have not required device ther- 
apy during the lifetime of the ICD should have another device im- 
planted.234 – 238 
Subcutaneous defibrillators may be as effective as conventional 
ICDs with a lower risk from the implantation procedure.256,257 
They may be the preferred option for patients with difficult access 
or who require ICD explantation due to infection. Patients must be 
carefully selected, as they have limited capacity to treat serious bra- 
dyarrhythmia and can deliver neither antitachycardia pacing nor 
CRT. Substantial RCTs with these devices and more data on safety 
and efficacy are awaited.258,259 
A wearable ICD (an external defibrillator with leads and elec- 
trode pads attached to a wearable vest) that is able to recognize 
and interrupt VT/ventricular fibrillation may be considered for a lim- 
ited period of time in selected patients with HF who are at high risk 
for sudden death but otherwise are not suitable for ICD implant- 
ation (e.g. those with poor LVEF after acute myocardial damage until 
LV function recovers, patients scheduled for heart transplant- 
ation).239 – 241,260 However, no prospective RCTs evaluating this de- 
vice have been reported. 
For detailed recommendations on the use/indications of ICD we 
refer the reader to the ESC/European Heart Rhythm Association 
(EHRA) guidelines on ventricular tachyarrhythmias and sudden car- 
diac death.260 
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8.2 Cardiac resynchronization therapy 
 
Recommendations for cardiac resynchronization therapy implantation in patients with heart failure 
 
Recommendations Class a Level b Ref c 
CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration ≥150 msec and LBBB QRS 
morphology and with LVEF ≤35% despite OMT in order to improve symptoms and reduce morbidity and mortality. 
 
I  A  261–272 
CRT should be considered for symptomatic patients with HF in sinus rhythm with a QRS duration ≥150 msec and non-LBBB 
QRS morphology and with LVEF ≤35% despite OMT in order to improve symptoms and reduce morbidity and mortality. 
 
IIa  B  261–272 
CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration of 130–149 msec and LBBB QRS 
morphology and with LVEF ≤35% despite OMT in order to improve symptoms and reduce morbidity and mortality. 
 
I  B  266, 273 
CRT may be considered for symptomatic patients with HF in sinus rhythm with a QRS duration of 130–149 msec and non-LBBB 
QRS morphology and with LVEF ≤35% despite OMT in order to improve symptoms and reduce morbidity and mortality. 
 
IIb  B  266, 273 
CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class who have an indication for ventricular 
pacing and high degree AV block in order to reduce morbidity.This includes patients with AF (see Section 10.1). 
 
I  A  274–277 
CRT should be considered for patients with LVEF ≤35% in NYHA Class III–IVd despite OMT in order to improve symptoms and 
reduce morbidity and mortality, if they are in AF and have a QRS duration ≥130 msec provided a strategy to ensure bi-ventricular 
capture is in place or the patient is expected to return to sinus rhythm. 
 
IIa 
 
B 
 
275, 
278–281 
Patients with HFrEF who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite OMT 
and who have a high proportion of RV pacing may be considered for upgrade to CRT.This does not apply to patients with stable HF. 
 
IIb 
 
B 
 
282 
 
CRT is contra-indicated in patients with a QRS duration < 130 msec. 
 
III 
 
A 266, 283–285 
 
AF ¼ atrial fibrillation; AV ¼ atrio-ventricular; CRT ¼ cardiac resynchronization therapy; HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection fraction; ICD ¼ 
implantable cardioverter-defibrillator; LBBB ¼ left bundle branch block; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association; OMT ¼ optimal medical 
therapy; QRS ¼ Q, R and S waves (combination of three of the graphical deflections); RV ¼ right ventricular. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
dUse judgement for patients with end-stage HF who might be managed conservatively rather than with treatments to improve symptoms or prognosis. 
 
CRT improves cardiac performance in appropriately selected pa- 
tients and improves symptoms286  and well-being286  and reduces 
morbidity and mortality.266 Of the improvement in quality-adjusted 
life-years (QALYs) with CRT among patients with moderate to se- 
vere HF, two-thirds may be attributed to improved quality of life and 
one-third to increased longevity.287 
Only the COMPANION265 and CARE-HF trials262,263 compared 
the effect of CRT to guideline-advised medical therapy. Most other 
trials have compared CRT-D to ICD, and a few have compared 
CRT-P to backup pacing. The prevention of lethal bradycardia might 
be an important mechanism of benefit shared by all pacing devices. 
In CARE-HF, at baseline, 25% of patients had a resting heart rate of 
≤60 bpm.262 – 264 If prevention of bradycardia is important, the ef- 
fect of CRT will appear greater in trials where there is no device 
in the control group. 
Most studies of CRT have specified that the LVEF should be ,35%, 
but RAFT267 and MADIT-CRT268,269 specified an LVEF ,30%, while 
REVERSE270 – 272  specified ,40% and BLOCK-HF274  ,50%. Rela- 
tively few patients with an LVEF of 35– 40% have been randomized, 
but an individual participant data (IPD) meta-analysis suggests no 
diminution of the effect of CRT in this group.266 
Not all patients respond favourably to CRT.286 Several character- 
istics predict improvement in morbidity and mortality, and the ex- 
tent of reverse remodelling is one of the most important 
mechanisms of action of CRT. Patients with ischaemic aetiology 
will have less improvement in LV function due to myocardial scar tis- 
sue, which is less likely to undergo favourable remodelling.288 Con- 
versely, women may be more likely to respond than men, possibly 
due to smaller body and heart size.273,285,289  QRS width predicts 
CRT response and was the inclusion criterion in all randomized 
trials. But QRS morphology has also been related to a beneficial re- 
sponse to CRT. Several studies have shown that patients with left 
bundle branch block (LBBB) morphology are more likely to respond 
favourably to CRT, whereas there is less certainty about patients 
with non-LBBB morphology. However, patients with LBBB morph- 
ology often have wider QRS duration, and there is a current debate 
about whether QRS duration or QRS morphology is the main pre- 
dictor of a beneficial response to CRT. Evidence from two IPD 
meta-analyses indicates that after accounting for QRS duration, 
there is little evidence to suggest that QRS morphology or aetiology 
of disease influence the effect of CRT on morbidity or mortal- 
ity.266,273 In addition, none of the landmark trials selected patients 
for inclusion according to QRS morphology, sex or ischaemic aeti- 
ology, nor were they powered for subgroup analyses. 
The Echo-CRT283,284 trial and an IPD meta-analysis266 suggest 
possible harm from CRT when QRS duration is ,130 ms, thus im- 
plantation of CRT is not recommended if QRS duration is ,130 
ms.266,283,284 
If a patient is scheduled to receive an ICD and is in sinus rhythm 
with a QRS duration ≥130 ms, CRT-D should be considered if 
QRS is between 130 and 149 ms and is recommended if QRS is 
≥150 ms. However, if the primary reason for implanting a CRT 
is for the relief of symptoms, then the clinician should choose 
CRT-P or CRT-D, whichever they consider appropriate. Clinical 
practice varies widely among countries. The only randomized trial 
to compare CRT-P and CRT-D265 failed to demonstrate a differ- 
ence in morbidity or mortality between these technologies.288 If 
the primary reason for implanting CRT is to improve prognosis, 
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then the majority of evidence lies with CRT-D for patients in 
NYHA Class II and with CRT-P for patients in NYHA Classes 
III – IV. It is unclear whether CRT reduces the need for an ICD 
(by reducing the arrhythmia burden) or increases the benefit 
from an ICD (by reducing mortality rates from worsening HF, lead- 
ing to longer exposure to the risk of arrhythmia). 
When LVEF is reduced, RV pacing may exacerbate cardiac dyssyn- 
chrony. This can be prevented by CRT, which might improve patient 
outcomes.274,275,277,290 However, a difference in outcome was not 
observed between CRT and RV pacing in a subgroup analysis of 
RAFT267 or in patients without HFrEF in BioPACE.291 On balance, 
CRT rather than RV pacing is recommended for patients with HFrEF 
regardless of NYHA class who have an indication for ventricular pa- 
cing in order to reduce morbidity, although no clear effect on mor- 
tality was observed. Patients with HFrEF who have received a 
conventional pacemaker or an ICD and subsequently develop wor- 
sening HF with a high proportion of RV pacing, despite OMT, should 
be considered for upgrading to CRT. 
Only two small trials have compared pharmacological therapy 
alone vs. CRT in patients with AF, with conflicting results. Several 
studies have indicated that CRT is superior to RV pacing in patients 
undergoing atrio-ventricular (AV) node ablation.275,277,290 How- 
ever, CRT is not an indication to carry out AV node ablation except 
in rare cases when ventricular rate remains persistently high (.110 
bpm) despite attempts at pharmacological rate control. A subgroup 
analysis of patients with AF from the RAFT study found no benefit 
from CRT-D compared with ICD, although less than half of patients 
had .90% biventricular capture.276 Observational studies report 
that when biventricular capture is ,98%, the prognosis of patients 
with CRT declines.277 Whether this association reflects a loss of re- 
synchronization (which might be remedied by device programming), 
poor placing of the LV lead (which might be avoided at implantation) 
or greater difficulty in pacing severely diseased myocardium (which 
might not be amenable to the above) is uncertain. This observation 
has not been confirmed in a randomized trial. 
Imaging tests for dyssynchrony have not yet been shown to be of 
value in selecting patients for CRT.292 Patients with extensive myo- 
cardial scar will have less improvement in LV function with CRT, but 
this is true of any treatment for HFrEF and does not reliably predict 
less clinical benefit.293 Pacing thresholds are higher in scarred myo- 
cardium and, if possible, lead placement should avoid such re- 
gions.294,295 Although patients with extensive scarring have an 
intrinsically worse prognosis, there is little evidence that they obtain 
less prognostic benefit from CRT.266 
The reader is directed to guidelines on pacing and CRT for re- 
commendations on device implantation procedures. The value of 
trying to optimize AV or VV intervals after implantation using 
echo- or electrocardiographic criteria or blood pressure response 
is uncertain, but may be considered for patients who have had a dis- 
appointing response to CRT.296,297 
 
8.3 Other   implantable   electrical   devices 
For patients with HFrEF who remain symptomatic despite OMT and do 
not have an indication for CRT, new device therapies have been pro- 
posed and in some cases are approved for clinical use in several Euro- 
pean Union (EU) countries but remain under trial evaluation. 
Cardiac contractility modulation (CCM) is similar in its mode of 
insertion to CRT, but it involves non-excitatory electrical stimula- 
tion of the ventricle during the absolute refractory period to 
enhance contractile performance without activating extra systolic 
contractions. CCM has been evaluated in patients with HFrEF in 
NYHA Classes II – III with normal QRS duration (,120 ms).221,222 
An individual patient data meta-analysis demonstrated an improve- 
ment in exercise tolerance (peak VO2) and quality of life (Minnesota 
Living with Heart Failure questionnaire). Thus CCM may be consid- 
ered in selected patients with HF. The effect of CCM on HF morbid- 
ity and mortality remains to be established. 
Most other devices under evaluation involve some modification 
of the activity of the autonomic nervous system (ANS) by targeted 
electrical stimulation.298,299 These include vagal nerve stimulation, 
spinal cord stimulation, carotid body ablation and renal denervation, 
but so far none of the devices has improved symptoms or outcomes 
in RCTs. 
Devices for remote monitoring are discussed in Section 14. 
 
 
9. Treatment of heart failure with 
preserved ejection fraction 
 
While there is clear agreement that the diagnosis of HFrEF requires 
an LVEF ,40%, the exact definition of HFpEF is less clear. Accord- 
ing to the definition provided in this document (see Section 3), the 
diagnosis of HFpEF requires an LVEF ≥50%, whereas patients with 
LVEF between 40 and 49% are considered to have HFmrEF (for de- 
tails, please refer to Section 3). Patients with HFmrEF have generally 
been included in trials of HFpEF. Accordingly, the guidance in this 
section applies to patients with both HFmrEF and HFpEF. As new 
data and analyses become available, it might be possible to make re- 
commendations for each phenotype separately. 
In clinical practice and clinical trials, compared with HFrEF patients, 
only slightly fewer patients with HFpEF and HFmrEF currently appear 
to receive diuretics, beta-blockers, MRAs and ACEIs or ARBs.166,300 – 
302 This may reflect treatment of cardiovascular co-morbidities, such 
as hypertension, CAD and AF, or extrapolation of results from trials 
conducted for these conditions showing a reduction in new-onset 
HF,127 or failure to distinguish between guideline recommendations 
for HFrEF and HFmrEF/HFpEF or a belief that existing clinical trials 
provide some evidence of benefit with these agents. 
A summary of phase II and III clinical trials of patients with HFpEF 
and HFmrEF is presented in Web Table 9.1. 
The pathophysiology underlying HFpEF and HFmrEF is heteroge- 
neous, and they are associated with different phenotypes including 
diverse concomitant cardiovascular diseases (e.g. AF, arterial hyper- 
tension, CAD, pulmonary hypertension) and non-cardiovascular 
diseases [diabetes, chronic kidney disease (CKD), anaemia, iron de- 
ficiency, COPD and obesity].303,304 Compared with HFrEF patients, 
hospitalizations and deaths in patients with HFmrEF/HFpEF are 
more likely to be non-cardiovascular.305,306 Therefore patients 
should be screened for cardiovascular and non-cardiovascular co- 
morbidities, which if present should be managed with interventions 
that have been shown to improve symptoms, well-being or out- 
come related to that co-morbidity and not to exacerbate HF (see 
Section 11). 
No treatment has yet been shown, convincingly, to reduce mor- 
bidity or mortality in patients with HFpEF or HFmrEF. However, 
since these patients are often elderly and highly symptomatic, and 
often have a poor quality of life,307 an important aim of therapy 
may be to alleviate symptoms and improve well-being.308 
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9.1 Effect of treatment on symptoms and in cardiovascular mortality.130 However, aggressive manage- 153,320 
in heart failure with preserved ejection 
fraction 
Diuretics will usually improve congestion, if present, thereby im- 
proving symptoms and signs of HF. The evidence that diuretics 
improve symptoms is similar across the spectrum of LVEF.178,179 
Evidence that beta-blockers and MRAs improve symptoms in 
these patients is lacking. There is inconsistent evidence for an im- 
provement in symptoms in those treated with ARBs (only for can- 
desartan was there an improvement in NYHA class)309,310 and 
ACEIs.311 
9.2 Effect of treatment on hospitalization 
preserved ejection fraction 
For patients in sinus rhythm, there is some evidence that nebivo- 
lol,173,312,313 digoxin,314 spironolactone301 and candesartan310 
might reduce HF hospitalizations. For patients in AF, beta-blockers 
do not appear to be effective and digoxin has not been studied. The 
evidence in support of either ARBs315 or ACEIs311 is inconclusive. 
 
9.3 Effect of treatment on mortality in 
heart failure with preserved ejection 
fraction 
Trials of ACEIs, ARBs, beta-blockers and MRAs have all failed to re- 
duce mortality in patients with HFpEF or HFmrEF. However, in old- 
er patients with HFrEF, HFpEF or HFmrEF, nebivolol reduced the 
combined endpoint of death or cardiovascular hospitalization,173,312 
with no significant interaction between treatment effect and base- 
line LVEF.313 
 
9.4 Other considerations 
 
thromboembolic events (for details, see the ESC guidelines of 
AF316]. Antiplatelet agents are ineffective for this purpose. Renal 
dysfunction, which is common in this population, may contraindicate 
or increase the risk of haemorrhage with NOACs. 
The optimal ventricular rate in patients with HFmrEF/HFpEF and 
AF is uncertain, and aggressive rate control might be deleterious. 
Whether digoxin, beta-blockers or rate-limiting CCBs, or a combin- 
ation of these, should be preferred is unknown. Verapamil or diltia- 
zem should not be combined with a beta-blocker. There are 
insufficient data to recommend ablation strategies (either pulmon- 
ary venous or AV node) for HFpEF and HFmrEF. 
Circumstantial evidence suggests that treating hypertension, of- 
ten predominantly systolic, is important in HFmrEF/HFpEF.127,317 
Diuretics, ACEIs, ARBs and MRAs all appear appropriate agents, 
but beta-blockers may be less effective in reducing SBP. A recent 
study suggests that patients with hypertension and HFpEF or 
HFmrEF should not receive an ARB (olmesartan) if they are receiv- 
ing ACEIs and beta-blockers.318 
The first-line oral hypoglycaemic drug for patients with HFpEF 
and HFmrEF should be metformin319 (see also Section 11.6). Re- 
cently, a trial of empagliflozin showed a reduction in blood pressure 
and body weight, probably by inducing glycosuria and osmotic diur- 
esis. Its use was associated with a reduction in hospitalization for HF 
ment of dysglycaemia may be harmful. 
Myocardial ischaemia may contribute to symptoms, morbidity 
and mortality and should be considered when assessing patients. 
However, there is only anecdotal evidence that revascularization 
improves symptoms or outcome. Patients with angina should follow 
the same management route as patients with HFrEF.112 
Patients with HFpEF and HFmrEF have impaired exercise toler- 
ance, commonly accompanied by an augmented blood pressure re- 
sponse to exercise and chronotropic incompetence. Combined 
endurance/resistance training appears safe for patients with HFpEF 
and HFmrEF and improves exercise capacity (as reflected by an in- 
crease in peak oxygen consumption), physical functioning score and 
diastolic  function.307,321 
 
Recommendations for treatment of patients with heart 
failure with preserved ejection fraction and heart failure 
with mid-range ejection fraction 
 
Recommendations Class a Level b Ref c 
it is recommended to screen 
patients with HFpEF or HFmrEF 
for both cardiovascular and non- 
cardiovascular comorbidities, which, 
if present, should be treated provided 
safe and effective interventions exist 
to improve symptoms, well-being 
and/or prognosis. 
 
 
 
 
I 
 
 
 
 
C 
 
Diuretics are recommended in 
congested patients with HFpEF 
or HFmrEF in order to alleviate 
symptoms and signs. 
 
 
I 
 
 
B 
 
 
178, 179 
 
HFmrEF ¼ heart failure with mid-range ejection fraction; HFpEF ¼ heart failure 
with preserved ejection fraction. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
 
 
 
10. Arrhythmias and conductance 
disturbances 
 
Ambulatory electrocardiographic monitoring can be used to investi- 
gate symptoms that may be due to arrhythmias,322 – 324 but evidence 
is lacking to support routine, systematic monitoring for all patients 
with HF to identify tachy- and bradyarrhythmias. There is no evidence 
that clinical decisions based on routine ambulatory electrocardio- 
graphic monitoring improve outcomes for patients with HF. 
Ambulatory electrocardiographic recording detects premature 
ventricular complexes in virtually all patients with HF. Episodes of 
asymptomatic, non-sustained VT are common, increasing in fre- 
quency with the severity of HF and ventricular dysfunction and indi- 
cating a poor prognosis in patients with HF, but provide little 
discrimination between sudden death or death due to progressive 
HF.316,325 Bradycardia and pauses are also commonly observed, es- 
pecially at night when sympathetic activity is often lower and para- 
sympathetic activity higher; sleep apnoea may be a trigger.326 – 328 
Pauses are associated with a poor prognosis in patients with CAD 
and left ventricular dysfunction.329 Bradyarrhythmias may make an 
important contribution to sudden death in HF.330 
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Recommendations Class a Level b Ref c 
Urgent electrical cardioversion is 
recommended if AF is thought to  
be contributing to the patient’s 
haemodynamic compromise in 
order to improve the patient clinical 
condition. 
 
 
 
I 
 
 
 
C 
 
For patients in NYHA Class IV, in 
addition to treatment for AHF, an 
intravenous bolus of amiodarone 
or, in digoxin-naïve patients, an 
intravenous bolus of digoxin should 
be considered to reduce the 
ventricular rate. 
 
 
 
IIa 
 
 
 
B 
 
 
 
348, 349 
For patients in NYHA Class I–III, a 
beta-blocker, usually given orally, is 
safe and therefore is recommended 
 
ventricular rate, provided the patient 
is euvolaemic. 
 
 
 
I 
 
 
 
A 
 
 
 
177 
For patients in NYHA Class I–III, 
digoxin, should be considered 
d 
despite beta-blockers or when beta-
blockers are not tolerated or contra-
indicated. 
 
 
 
IIa 
 
 
 
B 
 
 
 
197 
AV node catheter ablation may be 
considered to control heart rate 
and relieve symptoms in patients 
unresponsive or intolerant to 
intensive pharmacological rate and 
rhythm control therapy, accepting 
that these patients will become 
pacemaker dependent. 
 
 
 
 
IIb 
 
 
 
 
B 
 
 
 
 
290 
Treatment with dronedarone to 
improve ventricular rate control  
is not recommended due to safety 
concerns. 
 
 
III 
 
 
A 
 
 
347 
 
 
10.1 Atrial fibrillation 
AF is the most common arrhythmia in HF irrespective of concomi- 
tant LVEF; it increases the risk of thromboembolic complications 
(particularly stroke) and may impair cardiac function, leading to 
worsening symptoms of HF.316 Incident HF precipitated by AF is as- 
sociated with a more benign prognosis,331 but new-onset AF in a pa- 
tient with established HF is associated with a worse outcome, 
probably because it is both a marker of a sicker patient and because 
it impairs cardiac function.332,333 Patients with chronic HF and per- 
manent AF have a worse outcome than those in sinus rhythm, al- 
though this is largely explained by more advanced age and HF 
severity.332,333 Persistent ventricular rates .150 bpm may cause 
HFrEF that resolves with rate control or rhythm correction (‘tachy- 
cardiomyopathy’).334,335 AF should be classified and managed ac- 
cording to the current AF guidelines (i.e. first diagnosed episode, 
paroxysmal, persistent, long-standing persistent or permanent), rec- 
ognizing the uncertainty about the actual duration of the episode 
and about previous undetected episodes.316 
The following issues need to be considered in patients with HF 
presenting with AF, irrespective of LVEF, especially with a first diag- 
nosed episode of AF or paroxysmal AF:316 
 
• identification of potentially correctable causes (e.g. hypothyroid- 
ism or hyperthyroidism, electrolyte disorders, uncontrolled 
hypertension, mitral valve disease) and precipitating factors 
(e.g. recent surgery, chest infection or exacerbation of COPD/ 
asthma, acute myocardial ischaemia, alcohol binge), as this may 
determine management strategy; 
 
• assessment of ventricular rate and need for rate control; 
• evaluation of symptoms of HF and AF. 
 
For details, the reader should refer to the 2016 ESC guidelines on 
AF.316 
 
10.1.1 Prevention of atrial fibrillation in patients with heart 
failure 
Many  treatments  for  HF,  including  ACEIs,336   ARBs,337   beta- 
blockers177,338 and MRAs,339,340 will reduce the incidence of AF, 
but ivabradine may increase it.341 CRT has little effect on the inci- 
dence of AF.342 
Amiodarone will reduce the incidence of AF, induce pharmaco- 
logical cardioversion, maintain more patients in sinus rhythm after 
cardioversion and may be used to control symptoms in patients 
with paroxysmal AF if beta-blockers fail to do so.343 – 346  Amiodar- 
one should generally be restricted to short-term (,6 months) use 
in patients with paroxysmal or persistent AF to help attain sinus 
rhythm and to reduce the high rate of recurrent AF immediately 
 
with HF and AF.246,247,347 
 
10.1.2 Management of new-onset, rapid atrial fibrillation in 
patients with heart failure 
If the patient has no distressing symptoms of HF, then treatment 
 
rate control. For patients with marked congestion who nonetheless 
have few symptoms at rest, initial treatment with oral or intravenous 
(i.v.) digoxin is preferred. For patients in haemodynamic instability, 
an i.v. bolus of digoxin or amiodarone348,349 should be administered 
into a peripheral vein with extreme care to avoid extravasation into 
tissues; where uncertainty exists about venous access, amiodarone 
must not be given. Longer-term infusion of amiodarone should be 
given only by central or long-line venous access to avoid peripheral 
vein phlebitis. In patients with haemodynamic collapse, emergency 
electrical cardioversion is recommended (see also Section 12). 
 
Recommendations for initial management of a 
rapid ventricular rate in patients with heart failure and 
atrial fibrillation in the acute or chronic setting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
when ventricular rate remains high 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AF ¼ atrial fibrillation; AHF ¼ acute heart failure; AV ¼ atrio-ventricular; bpm ¼ 
beats per minute; HF ¼ heart failure; NYHA ¼ New York Heart Association. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
dThe optimal ventricular rate for patients with HF and AF has not been established, 
but the prevailing evidence suggests that strict rate control might be deleterious. A 
resting ventricular rate in the range of 60 – 100 bpm may be considered based on 
the current opinion of this Task Force,350,351 although one trial suggested that a 
resting ventricular rate of up to 110 bpm might still be acceptable, and this is 
currently recommended by the ESC guidelines on AF.198,316 This should be tested 
and refined by further research. 
 
 
10.1.3 Rate 
control 
Assessment of ventricular rate control from the radial pulse is not 
ideal, especially in patients with HF, as ventricular activation may 
not always generate a palpable pulse. Rate control should be docu- 
mented  electrocardiographically.  A  wearable  device  enables 
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ventricular rate to be assessed during rest, exercise and sleep, but 
the value of routine monitoring has not yet been established. Im- 
planted devices such as pacemakers, CRT or ICDs can also be 
used to measure ventricular rate. 
The optimal resting ventricular rate in patients with AF and HF is 
uncertain but may be between 60 – 100 bpm.350,352 – 354 One trial 
suggested that a resting ventricular rate of up to 110 bpm might still 
be acceptable,198,202 and 2016 ESC AF guidelines recommend this 
threshold as the target for rate control therapy.316 However, this 
Task Force believes that a lower rate for patients with HF may be 
preferable (60 – 100 bpm). Ventricular rates ,70 bpm are asso- 
ciated with a worse outcome.351 This may explain why beta- 
blockers titrated to guideline-target doses failed to reduce morbid- 
ity or mortality in patients with HFrEF and AF,177 and might also ex- 
plain the association between digoxin and adverse outcomes 
reported in some observational studies of AF.355 – 357 The optimal 
ventricular rate during exercise is also uncertain, but may be 
,110 bpm during light exercise.354 Beta-blockers, digoxin and their 
combination may be used to control ventricular rate.358 It is uncer- 
 
first-line agent even if it is not clear that they reduce morbidity and 
mortality in patients with AF. Beta-blockers reduce ventricular rate 
during periods of activity, while digoxin exerts a greater effect at 
night.358 Persistently high ventricular rates may indicate thyrotoxi- 
cosis or excessive sympathetic activity due to congestion, which 
might respond to diuresis. Although amiodarone and non- 
dihydropyridine CCBs can reduce ventricular rate, they have 
more adverse effects and should generally be avoided in patients 
with HFrEF and, with less certainty, in patients with HFpEF and 
HFmrEF. Rarely, ventricular rate cannot be reduced below 100 – 
110 bpm by pharmacological means alone and AV node ablation 
with ventricular pacing may be considered; in this situation, for pa- 
tients with HFrEF, CRT should be considered instead of convention- 
al RV pacing. There is little evidence, other than from registries, to 
support a strategy of AV node ablation and CRT compared with 
pharmacological therapy alone in patients with AF and a resting ven- 
tricular rate ,100 – 110 bpm (see Section 8.2).281 However, in pa- 
tients with a fast ventricular rate and intractable symptoms, AV node 
ablation may be considered. Also, if the patient is indicated for an 
ICD, AV node ablation with implantation of CRT-D may be a pre- 
ferred option, especially if the patient has moderate to severe 
symptoms. 
 
10.1.4 Rhythm 
control 
In patients with chronic HF, a rhythm control strategy (including 
pharmacological or electrical cardioversion) has not been shown to 
be superior to a rate control strategy in reducing mortality or morbid- 
ity.359 Urgent cardioversion is indicated only if the AF is life threaten- 
ing, otherwise both HF and ventricular rate should be controlled 
prior to cardioversion. A rhythm control strategy is probably best re- 
served for patients with a reversible secondary cause of AF (e.g. 
hyperthyroidism) or an obvious precipitant (e.g. recent pneumonia) 
and in patients with troublesome symptoms due to AF after optimiza- 
tion of rate control and HF therapy. The use of class I antiarrhythmic 
agents and dronedarone increases morbidity and mortality in patients 
with HF and AF and should be avoided.246,247,347 Amiodarone will 
cause some patients with chronic AF to revert to sinus rhythm, 
may reduce symptomatic paroxysms of AF and will help maintain 
patients  in  sinus  rhythm  after  spontaneous  or  electrical 
cardioversion.343 – 346 When used, the need for continued administra- 
tion of amiodarone should be regularly reviewed and justified. 
The safety and efficacy of catheter ablation in the atria and pul- 
monary veins (PV) as a rhythm control strategy in HF is at present 
uncertain except for tachycardia induced cardiomyopathy.316 One 
small study suggested that AF ablation was superior to AV node ab- 
lation and CRT.360 Another study, including 203 patients with per- 
sistent AF, HF and an ICD or CRT device, showed that AF ablation 
was superior to amiodarone in correcting AF, and this was asso- 
ciated with fewer hospitalizations for HF and lower mortality. 
Two small studies of AF ablation compared with rate control met 
with mixed success in terms of procedural complications and suc- 
cess in improving symptoms.278,279 The most recent evidence 
from a meta-analysis that included 914 patients suggests an encour- 
aging success rate of PV ablation of AF in patients with LV dysfunc- 
tion, with improvements in LVEF and functional capacity.361 These 
results need to be confirmed in ongoing RCTs such as CASTLE 
AF,362  AMICA and CABANA. 
 
 
Recommendations for a rhythm control management 
strategy in patients with atrial fibrillation, symptomatic 
heart failure (NYHA Class II – IV) and left ventricular 
systolic dysfunction and no evidence of acute 
decompensation 
 
Recommendations Class a Level b Ref c 
Electrical cardioversion or 
pharmacological cardioversion with 
amiodarone may be considered in 
patients with persisting symptoms 
and/or signs of HF, despite OMT and 
adequate control of ventricular rate, 
to improve clinical/symptomatic 
status. 
 
 
 
 
IIb 
 
 
 
 
B 
 
 
 
 
344 
AF ablation may be considered in 
order to restore sinus rhythm to 
improve symptoms in patients with 
persisting symptoms and/or signs 
of HF, despite OMT and adequate 
control of ventricular rate, to 
improve clinical/symptomatic status. 
 
 
 
IIb 
 
 
 
B 
 
 
 
279, 363 
Amiodarone may be considered 
prior to (and following) successful 
electrical cardioversion to maintain 
sinus rhythm. 
 
 
IIb 
 
 
B 
 
 
342, 360 
Dronedarone is not recommended 
because of an increased risk 
of hospital admissions for 
cardiovascular causes and an 
increased risk of premature death in 
NYHA Class III–IV patients. 
 
 
 
III 
 
 
 
A 
 
 
 
247, 347 
Class I antiarrhythmic agents are 
not recommended because of an 
increased risk of premature death. 
 
III 
 
A 
 
248, 364, 
365 
 
AF ¼ atrial fibrillation; HF ¼ heart failure; NYHA ¼ New York Heart Association, 
OMT ¼ optimal medical therapy. 
Patients should generally be anticoagulated for 6 weeks prior to electrical 
cardioversion. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
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10.1.5 Thromboembolism prophylaxis 
Patients with HF and AF should generally be anticoagulated and the 
balance of benefit and risk of bleeding (using CHA2DS2-VASc and 
HAS-BLED scores; for details, please see Web Tables 10.1 and 
10.2.) should be evaluated as recommended in the ESC guidelines 
for AF.316 A substantial proportion of patients with HF will have 
both benefit and risk scores ≥3, indicating that careful consider- 
ation should be given before prescribing an oral anticoagulant and 
that regular review is subsequently needed (and correctable risk 
factors for bleeding addressed) if an oral anticoagulant is given. 
NOACs are preferred for patients with HF with non-valvular AF, as 
NOACs compared with vitamin K antagonists seem to be at least 
similarly effective and even safer (less intracranial haemorrhage) in 
patients with HF than in subjects without HF,316,366,367 although con- 
cerns exist about their safety in older patients with HF and poor renal 
function368,369 [for a detailed description of the interaction between 
NOAC and renal function, see Heidbuchel et al.370]. In patients with 
HF and AF who have mechanical heart valves or at least moderate mi- 
tral stenosis, only oral vitamin K antagonists should be used for pre- 
vention of thromboembolic stroke.370 
The dabigatran dose should be reduced to 110 mg b.i.d. when cre- 
atinine clearance is 30 – 49 mL/min, rivaroxaban to 15 mg daily and 
edoxaban to 30 mg daily when creatinine clearance is 30 – 50 mL/ 
min and apixaban to 2.5 mg twice daily if a patient has two or 
more of the following: age ≥80 years, serum creatinine ≥1.5 mg/ 
dL or body weight ≤60 kg.370 – 375 The summary of the recommen- 
dations for the prevention of thromboembolism in patients with 
symptomatic HF and paroxysmal or persistent/permanent AF is 
presented in the recommendations table. For further details, please 
refer to the recent ESC guidelines on AF.316 
A left atrial occlusion device could be considered in a patient with 
AF as an alternative to an oral anticoagulant who is at high-risk both 
of thromboembolism and of bleeding in order to avoid the risk of 
haemorrhage due to anticoagulation risk.381,382 
 
Recommendations for the prevention of thrombo-embolism in patients with symptomatic heart failure (NYHA Class II – 
IV) and paroxysmal or persistent/permanent atrial fibrillation 
 
Recommendations Class a Level b Ref c 
The CHA2DS2-VASc and HAS-BLED scores are recommended tools in patients with HF for the estimation of the risk of 
thromboembolism and the risk of bleeding associated with oral anticoagulation, respectively. 
 
I 
 
B 
 
376, 377 
An oral anticoagulant is recommended to prevent thrombo-embolism for all patients with paroxysmal or persistent/permanent   
AF and a CHA2DS2-VASc score ≥2, without contra-indications, and irrespective of whether a rate or rhythm management strategy 
is used (including after successful cardioversion). 
 
I 
 
A 
 
372–375, 
378, 379 
NOAC treatment is contra-indicated in patients with mechanical valves or at least moderate mitral stenosis. III B 380 
In patients with AF of ≥48 h duration, or when the duration of AF is unknown, an oral anticoagulant is recommended at a 
therapeutic dose for ≥3 weeks prior to electrical or pharmacological cardioversion. 
 
I  B  
Intravenous heparin or LMWH and TOE quided strategy is recommended for patients who have not been treated with an 
anticoagulant dose for ≥3 weeks and require urgent electrical or pharmacological cardioversion for a life threatening arrhythmia. 
 
I  C  
Combination of an oral anticoagulant and an antiplatelet agent is not recommended in patients with chronic (>12 months 
after an acute event) coronary or other arterial disease, because of a high-risk of serious bleeding. Single therapy with an oral 
anticoagulant is preferred after 12 months. 
 
III 
 
C  
For patients with HF and non-valvular AF eligible for anticoagulation based on a CHA2DS2-VASc score, NOACs rather than 
warfarin should be considered for anticoagulation as NOACs are associated with a lower risk of stroke, intracranial haemorrhage 
and mortality, which outweigh the increased risk of gastrointestinal haemorrhage. 
 
IIa 
 
B 
 
367 
 
AF ¼ atrial fibrillation; CHA2DS2-VASc ¼ Congestive heart failure or left ventricular dysfunction, Hypertension, Age ≥ 75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, 
Age 65 – 74, Sex category (female); HAS-BLED ¼ Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, 
Elderly (.65 years), Drugs/alcohol concomitantly (1 point each); HF ¼ heart failure; LMWH ¼ low molecular weight heparin; NOAC ¼ non-vitamin K antagonist oral 
anticoagulant; NYHA ¼ New York Heart Association; TOE ¼ transoesophageal echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
 
 
10.2 Ventricular 
arrhythmias 
The initial management of asymptomatic ventricular arrhythmias 
is correction of electrolyte abnormalities, particularly low serum 
potassium and magnesium, withdrawal of agents that might 
provoke arrhythmias and, in patients with HFrEF, optimization 
of pharmacological therapy with ACEIs, beta-blockers and 
MRAs and sacubitril/valsartan, which all reduce the risk of sudden 
death.174,177,383,384 
The clinical relevance of myocardial ischaemia for the provoca- 
tion of ventricular arrhythmias is uncertain, although anecdotal 
cases of ischaemia-induced arrhythmias exist. Randomized trials of 
 
revascularization for patients with HFrEF have not reduced overall 
mortality,107,385 even in subgroups of patients with angina or myo- 
cardial ischaemia,115,386 but further analysis did suggest a reduction 
in sudden deaths.387 
Amiodarone (often in combination with a beta-blocker) may be 
used to suppress symptomatic ventricular arrhythmias, but it may 
adversely affect prognosis, especially in patients with more severe 
HF.227,244 Other antiarrhythmic drugs should be avoided.247 Trans- 
catheter radiofrequency modification of the arrhythmogenic sub- 
strate may reduce the number of appropriate ICD discharges 
and may be used to terminate arrhythmic storm in patients with 
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HF and frequent, recurrent ventricular tachyarrhythmias and 
therefore should be considered in such patients. Seeking the 
advice of the members of the HF Team with expertise in electro- 
physiology is recommended in patients with recalcitrant ventricu- 
lar arrhythmias. For further details we refer the reader to the ESC/ 
EHRA guidelines on ventricular arrhythmias and sudden cardiac 
death.260 
 
 
Recommendations for the management of ventricular 
tachyarrhythmias in heart failure 
 
Recommendations Class a Level b Ref c 
Potential aggravating/precipitating 
factors (e.g. low serum potassium/ 
magnesium, ongoing ischaemia) 
should be sought and corrected in 
patients with ventricular arrhythmias. 
 
 
IIa 
 
 
C 
 
Treatment with beta-blocker, MRA 
and sacubitril/valsartan reduces the 
risk of sudden death and is 
recommended for patients with 
HFrEF and ventricular arrhythmias 
(as for other patients)(see Section 7). 
 
 
 
I 
 
 
 
A 
 
 
162, 
170–175 
Implantation of an ICD or CRT-D 
device is recommended for selected 
patients with HFrEF (see Section 8). 
 
I 
 
A 
 
223–226, 
388 
Several strategies should be 
considered to reduce 
recurrent symptomatic arrhythmias 
in patients with an ICD 
(or in those who are not eligible  
for ICD), including attention to risk 
factors and optimal pharmacological 
treatment of HF, amiodarone, 
catheter ablation and CRT. 
 
 
 
 
IIa 
 
 
 
 
C 
 
Routine use of antiarrhythmic 
agents is not recommended in 
patients with HF and asymptomatic 
ventricular arrhythmias because 
of safety concerns (worsening HF, 
proarrhythmia, and death). 
 
 
 
III 
 
 
 
A 
 
 
247, 248, 
364, 365 
 
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor 
blocker; CRT ¼ cardiac resynchronization therapy; CRT-D ¼ defibrillator with 
cardiac resynchronization therapy; HF ¼ heart failure; HFrEF ¼ heart failure with 
reduced ejection fraction; ICD ¼ implantable cardioverter defibrillator; MRA ¼ 
mineralocorticoid receptor antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
 
 
 
10.3 Symptomatic bradycardia, pauses 
and atrio-ventricular block 
The ESC Guidelines on Pacing and CRT recommended intervention 
when pauses exceed 6 s, even when this is not associated with symp- 
toms.389 However, these recommendations were generated mainly 
for patients without obvious myocardial dysfunction, and shorter 
pauses might require intervention in patients with HFrEF.329 If 
pauses .3 s are identified on electrocardiographic monitoring, 
 
or  reduced  in  dose,  starting  with  rate-limiting  CCBs  then 
amiodarone, digoxin and ivabradine. For patients in AF, a reduction 
in the dose of beta-blockers allowing the daytime resting ventricular 
rate to rise to 70 – 90 bpm may be considered, since evidence that 
beta-blockers improve outcome in patients with AF is lacking.177 For 
patients with pauses but in sinus rhythm, a reduction in the dose of 
beta-blockers should be avoided unless the pauses are symptomatic, 
prolonged or frequent, in which case the relative merits of dose re- 
duction, beta-blocker withdrawal and (biventricular) pacing may be 
considered. However, evidence is lacking to support a strategy of 
pacing solely to permit initiation or titration of beta-blocker therapy 
in the absence of a conventional pacing indication; this strategy is not 
recommended. For patients with HFrEF and high-degree AV block, 
CRT is preferred over RV pacing (Section 8.2). When the cause of 
bradycardia or pauses is sinus node disease with intact AV conduc- 
tion, then therapeutic strategies that avoid inducing ventricular dys- 
synchrony are preferred, although clinical trial evidence to support 
this expert opinion for patients with HF is sparse. For other pacing 
indications, please consult the ESC Guidelines on Pacing and 
CRT.389 
 
 
Recommendations for the management of 
bradyarrhythmias in heart failure 
 
Recommendations Class a Level b Ref c 
When pauses >3 seconds are 
 
bradycardia is symptomatic and the 
resting ventricular rate is <50 bpm 
in sinus rhythm or <60 bpm in AF,  
it should be considered whether 
there is need for any rate limiting 
medications prescribed; for patients 
in sinus rhythm beta-blockers should 
be reduced in dose or withdrawn 
only as a last resort. 
 
 
 
 
 
IIa 
 
 
 
 
 
C 
 
For patients with symptomatic, 
prolonged or frequent pauses 
despite adjustment of rate limiting 
medication, either beta-blocker 
withdrawal or pacing may be 
 
 
 
IIb 
 
 
 
C 
 
Pacing solely to permit initiation or 
titration of beta-blocker therapy in 
the absence of a conventional pacing 
indication is not recommended. 
 
 
III 
 
 
C 
 
In patients with HFrEF who require 
pacing and who have high degree AV 
block, CRT rather than RV pacing is 
recommended. 
 
 
I 
 
 
A 
 
274, 275, 
290 
In patients with HFrEF who require 
pacing who do not have high degree 
AV block, pacing modes that avoid 
inducing or exacerbating ventricular 
dyssynchrony should be considered. 
 
 
IIa 
 
 
C 
 
 
AF ¼ atrial fibrillation; AV ¼ atrio-ventricular; bpm ¼ beats per minute; CRT ¼ 
cardiac resynchronization therapy; ECG ¼ electrocardiogram; HFrEF ¼ heart 
failure with reduced ejection fraction; RV ¼ right ventricular. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
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1. interfere  with  the  diagnostic  process  of  HF  (e.g. COPD  as  a 
potentially confounding cause of dyspnoea).390, 391 
2. aggravate HF symptoms and further impair quality of life.391, 392 
3. contribute to the burden of hospitalizations and mortality,393  as the 
main cause of readmissions at 1 and 3 months.394 
4. may affect the use of treatments for HF (e.g. renin–angiotensin 
system inhibitors contra-indicated in some patients with severe renal 
dysfunction or beta-blockers relatively contra-indicated in asthma).395, 396 
5. evidence base for HF treatment is more limited as co-morbidities were 
 
is therefore often lacking in the presence of co-morbidities. 
6. drugs used to treat co-morbidities may cause worsening HF (e.g. 
NSAIDs given for arthritis, some anti-cancer drugs).397 
7. interaction between drugs used to treat HF and those used to treat 
 
occurrence of side effects (e.g. beta-blockers for HFrEF and beta- 
agonists for COPD and asthma).391, 395, 396 
 
 
11. Co-morbidities 
 
11.1. Heart failure and co-morbidities 
Co-morbidities are of great importance in HF (Table 11.1) and may 
affect the use of treatments for HF (e.g. it may not be possible to use 
renin – angiotensin system inhibitors is some patients with severe re- 
nal dysfunction) (see Section 7). The drugs used to treat co- 
morbidities may cause worsening of HF (e.g. NSAIDs given for arth- 
ritis, some anti-cancer drugs) (see Section 7). Management of co- 
morbidities is a key component of the holistic care of patients 
with HF (see Section 14). Many co-morbidities are actively managed 
by specialists in the field of the co-morbidity, and these physicians 
will follow their own specialist guidelines. The current guidelines 
will identify where the presence of HF should change the way a co- 
morbidity would normally be treated. This may be because either 
safety or efficacy may be different in the presence of HF (or may sim- 
ply be unknown) or because of evidence of particular effects in an 
HF population, either beneficial or detrimental. HFpEF has an even 
higher prevalence of co-morbidities compared with HFrEF, and 
many of these may be instrumental in the progression of this 
syndrome.398 
 
11.2 Angina and coronary artery disease 
11.2.1 Pharmacological management 
Beta-blockers, and in selected patients ivabradine,180 are effective 
agents for angina control, as well as an essential component of 
HFrEF therapy. In HFpEF patients, they may also be used for angina 
relief, although this has never been formally tested. In the SIGNIFY 
trial in patients with activity-limiting angina without HF, ivabradine 
increased the risk of death from cardiovascular causes or non-fatal 
myocardial infarction and therefore is not recommended in this 
setting.399 
Trimetazidine has been shown to exert some beneficial effect as 
an add-on to beta-blockers in patients with HF and angina.400 – 406 
There are data suggesting that it may improve NYHA functional 
capacity, exercise duration and LV function in patients with 
HFrEF.402 – 406 Certain other effective anti-anginal drugs have 
been studied in sizeable numbers of HFrEF/LV dysfunction patients 
and shown to be safe [e.g. amlodipine,215,407 nicorandil408 and ni- 
trates183,184,409]. The safety of other anti-anginal agents in HFrEF, 
such as ranolazine, is uncertain, while other drugs, specifically dil- 
tiazem and verapamil, are thought to be unsafe in patients with 
HFrEF (although they may be used in HFpEF).214 Dihydropyridine 
CCBs may all increase sympathetic tone, and their safety in 
HFrEF [except amlodipine215 and felodipine216] and HFpEF is 
uncertain. 
 
11.2.2 Myocardial revascularization 
For indications for invasive coronary angiography in patients with 
HF, please refer to Section 5.8. 
Percutaneous and surgical revascularization are complementary 
approaches for symptomatic relief of angina in HFpEF, but whether 
these interventions improve outcomes is not entirely clear. Recent 
ESC guidelines on myocardial revascularization recommended 
coronary  artery  bypass  grafting  (CABG)  for  patients  with 
 
 
Table 11.1    Importance of co-morbidities in patients 
with heart failure 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        H 
h 
a 
F ¼ heart failure; COPD ¼ chronic obstructive pulmonary disease; HFrEF ¼ 
eart failure with reduced ejection fraction; NSAIDs ¼ non-steroidal 
nti-inflammatory drugs. 
 
 
 
 
significant left main stenosis and left main equivalent (proximal 
stenosis of both the left anterior descending and left circumflex ar- 
teries) to improve prognosis.112,113 However, one needs to be 
aware of a lack of studies including patients who have well-defined 
HF, therefore this recommendation is solely based on expert opin- 
ion. On the basis of the results of the STICH trial [which excluded 
patients with left main disease and Canadian Cardiovascular Soci- 
ety (CCS) angina classes III – IV], CABG is also recommended in pa- 
tients with HFrEF, significant CAD (left anterior descending artery 
or multivessel disease) and LVEF ≤35% to reduce death and hos- 
pitalization for cardiovascular causes.385 Patients with .10% dys- 
functional but viable LV myocardium may be more likely to benefit 
from myocardial revascularization (and those with ≤10% are less 
likely to benefit), although this approach to patient selection for 
revascularization is unproven. In the STICH trial, neither the pres- 
ence of viability nor the severity of LV remodelling identified those 
who benefited from CABG in terms of a reduction in mortality.118 
For the assessment of techniques to assess myocardial viability, 
please refer to Section 5. Post hoc analyses from the STICH trial 
revealed that the presence of inducible myocardial ischaemia (ei- 
ther on radionuclide stress test or dobutamine stress echocardio- 
gram) or angina does not identify those with worse prognosis and 
greater benefit from CABG over OMT.115,386 However, CABG 
does improve angina to a greater extent than medical therapy 
alone. 
The choice between CABG and PCI should be made by the Heart 
Team after careful evaluation of the patient’s clinical status and cor- 
onary anatomy, expected completeness of revascularization, coex- 
isting valvular disease and co-morbidities. 
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Recommendations Class a Level b Ref c 
Step 1 
  I  A  167–173 
Step 2: on top of beta-blocker or if a beta-blocker is not tolerated 
Ivabradine should be considered as an anti-anginal drug in suitable HFrEF patients (sinus rhythm and HR ≥70 bpm) as per 
recommended HFrEF management. 
 
IIa 
 
B 180, 410, 411 
Step 3: For additional angina symptom relief – except from any combination not recommended 
 
A short-acting oral or transcutaneous nitrate should be considered (effective anti-anginal treatment, safe in HF).  IIa  A 183, 184, 409 
A long acting oral or transcutaneous nitrate should be considered (effective anti-anginal treatment, not extensively studied in HF). IIa B 183, 184 
Trimetazidine may be considered when angina persists despite treatment with a beta-blocker (or alternative) to relieve angina 
(effective anti-anginal treatment, safe in HF). 
 
IIb 
 
A 
 
400–403 
Amlodipine may be considered in patients unable to tolerate a beta-blocker to relieve angina (effective anti-anginal treatment, safe in HF). IIb B 215, 407 
Nicorandil may be considered in patients unable to tolerate a beta-blocker to relieve angina (effective anti-anginal treatment, 
but safety in HF uncertain). 
 
IIb  C  
Ranolazine may be considered in patients unable to tolerate a beta-blocker to relieve angina (effective anti-anginal treatment, but 
safety in HF uncertain). 
 
IIb  C  
Step 4: Myocardial revascularization 
 
Myocardial revascularization is recommended when angina persists despite treatment with anti-angina drugs. 
 
I 
 
A 385, 412, 413 
Alternatives to myocardial revascularization: combination of ≥3 antianginal drugs (from those listed above) may be considered 
when angina persists despite treatment with beta-blocker, ivabradine and an extra anti-angina drug (excluding the combinations 
not recommended below). 
 
IIb 
 
C  
The following are NOT recommended: 
(1) Combination of any of ivabradine, ranolazine, and nicorandil because of unknown safety. 
(2) Combination of nicorandil and a nitrate (because of lack of 
   
III 
III 
C 
C 
Diltiazem and verapamil are not recommended because of their negative inotropic action and risk of worsening HF. III C 214 
 
 
 
Recommendations for the treatment of stable angina pectoris with symptomatic (NYHA Class II-IV) heart failure with 
reduced ejection fraction112,113 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      b 
a 
b 
c 
pm ¼ beats per minute; HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection fraction; NYHA ¼ New York Heart Association. 
Class of recommendation. 
Level of evidence. 
Reference(s) supporting recommendations. 
 
 
 
 
11.3 Cachexia and sarcopenia (for frailty, 
please refer to Section 14) 
Cachexia is a generalized wasting process affecting all body com- 
partments [i.e. lean tissue (skeletal muscle), fat tissue (energy re- 
serves) and bone tissue (osteoporosis)]. It may occur in 5 – 15% of 
patients with HF, especially those with HFrEF, and more advanced 
disease status.414 – 416 This serious complication is associated with 
more severe symptoms and reduced functional capacity, more fre- 
quent hospitalization and decreased survival. Cachexia in HF can be 
diagnosed and defined as involuntary non-oedematous weight loss 
≥6% of total body weight within the previous 6 – 12 months.414 – 417 
The causes are multifactorial, and in individual patients they are 
difficult to determine. These may include pro-inflammatory immune 
activation, neurohormonal derangements, poor nutrition and mal- 
absorption, impaired calorie and protein balance, anabolic hormone 
resistance, reduced anabolic drive, prolonged immobilization and 
physical deconditioning, together characterized by catabolic/anabol- 
ic imbalance.418 Skeletal muscle wasting, when associated with im- 
paired mobility and symptoms (termed sarcopenia or myopenia), 
occurs in 30 – 50% of patients with HFrEF.419  In its most severe 
form it is associated with frailty and poor morbidity and mortality.420 
Potential treatments may include appetite stimulants, exercise 
training120 and anabolic agents, including testosterone, in combin- 
ation  with   the  application  of  nutritional   supplements   and 
anti-catabolic interventions, although none is of proven benefit 
and their safety is unknown.421 
 
11.4 Cancer 
Certain chemotherapeutic agents can cause (or aggravate) LV sys- 
tolic dysfunction and HF. The best recognized of these are the 
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anthracyclines (e.g. doxorubicin), trastuzumab and tyrosine kinase 
inhibitors.397,422 A recent Cochrane review found that dexrazoxane 
may confer some cardioprotection in patients receiving anthracy- 
clines.423 Pre- and post-evaluation of LVEF, if available with myocar- 
dial strain imaging, is essential in patients receiving cardiotoxic 
chemotherapy, as detailed elsewhere.397,422 A risk score for identi- 
fying women with breast cancer at risk of developing HF during tras- 
tuzumab therapy has been developed based on age, chemotherapy 
details, baseline cardiovascular status and other co-morbidities, and 
may be helpful.424 Chemotherapy should be discontinued and 
HFrEF therapy commenced in patients developing moderate to se- 
vere LV systolic dysfunction. If LV function improves, the risks and 
benefits of further chemotherapy need to be reconsid- 
ered.397,425,426 Mediastinal irradiation can also lead to a variety of 
long-term cardiac complications. Cardiac biomarkers (NPs and tro- 
ponins) can be used to identify patients at higher risk of cardiotoxi- 
city and may be helpful in monitoring the use and dosing of 
cardiotoxic cytotoxics.397,425,426 
 
 
11.5 Central nervous system (including 
depression, stroke and autonomic 
dysfunction) 
Stroke and HF commonly coexist because of an overlap of shared 
risk factors. Both contribute to a worse prognosis. Stroke may 
make self-care more difficult for the HF patient. Management of 
high-risk stroke patients may require balancing the risk of anticoagu- 
lant and antiplatelet therapies. 
Autonomic dysfunction is common in HFrEF, especially when se- 
vere.427 Combined with low blood pressure, it can make fainting and 
injuries more likely and can interfere with optimal dosing of beta- 
blockers, ACEIs, ARBs and MRAs. Diuretic dosage may be reduced 
to reduce the severity of postural hypotension. 
Depression is common and is associated with worse clinical sta- 
tus and a poor prognosis in HF.428 – 430 It may also contribute to 
poor adherence and social isolation. A high index of suspicion is 
needed to make the diagnosis, especially in the elderly. Routine 
screening using a validated questionnaire is good practice. Until 
now, the Beck Depression Inventory (BDI) and Cardiac Depression 
Scale have been formally validated as reliable tools for the assess- 
ment of depressive mood in patients with HF,431,432 but other ques- 
tionnaires have been broadly used in this group of patients (e.g. 
Geriatric Depression Scale, Hamilton Depression Scale, Hospital 
Anxiety and Depression Scale). 
Psychosocial intervention and pharmacological treatment are 
helpful, as well as exercise training, in patients with HFrEF and 
depression.433 Cognitive behavioural therapy delivered in pa- 
tients with HF and major depression beyond standard care 
and a structured education programme were able to reduce 
depression severity, anxiety and fatigue symptoms, as well as 
improve social functioning and mental and HF-related quality 
of life.434 
Selective serotonin reuptake inhibitors are thought to be safe, al- 
though the Sertraline Antidepressant Heart Attack Randomized 
Trial did not confirm that sertraline provides a greater reduction 
in depressive symptoms or improvement in cardiovascular status 
compared with placebo in HFrEF patients, but this trial was not 
powered enough to prove the latter.435 Similarly, escitalopram 
had no effect on either depression or clinical outcomes during the 
24-month follow-up as compared with placebo in patients with 
HFrEF and depression. Importantly, tricyclic antidepressants should 
be avoided, because they may cause hypotension, worsening HF and 
arrhythmias.429,435 
 
11.6 Diabetes 
Dysglycaemia and diabetes are very common in HF, and diabetes is 
associated with poorer functional status and worse prognosis. In pa- 
tients with HFrEF, interventions that reduce morbidity and mortality 
confer similar benefit in the presence or absence of diabetes.320 For 
instance, beta-blockers improve outcome similarly, whether or not 
the patient has diabetes, although different beta-blockers may vary 
in their effects on glycaemic indices.436 
Whether strict glycaemic control alters the risk of cardiovascular 
events in patients with HF is uncertain.437 Among patients with HF 
who have not been treated for diabetes, higher HbA1c is associated 
with greater risk of cardiovascular events,438,439 but this may not be 
the case once treatment for diabetes has been commenced.439 
In patients with diabetes and HF, glycaemic control should be im- 
plemented gradually and moderately, giving preference to those 
drugs, such as metformin, that have been shown to be safe and ef- 
fective. In contrast to what was previously believed, metformin is 
safe to use in patients with HFrEF, and it should be the treatment 
of choice in patients with HF440,441 but is contraindicated in patients 
with severe renal or hepatic impairment, because of the risk of lactic 
acidosis. 
Insulin is required for patients with type 1 diabetes and to treat 
symptomatic hyperglycaemia in patients with type 2 diabetes and 
pancreatic islet b cell exhaustion. However, insulin is a powerful 
sodium-retaining hormone, and when combined with a reduction 
in glycosuria, may exacerbate fluid retention, leading to HF wor- 
sening. Sulphonylurea derivatives have also been associated with 
an increased risk of worsening HF and should be used with 
caution. 
Thiazolidinediones (glitazones) cause sodium and water 
retention and increased risk of worsening HF and hospitalization 
and are not recommended in patients with HF.209,210 
Dipeptidylpeptidase-4 inhibitors (DPP4is; gliptins), which increase 
incretin secretion, thereby stimulating insulin release, and long- 
acting glucagon-like peptide 1 (GLP-1) receptor agonists, which 
act as incretin mimetics, improve glycaemic indices but do not re- 
duce and may increase the risk of cardiovascular events and wor- 
sening HF.320,442,443 Importantly, there are no data on the safety of 
gliptins and GLP-1 analogues in patients with HF. 
Recently, empagliflozin, an inhibitor of sodium-glucose co- 
transporter 2, reduced hospitalization for HF and mortality, but 
not myocardial infarction or stroke, in patients with diabetes at 
high cardiovascular risk, some of whom had HF.130 In the absence 
of other studies with drugs from this group, the results obtained 
with empaglifozin cannot be considered as a proof of a class 
effect. 
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As glycaemic derangement progresses, the judgement on gly- 
caemic control should be made according to cardiac conditions, 
and if the new anti-diabetic drugs are to be prescribed, they have 
to be closely monitored by an HF team. 
 
11.7 Erectile dysfunction 
Erectile dysfunction is a common and important component of qual- 
ity of life in men with HF.444,445 Its treatment should include optimal 
The management of acute hyperkalaemia (.6.0 mmol/L) may re- 
quire a short-term cessation of potassium-retaining agents and 
RAAS inhibitors, but this should be minimized and RAAS inhibitors 
should be carefully reintroduced as soon as possible while monitor- 
ing potassium levels. A Cochrane review452 found no trial evidence 
of major outcome benefits for any emergency therapy regimen for 
hyperkalaemia. Two new potassium binders (patiromer and sodium 
zirconium cyclosilicate) are currently under consideration for regu- 
453,454 
latory approval. Initial results from patients with HF are avail- 
therapies for underlying cardiovascular diseases and other interfer- 
ing co-morbidities (e.g. diabetes) and amelioration of anxiety and 
depressive symptoms. Some drugs applied for HF therapy (e.g. thia- 
zide diuretics, spironolactone and beta-blockers) may augment 
erectile dysfunction.444,445 Phosphodiesterase type 5 inhibitors 
(PDE5Is) have been shown to have favourable haemodynamic and 
anti-remodelling effects and to improve exercise capacity and qual- 
ity of life in patients with HFrEF,446,447 but they are contraindicated 
in patients taking nitrates. 
 
11.8 Gout and 
arthritis 
Hyperuricaemia and gout are common in HF and may be caused or 
aggravated by diuretic treatment. Hyperuricaemia is associated with 
a worse prognosis in HFrEF.448 The current European League 
Against Rheumatism (EULAR) guideline for the management of 
gout recommends that urate-lowering therapy (ULT) is indicated 
in patients with recurrent acute flares, arthropathy, tophi or radio- 
graphic changes of gout, aiming to maintain a serum urate level be- 
low the saturation point for monosodium urate [,357 mmol/L 
(,6  mg/dL)].449 
Xanthine oxidase inhibitors (allopurinol, oxypurinol) may be used 
to prevent gout, although their safety in HFrEF is uncertain.450 Gout 
attacks are better treated with colchicine rather than with NSAIDs 
able and confirm the efficacy of these therapies in reducing serum 
potassium455 and preventing recurrent hyperkalaemia in patients 
with HF and CKD in the context of treatment with RAAS 
inhibitors.456 
 
 
11.10 Hyperlipidaemia 
Elevated low-density lipoprotein cholesterol is uncommon in 
HFrEF; patients with advanced HFrEF often have low concentrations 
of low-density lipoprotein, which is associated with a worse progno- 
sis. Rosuvastatin did not reduce the primary composite mortality/ 
morbidity endpoints in two large RCTs in patients with HF with 
or without IHD, but it also did not increase risk, and may have re- 
duced, hospitalizations.205,457 Therefore there is no evidence to rec- 
ommend the initiation of statins in most patients with HF. However, 
in patients who are already receiving a statin for CAD, a continu- 
ation of this therapy may be considered. 
 
 
11.11 Hypertension 
Hypertension is associated with an increased risk of developing HF; 
antihypertensive therapy markedly reduces the incidence of HF 
(with an exception of a-adrenoceptor blockers, which are less ef- 
458 
(although colchicine should not be used in patients with very severe fective than other antihypertensives in preventing HF). A recent 
renal dysfunction and may cause diarrhoea). Intra-articular corticos- 
teroids are an alternative for monoarticular gout, but systemic corti- 
costeroids cause sodium and water retention. 
Arthritis is a common co-morbidity and is a common cause of 
prospective cohort study documented that in a population with in- 
cident HF, higher baseline systolic, diastolic and pulse pressure levels 
were associated with a higher rate of adverse events, which further 
supports the importance for optimized blood pressure control in 
459 
both self-taken and prescribed drugs that can worsen renal function this population. Blood pressure control is an element of the hol- 
and HF, especially NSAIDs. Rheumatoid arthritis is associated with 
an increased risk of HFpEF. The safety of disease-modifying drugs 
commonly given to patients with rheumatoid arthritis has not 
been established in HF. 
 
11.9     Hypokalaemia   and   hyperkalaemia 
Both hypokalaemia and hyperkalaemia are associated with HF and 
with many drugs used for HF treatment.451 Both can aggravate ven- 
tricular arrhythmias. 
Loop and thiazide diuretics reduce serum potassium, while 
ACEIs, ARBs and MRAs can all increase serum potassium. Amiloride 
and triamterene are sometimes used as adjunct diuretics in resistant 
oedema and to assist in preventing hypokalaemia. The treatment of 
hypokalaemia can involve recommending high potassium foods or 
prescribing potassium supplements. 
istic management of patients with HF. 
Negatively inotropic CCBs (i.e. diltiazem and verapamil) should 
not be used to treat hypertension in patients with HFrEF (but are 
believed to be safe in HFpEF), and moxonidine should also be 
avoided in patients with HFrEF, as it increased mortality in patients 
in one RCT.460 If blood pressure is not controlled with an ACEI (or 
an ARB), a beta-blocker, an MRA and a diuretic, then hydralazine 
and amlodipine215 [or felodipine216] are additional blood pressure 
lowering agents that have been shown to be safe in systolic HF. The 
blood pressure targets recommended in hypertension guide- 
lines317 are applicable to HF. Uncontrolled hypertension in 
patients with HFrEF is very rare, provided they are optimally trea- 
ted for HF. In contrast, treatment of hypertension is an important 
issue in patients with HFpEF. In patients with AHF, i.v. nitrates (or 
sodium nitroprusside) are recommended to lower blood pressure 
(see Section 12). 
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Recommendations Class a Level b Ref c 
Step 1 
 
 
 
 
They are also safe in HFpEF. 
 
 
 
I 
 
 
 
A 
2, 164, 
165, 167, 
168, 
171–174, 
182, 
461–463 
Step 2 
A thiazide diuretic (or if the patient is being treated with a thiazide diuretic, switching to a loop diuretic) is recommended to 
reduce blood pressure when hypertension persists despite treatment with a combination of an ACE-I (or alternatively ARB but 
NOT together withan ACE-I), a beta-blocker and an MRA. 
 
I 
 
C  
Step 3 
Amlodipine or hydralazine is recommended to reduce blood pressure when hypertension persists despite treatment with a 
combination of an ACE-I (or alternatively ARB but NOT together withan ACE-I), a beta-blocker, an MRA and a diuretic. 
 
I 
 
A 183, 184, 215, 409 
Felodipine should be considered to reduce blood pressure when hypertension persists despite treatment with a combination of 
an ACE-I (or alternatively ARB but NOT together withan ACE-I), a beta-blocker, an MRA and a diuretic. 
 
IIa 
 
B 
 
216 
Moxonidine is not recommended to reduce blood pressure because of safety concerns in HFrEF patients (increased mortality). III B 460 
Alpha-adrenoceptor antagonists are not recommended to reduce blood pressure because of safety concerns in HFrEF patients  III  A 458, 464, 465 
Diltiazem and verapamil are not recommended to reduce blood pressure in patients with HFrEF because of their negative 
inotropic action and risk of worsening HF. 
 
III 
 
C 
 
214 
 
 
 
Recommendations for the treatment of hypertension in patients with symptomatic (NYHA Class II-IV) heart failure with 
reduced ejection fraction 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; HF ¼ heart failure; HFmrEF ¼ heart failure with mid-range ejection fraction; HFpEF ¼ heart failur with preserved ejection fraction; HFrEF ¼ heart failure with reduced ejection fraction; MRA ¼ mineralocorticoid receptor antagonist; NYHA ¼ New York Heart Association. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
e 
 
 
 
11.12 Iron deficiency and 
anaemia 
Iron deficiency is common in HF, as it is with other chronic ill- 
nesses, and it can lead to anaemia and/or skeletal muscle dysfunc- 
tion without anaemia.466 Within an HF population, iron deficiency 
is associated with a worse prognosis.467,468 Intravenous iron has 
been specifically studied in two RCTs in patients with HF and 
iron deficiency (serum ferritin ,100 mg/L or ferritin between 
100 and 299 mg/L and transferrin saturation ,20%)469,470 both 
with and without anaemia. Intravenous ferric carboxymaltose 
(FCM) has been shown to improve self-reported patient global as- 
sessment, quality of life and NYHA class (over 6 months) in the 
FAIR-HF trial469 both in anaemic and non-anaemic patients with 
HF,471 and in the CONFIRM-HF trial470, exercise capacity im- 
proved over 24 weeks. In the analysis of secondary endpoints in 
the CONFIRM-HF trial, i.v. iron reduced the risk of HF hospitaliza- 
tions in iron-deficient patients with HFrEF.470 A meta-analysis of 
i.v. iron therapy in HFrEF patients with iron deficiency over up 
to 52 weeks showed reduced hospitalization rates and improved 
HF symptoms, exercise capacity and quality of life.472 Treatment 
with FCM may therefore result in sustainable improvement in func- 
tional capacity, symptoms and quality of life. Treatment was also 
associated with a significant reduction in hospitalizations for wor- 
sening HF. The number of deaths and the incidence of adverse 
events were similar. Neither i.v. iron trial was powered to test 
for an effect on major outcomes or to evaluate separately the ef- 
fects in anaemic and non-anaemic patients. The effect of treating 
iron deficiency in HFpEF/HFmrEF and the long-term safety of 
iron therapy in either HFrEF, HFmrEF or HFpEF is unknown. The 
safety of i.v. iron is unknown in patients with HF and haemoglobin 
.15 g/dL.469,470 Patients with iron deficiency need to be screened 
for any potentially treatable/reversible causes (e.g. gastrointestinal 
sources of bleeding). 
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Recommendations Class a Level b Ref c 
 
Intravenous FCM should be 
considered in symptomatic patients 
 
(serum ferritin <100 µg/L, or 
ferritin between 100–299 µg/L and 
transferrin saturation <20%) in 
order to alleviate HF symptoms, 
and improve exercise capacity and 
quality of life. 
 
 
 
 
IIa 
 
 
 
 
A 
 
 
 
 
469, 470 
Diabetes 
Metformin should be considered as 
 
control in patients with diabetes 
and HF, unless contra-indicated. 
 
 
IIa 
 
 
C 
 
 
440 ,441 
 
 
 
R 
c 
ecommendations for the treatment of other 
o-morbidities in patients with heart failure 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        F 
r 
a 
b 
c 
T 
CM ¼ ferric carboxymaltose; HF ¼ heart failure; HFrEF ¼ heart failure with 
educed ejection fraction. 
Class of recommendation. 
Level of evidence. 
Reference(s) supporting recommendations. 
reatments not recommended for other co-morbidities in patients with heart failur 
 
 
 
 
e 
 
 
Treatments not recommended of other co-morbidities 
in patients with heart failure 
 
Recommendations Class a Level b Ref c 
Sleep apnoea 
Adaptive servo-ventilation is 
not recommended in patients 
with HFrEF and a predominant 
central sleep apnoea because 
of an increased all-cause and 
cardiovascular mortality. 
 
 
 
III 
 
 
 
B 
 
 
 
473 
Diabetes 
Thiazolidinediones (glitazones) are 
not recommended in patients with 
HF, as they increase the risk of HF 
worsening and HF hospitalization. 
 
 
III 
 
 
A 
 
 
209, 210 
Arthritis 
NSAIDs or COX-2 inhibitors are 
not recommended in patients with 
HF, as they increase the risk of HF 
worsening and HF hospitalization. 
 
 
III 
 
 
B 
 
 
211–213 
 
COX-2 ¼ cyclooxygenase 2; HF ¼ heart failure; HFrEF ¼ heart failure with 
reduced ejection fraction; NSAID ¼ non-steroidal anti-inflammatory drug. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
 
 
Anaemia (defined as a haemoglobin concentration ,13.0 g/dL in 
men and ,12.0 g/dL in women) is common in HF, particularly in 
hospitalized patients. It is more common in women, the elderly 
and in patients with renal impairment and is associated with ad- 
vanced myocardial remodelling, inflammation and volume over- 
load.474 Anaemia is associated with advanced symptoms, worse 
 
 
functional status, greater risk of HF hospitalization and reduced sur- 
vival. A diagnostic workup to seek a cause for any finding of anaemia 
is indicated (e.g. occult blood loss, iron deficiency, B12/folate defi- 
ciency, blood dyscrasias), although in many patients no specific 
cause is found. The erythropoietin-stimulating agent darbepoetin 
alfa did not improve clinical outcomes in HFrEF patients with mild 
to moderate anaemia, but led to an excess of thromboembolic 
events and is therefore not recommended.475 
 
 
 
11.13 Kidney dysfunction (including 
chronic kidney disease, acute kidney 
injury, cardio-renal syndrome and 
prostatic  obstruction) 
HF and CKD frequently coexist, share many risk factors (diabetes, 
hypertension, hyperlipidaemia) and interact to worsen progno- 
sis.476,477  CKD is generally defined as an eGFR ,60 mL/min/ 
1.73 m2  and/or the presence of albuminuria (high 30 – 300 or 
very high .300 mg albumin/1 g of urine creatinine). Patients 
with severe renal dysfunction (eGFR ,30 mL/min/1.73m2) have 
systematically been excluded from randomized clinical trials and 
therefore there is lack of evidence-based therapies in these 
patients. 
A further deterioration in renal function, termed worsening renal 
 
usually by .26.5 mmol/L (0.3 mg/dL) and/or a 25% increase or a 
20% drop in GFR. The importance of these apparently small changes 
is that they are frequent, they promote the development and pro- 
gression of CKD478 and, as a consequence, can worsen the progno- 
sis of HF. Increases in creatinine during an AHF hospitalization are 
not always clinically relevant, especially when they are accompanied 
by appropriate decongestion, diuresis and haemoconcentration.479 
Large increases in serum creatinine, termed acute kidney injury 
(AKI), are relatively rare in HF and are probably associated with 
the combination of diuretic therapy with other potentially nephro- 
toxic drugs such as some antibiotics (gentamicin and trimethoprim), 
contrast media, ACEIs, ARBs, NSAIDs, etc. Of relevance, some of 
these drugs may accumulate if they are renally excreted. In HF, 
WRF is relatively common, especially during initiation and up- 
titration of RAAS inhibitor therapy. Despite the fact that RAAS 
blockers can frequently cause a decrease in GFR in patients with 
HF, this reduction is usually small and should not lead to treatment 
discontinuation unless there is a marked decrease, as the treatment 
benefit in these patients is probably largely maintained.480 When 
large increases in serum creatinine occur, care should be taken to 
evaluate the patient thoroughly and should include assessment of 
a possible renal artery stenosis, excessive hyper- or hypovolaemia, 
concomitant  medication  and  hyperkalaemia,  which  frequently 
coincides with WRF. 
Diuretics, especially thiazides, but also loop diuretics, may be less ef- 
fective in patients with a very low GFR, and if used, should be dosed ap- 
propriately (higher doses to achieve similar effects). Renally excreted 
drugs (e.g. digoxin, insulin and low molecular weight heparin) may accu- 
mulate in patients with renal impairment and may need dose adjustment 
if renal function deteriorates. Patients with HF and coronary or periph- 
eral vascular disease are at risk of acute renal dysfunction when they 
undergo contrast media enhanced angiography [contrast-induced acute 
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kidney injury (CI-AKI)]. Renal dysfunction and worsening renal function 
is further discussed in the section about AHF (see Section 12). 
Prostatic obstruction is common in older men and can interfere 
with renal function; it should therefore be ruled out in men with HF 
with deteriorating renal function. a-adrenoceptor blockers cause 
hypotension and sodium and water retention, and may not be 
safe in HFrEF.458,464,465 For these reasons, 5-a-reductase inhibitors 
are generally preferred  in the  medical  treatment  of  prostatic 
obstruction in patients with HF. 
 
11.14 Lung disease (including asthma and 
chronic   obstructive  pulmonary   disease) 
The diagnosis of COPD and asthma may be difficult in patients with 
HF, due to overlap in symptoms and signs, but also problems in the 
interpretation of spirometry, especially in HFpEF.48,49,391  COPD 
(and asthma) in patients with HF may be overdiagnosed.481 Spirom- 
etry should be performed when patients have been stable and euvo- 
laemic for at least 3 months, to avoid the confounding effect of 
pulmonary congestion causing external obstruction of alveoli and 
bronchioles.482 Both correctly and incorrectly labelled COPD are as- 
sociated with worse functional status and a worse prognosis in HFrEF. 
Beta-blockers are only relatively contraindicated in asthma, but 
not in COPD, although a more selective b1-adrenoceptor antagon- 
ist  (i.e. bisoprolol, metoprolol succinate, or nebivolol) is pre- 
ferred.48,49,391  The contraindication to beta-blockers in asthma, as 
mentioned on pharmacy leaflets, is based on small case series pub- 
lished in the 1980s and late 1990s with very high initial dosages in 
young patients with severe asthma. In clinical practice, starting with 
low doses of cardioselective beta-blockers combined with close 
monitoring for signs of airway obstruction (wheezing, shortness of 
breath with lengthening of the expiration) may allow the use of pro- 
foundly effective beta-blockers in HFrEF, especially in older people 
where true severe asthma is uncommon. Therefore, according to 
the 2015 GINA global strategy report,395,396 asthma is not an absolute 
contraindication, but these medications should only be used under 
close medical supervision by a specialist, with consideration of the 
risks for and against their use. The long-term safety of cardioactive in- 
haled pulmonary drugs is uncertain and the need for their use should 
be reconsidered in patients with HFrEF, especially as their benefit in 
asthma and COPD may be symptomatic only without a clear effect on 
mortality. Oral corticosteroids can cause sodium and water reten- 
tion, potentially leading to worsening of HF, but this is not believed 
to be a problem with inhaled corticosteroids. Pulmonary hyperten- 
sion can complicate severe long-standing COPD, which, as a result, 
makes right-sided HF and congestion more likely. Non-invasive ven- 
tilation, added to conventional therapy, improves the outcome of pa- 
tients with acute respiratory failure due to hypercapnic exacerbation 
of COPD or HF in situations of acute pulmonary oedema. 
 
11.15 Obesity 
Obesity is a risk factor for HF141 and complicates its diagnosis, because 
it can cause dyspnoea, exercise intolerance and ankle swelling and may 
result in poor-quality echocardiographic images. Obese individuals also 
have reduced NP levels.62 Obesity is more common in HFpEF than in 
HFrEF, although it is possible that misdiagnosis may explain at least 
some of this difference in prevalence. Although obesity is an independ- 
ent risk factor for developing HF, once HF is diagnosed, it is well 
established that obesity is associated with lower mortality across a 
wide range of body mass indexes (BMIs) (see also cachexia in Section 
11.3)—the so-called obesity paradox also seen in other chronic ill- 
nesses.414,416 Obesity should be managed as recommended in the 
ESC guidelines on cardiovascular disease prevention,483 if the aim is 
to prevent future development of HF. However, these guidelines do 
not refer to the HF patient in whom higher BMI is not adverse, and, al- 
though often recommended for symptom benefit and risk factor con- 
trol, weight loss as an intervention has never been prospectively shown 
to be either beneficial or safe in HFrEF. When weight loss is occurring 
in HF, it is associated with high mortality and morbidity, worse symp- 
tom status and poor quality of life. In patients with HF with moderate 
degrees of obesity (BMI ,35 kg/m2), weight loss cannot be recom- 
mended. In more advanced obesity (BMI 35–45 kg/m2), weight loss 
may be considered to manage symptoms and exercise capacity. 
 
11.16 Sleep disturbance and 
sleep-disordered  breathing 
Sleep-disordered breathing (SDB) occurs in more than one-third of 
patients with HF,484 being even more prevalent in patients with 
AHF.485 The most common types are: central sleep apnoea (CSA, 
similar to Cheyne Stokes respiration, CSR), obstructive sleep ap- 
noea (OSA), and a mixed pattern of the two. Other causes of sleep 
disturbance include anxiety, depression, decubitus or paroxysmal 
pulmonary congestion (orthopnoea and paroxysmal nocturnal dys- 
pnoea) and diuretic therapy causing nocturnal diuresis. Reviewing 
sleep history (including asking a partner) is part of the holistic 
care of patients with HF (see Section 14). CSA and OSA have 
been shown to be associated with a worse prognosis in HF.485,486 
OSA is associated with an increased risk of incident HF in men.487 
CSA is the most common form of SDB in HFrEF, and HFrEF is 
the most common cause of CSA, so they are closely linked. Screen- 
ing for, and the diagnosis and treatment of, sleep apnoea is discussed 
in detail elsewhere.484,488 Diagnosis used to require overnight poly- 
somnography, although advanced home testing equipment which 
can distinguish the type of sleep apnoea has been developed. 
Nocturnal oxygen supplementation, continuous positive airway 
pressure (CPAP), bi-level positive airway pressure (BiPAP), and adap- 
tive servo-ventilation (ASV) may be considered to treat nocturnal 
hypoxaemia in OSA as recommended in other guidelines.489,490 An 
apnoea/hypopnoea index (AHI) of above 30 per hour can be treated 
using any of CPAP, BiPAP, ASV and nocturnal oxygen supplementa- 
tion, which have all been shown to be effective in this regard. It should 
be noted, however, that none of these interventions has been pro- 
spectively shown to be beneficial on major outcomes in HFrEF. 
CPAP in HF related CSA has been shown to reduce the fre- 
quency of episodes of apnoea and hypopnoea, and improve LVEF 
and 6 minute walk test distance, but did not improve prognosis or 
the rate of HF related hospitalizations.491 
The recently published SERVE-HF473  trial has shown that ASV 
used in patients with HFrEF and a predominantly CSA was neutral 
regarding the composite primary endpoint (all-cause death, lifesav- 
ing cardiovascular intervention, i.e. cardiac transplantation, implant- 
ation of a ventricular assist device, resuscitation after sudden cardiac 
arrest, or appropriate lifesaving shock, or unplanned hospitalization 
for HF worsening), but more importantly led to an increase in both 
all-cause and cardiovascular mortality. Therefore ASV is not recom- 
mended in patients with HFrEF and predominantly CSA. 
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The safety and efficacy of alternative approaches to treating CSA 
in HFrEF patients, such as implantable phrenic nerve stimula- 
tion,219,220,492 are presently undergoing clinical investigation and 
may require additional long term study. 
 
11.17. Valvular heart disease 
ValvularheartdiseasemaycauseoraggravateHF.Thissectionbrief- 
ly addresses problems particularly relevant to HF, and the reader is 
referred to the recent guidelines on valvular disease for more 
information.493,494 
Patients with HF and concomitant valvular heart disease constitute a 
high-risk population. Thus, the whole process of decision-making 
through a comprehensive evaluation of the risk– benefit ratio of differ- 
ent treatment strategies should be made by a multidisciplinary ‘heart 
team’ with a particular expertise in valvular heart disease, including car- 
diologists with expertise in HF, cardiac surgeons, a structural valve 
interventionist if a catheter-based therapy is being considered, imaging 
specialists, anaesthetists and, if needed, general practitioners, geriatri- 
cians, or intensive care specialists. This may be particularly beneficial 
in patients with HF being considered for surgery, transcatheter aortic 
valve implantation or transcatheter mitral valve intervention. 
All patients should receive OMT. In those with HFrEF pharmaco- 
logical therapy should be planned according to a previously described 
algorithm (see Section 7 for details). Care must be taken using vaso- 
dilators (ACEI, ARBs, CCBs, hydralazine, and nitrates) in patients with 
Primary (organic) mitral regurgitation 
Surgery is indicated in symptomatic patients with severe organic 
mitral regurgitation with no contra-indications to surgery. The deci- 
sion of whether to replace or repair depends mostly on valve anat- 
omy, surgical expertise available, and the patient’s condition. 
When the LVEF is , 30%, a durable surgical repair may improve 
symptoms, although its effect on survival is unknown. In this situ- 
ation, the decision to operate should take account of response to 
medical therapy, co-morbidities, and the likelihood that the valve 
can be repaired (rather than replaced). 
 
Secondary mitral regurgitation 
This occurs because LV enlargement and remodelling lead to 
reduced leaflet closing. Effective medical therapy (including CRT 
in suitable patients) leading to reverse remodelling of the LV may 
reduce functional mitral regurgitation, and every effort should be 
made to optimize medical treatment in these patients. 
Combined valve and coronary surgery should be considered in 
symptomatic patients with LV systolic dysfunction (LVEF , 30%), 
coronary arteries suitable for revascularization, and evidence of via- 
bility. Surgery is also recommended in patients with severe mitral re- 
gurgitationundergoingCABGwithLVEF.30%. 
However, a recent study in patients with moderate, secondary is- 
chaemic mitral regurgitation did not prove that the addition of mitral 
valve repair to CABG would lead to a higher degree of LV reverse re- 
501 
severe aortic stenosis in order not to cause hypotension. modelling. Also, there is no evidence favouring mitral valve repair 
 
11.17.1. Aortic stenosis 
The main concern in patients with severe aortic stenosis and re- 
duced LVEF is the entity of ‘low-flow, low-gradient’ aortic stenosis 
(valve area , 1 cm2, LVEF , 40%, mean pressure gradient , 40 
mmHg). In such individuals, low-dose dobutamine stress echocardi- 
ography should be considered to differentiate between patients 
with moderate aortic stenosis, and those with severe stenosis and 
low flow across the valve due to low stroke volume, and to evaluate 
for contractile or flow reserve. 
If the mean gradient is . 40 mmHg, there is theoretically no low- 
er LVEF limit for aortic valve replacement in symptomatic patients 
with severe aortic stenosis. 
Transaortic valve implantation (TAVI) is recommended in pa- 
tients with severe aortic stenosis who are not suitable for surgery 
as assessed by a ‘heart team’ and have predicted post-TAVI survival 
. 1 year. TAVI should be also considered in high-risk patients with 
severe aortic stenosis who may still be suitable for surgery, but in 
whom TAVI is favoured by a ‘heart team’ based on the individual 
risk profile and anatomic suitability.495,496 In a recent trial in patients 
with severe aortic stenosis, TAVI with a self-expanding transcath- 
eter aortic valve bioprosthesis was associated with a significantly 
higher rate of survival at 1 year which was sustained at 2 years.497,498 
 
11.17.2. Aortic regurgitation 
In patients with severe aortic regurgitation, aortic valve repair or re- 
placement is recommended in all symptomatic patients and in 
asymptomatic patients with resting LVEF ≤ 50%, who are otherwise 
fit for surgery.499,500 
 
11.17.3. Mitral regurgitation 
This section refers to chronic settings while acute settings are 
discussed in Section 12. 
over replacement in the context of better outcomes and magnitude 
of LV remodelling.502 In the presence of AF, atrial ablation and LA ap- 
pendage closure may be considered at the time of mitral valve surgery. 
The role of isolated mitral valve surgery in patients with severe 
functional mitral regurgitation and severe LV systolic dysfunction 
(LVEF , 30%) who cannot be revascularized or have non-ischaemic 
cardiomyopathy is questionable, and in most patients conventional 
medical and device therapy are preferred. In selected cases, repair 
may be considered in order to avoid or postpone transplantation. 
The decision should be based on comprehensive evaluation (includ- 
ing strain echocardiography or magnetic resonance imaging499,503 
and discussed within the ‘heart team’. 
In patients with HF with moderate-severe, secondary mitral re- 
gurgitation who are judged inoperable or at high surgical risk, percu- 
taneous mitral valve intervention ( percutaneous edge-to-edge 
repair) may be considered in order to improve symptoms and qual- 
ity of life, although no RCT evidence of improvement has been pub- 
lished, only registry studies.504 – 506 
 
11.17.4. Tricuspid regurgitation 
Secondary (functional) tricuspid regurgitation (TR) frequently com- 
plicates the natural course of HF, due to annular dilatation and in- 
creased tricuspid leaflet tethering in relation to RV pressure and/ 
or volume overload. Severe TR causes/deteriorates symptoms 
and signs of right HF, thus diuretics are used to reduce peripheral 
oedema. As hepatic congestion is often present in these patients 
(additionally contributing to hyperaldosteronism), an addition of 
an MRA (in higher natriuretic doses) may improve decongestion.507 
Management of HF which underlies secondary TR should be opti- 
mized as TR may diminish, following the treatment of its cause. In- 
dications for surgical correction of secondary TR complicating HF 
are not clearly established.493,494 The need for correction of TR is 
usually considered at the time of surgical correction of left-sided 
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Recommendations Class a Level b Ref c 
2, LVEF <40%, mean 
pressure gradient <40 mmHg), low-dose dobutamine stress echocardiography should be considered to identify those with severe 
aortic stenosis suitable for valve replacement. 
 
IIa 
 
C  
TAVI is recommended in patients with severe aortic stenosis who are not suitable for surgery as assessed by a ‘heart team’ 
and have predicted post-TAVI survival >1 year. 
 
I  B 495, 496, 509 
TAVI should be considered in high-risk patients with severe aortic stenosis who may still be suitable for surgery, but in whom TAVI is  IIa  A  497, 498 
In patients with severe aortic regurgitation, aortic valve repair or replacement is recommended in all symptomatic patients and 
in asymptomatic patients with resting LVEF ≤ 
 
I 
 
C 
 
317 
 
Evidence-based medical therapy in patients with HFrEF is recommended in order to reduce functional mitral regurgitation. 
 
I 
 
C  
Combined surgery of secondary mitral regurgitation and coronary artery bypass grafting should be considered in symptomatic 
patients with LV systolic dysfunction (LVEF <30%), requiring coronary revascularization for angina recalcitrant to medical therapy. 
 
IIa 
 
C  
Isolated surgery of non-ischaemic regurgitant mitral valve in patients with severe functional mitral regurgitation and severe LV systolic 
dysfunction (LVEF <30%) may be considered in selected patients in order to avoid or postpone transplantation. 
 
IIb 
 
C  
 
 
 
 
Recommendations for treatment of valvular diseases in patients with heart failure 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       HFrEF ¼ heart failure with reduced ejection fraction; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; TAVI ¼ transaortic valve implantation. aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
 
 
valve lesions.493,494 A recent first report indicated that catheter- 
based interventions may be possible for TR.508 
 
12. Acute heart 
failure 
 
12.1 Definition and classification 
AHF refers to rapid onset or worsening of symptoms and/or signs 
of HF. It is a life-threatening medical condition requiring urgent 
evaluation and treatment, typically leading to urgent hospital 
admission. 
AHF may present as a first occurrence (de novo) or, more fre- 
quently, as a consequence of acute decompensation of chronic 
HF, and may be caused by primary cardiac dysfunction or precipi- 
tated by extrinsic factors, often in patients with chronic HF. Acute 
myocardial dysfunction (ischaemic, inflammatory or toxic), acute 
valve insufficiency or pericardial tamponade are among the most 
frequent acute primary cardiac causes of AHF. Decompensation 
of chronic HF can occur without known precipitant factors, but 
more often with one or more factors, such as infection, uncon- 
trolled hypertension, rhythm disturbances or non-adherence with 
drugs/diet (Table 12.1). 
A large number of overlapping classifications of AHF based on dif- 
ferent criteria have been proposed.510 – 513 In practice the most use- 
ful classifications are those based on clinical presentation at 
admission, allowing clinicians to identify patients at high risk of com- 
ates a pathway for personalized care in the AHF setting. In most 
mmHg) or elevated (.140 mmHg; hypertensive AHF) systolic 
blood pressure (SBP). Only 5 – 8% of all patients present with 
low SBP (i.e. ,90 mmHg; hypotensive AHF), which is associated 
with poor prognosis, particularly when  hypoperfusion is also 
present.514,515 
 
Table 12.1  Factors triggering acute heart failure 
 
Acute coronary syndrome. 
 
Excessive rise in blood pressure. 
Infection (e.g. pneumonia, infective endocarditis, sepsis). 
 
Bradyarrhythmia. 
Toxic substances (alcohol, recreational drugs). 
Drugs (e.g. NSAIDs, corticosteroids, negative inotropic substances, 
cardiotoxic chemotherapeutics). 
Exacerbation of chronic obstructive pulmonary disease. 
Pulmonary embolism. 
Surgery and perioperative complications. 
Increased sympathetic drive, stress-related cardiomyopathy. 
Metabolic/hormonal derangements (e.g. thyroid dysfunction, diabetic 
ketosis, adrenal dysfunction, pregnancy and peripartum related 
abnormalities). 
Cerebrovascular insult. 
Acute mechanical cause: myocardial rupture complicating ACS (free wall 
rupture,ventricular septal defect,acute mitral regurgitation),chest trauma 
or cardiac intervention, acute native or prosthetic valve incompetence 
secondary to endocarditis, aortic dissection or thrombosis. 
 
ACS ¼ acute coronary syndromes; NSAIDs ¼ non-steroidal anti-inflammatory 
drugs. 
 
 
Another approach is to classify patients according to the presence 
of the following precipitants/causes leading to decompensation, 
which need to be treated/corrected urgently (see Section 12.3.1): 
ACS,  hypertensive  emergency,  rapid  arrhythmias  or  severe 
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Figure 12.1 Clinical profiles of patients with acute heart failure based on the presence/absence of congestion and/or hypoperfusion 
 
 
 
bradycardia/conduction disturbance, acute mechanical cause under- 
lying AHF or acute pulmonary embolism. 
Clinical classification can be based on bedside physical examination 
in order to detect the presence of clinical symptoms/signs of conges- 
tion (‘wet’ vs. ‘dry’ if present vs. absent) and/or peripheral hypoperfu- 
sion (‘cold’ vs. ‘warm’ if present vs. absent) (Figure 12.1).514,515 The 
combination of these options identifies four groups: warm and wet 
(well perfused and congested) —most commonly present; cold and 
wet (hypoperfused and congested); cold and dry (hypoperfused with- 
out congestion); and warm and dry (compensated, well perfused with- 
out congestion). This classification may be helpful to guide therapy in 
the initial phase and carries prognostic information.510,514,515 
Patients with HF complicating AMI can be classified according to 
Killip and Kimball13 into class I, no clinical signs of HF; class II, HF with 
rales and S3 gallop; class III, with frank acute pulmonary oedema; 
class IV, cardiogenic shock, hypotension (SBP ,90 mmHg) and evi- 
dence of peripheral vasoconstriction such as oliguria, cyanosis and 
diaphoresis. 
Definitions of the terms used in this section related to clinical 
presentation of patients with AHF are provided in Table 12.2. 
 
12.2 Diagnosis and initial prognostic 
evaluation 
The diagnostic workup needs to be started in the pre-hospital set- 
ting and continued in the emergency department (ED) in order to 
establish the diagnosis in a timely manner and initiate appropriate 
management. The greater benefit of early treatment is well estab- 
lished in ACS and now needs to be considered in the setting of 
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Table 12.2   Definitions of the terms used in Section 12 on acute heart failure 
 
Term  
Symptoms/signs of congestion (left-sided) Orthopnoea, paroxysmal nocturnal dyspnoea, pulmonary rales (bilateral), peripheral oedema (bilateral). 
Symptoms/signs of congestion (right-sided)  
symptoms of gut congestion. 
Symptoms/signs of hypoperfusion Clinical: cold sweated extremities, oliguria, mental confusion, dizziness, narrow pulse pressure. 
Laboratory measures: metabolic acidosis, elevated serum lactate, elevated serum creatinine. 
Hypoperfusion is not synonymous with hypotension, but often hypoperfusion is accompanied by hypotension. 
Hypotension Systolic BP <90 mmHg 
Bradycardia Heart rate <40 bpm 
Tachycardia Heart rate >120 bpm 
Abnormal respiratory effort Respiratory rate >25 breaths/min with use of accessory muscles for breathing, or respiratory rate 
<8 breaths/min despite dyspnoea. 
Low O2 saturation O2 saturation (SaO2) <90% in pulse oximetry 
Normal SaO2 neither excludes hypoxaemia (low PaO2) nor tissue hypoxia. 
Hypoxaemia O2 partial pressure (PaO2) in arterial blood <80 mmHg (<10,67 kPa) (blood gas analysis). 
Hypoxaemic respiratory failure (type I) PaO2 <60 mmHg (<8 kPa) 
Hypercapnia CO2 partial pressure (PaCO2) in arterial blood >45 mmHg (>6 kPa) (blood gas analysis). 
Hypercapnic respiratory failure (type II) PaCO2 >50 mmHg (>6,65 kPa). 
Acidosis pH <7.35 
Elevated blood lactate >2 mmol/L 
Oliguria Urine output <0.5 mL/kg/h 
 
BP ¼ blood pressure; bpm ¼ beats per minute; PaCO2 ¼ partial pressure of carbon dioxide in arterial blood; PaO2 ¼ partial pressure of oxygen in arterial blood; SaO2 ¼ oxygen 
saturation. 
 
 
 
 
AHF.516,517 In parallel, coexisting life-threatening clinical conditions 
and/or precipitants that require urgent treatment/correction need 
to be immediately identified and managed (Figure 12.2). Typically, 
an initial step in the diagnostic workup of AHF is to rule out alter- 
native causes for the patient’s symptoms and signs (i.e. pulmonary 
infection, severe anaemia, acute renal failure). 
When AHF is confirmed clinical evaluation is mandatory to select 
further management. 
It is recommended that initial diagnosis of AHF should be based 
on a thorough history assessing symptoms, prior cardiovascular his- 
tory and potential cardiac and non-cardiac precipitants, as well as on 
the assessment of signs/symptoms of congestion and/or hypoperfu- 
sion by physical examination and further confirmed by appropriate 
additional investigations such as ECG, chest X-ray, laboratory as- 
sessment (with specific biomarkers) and echocardiography. 
In patients presenting with AHF, early initiation of appropriate 
therapy (along with relevant investigations) is of key import- 
ance.516 – 518 
Typically, symptoms and signs of AHF reflect fluid overload (pul- 
monary congestion and/or peripheral oedema) or, less often, re- 
duced cardiac output with peripheral hypoperfusion (Table 12.2). 
Since the sensitivity and specificity of symptoms and signs are often 
not satisfactory, careful clinical evaluation needs to be followed by 
these additional investigations: 
 
• Chest X-ray can be a useful test for the diagnosis of AHF. Pulmon- 
ary venous congestion, pleural effusion, interstitial or alveolar oe- 
dema and cardiomegaly are the most specific findings for AHF, 
although in up to 20% of patients with AHF, chest X-ray is nearly 
normal.519 Supine chest radiographs are of limited value in AHF. 
Chest X-ray is also useful to identify alternative non-cardiac dis- 
eases that may cause or contribute to the patient’s symptoms 
(i.e. pneumonia, non-consolidative pulmonary infections). 
• ECG is rarely normal in AHF (high negative predictive value).520 It 
is also helpful in identifying underlying cardiac disease and poten- 
tial precipitants (rapid AF, acute myocardial ischaemia). 
• Immediate echocardiography is mandatory only in patients with 
haemodynamic instability (particularly in cardiogenic shock) 
and in patients suspected of acute life-threatening structural or 
functional cardiac abnormalities (mechanical complications, 
acute valvular regurgitation, aortic dissection). Early echocardiog- 
raphy should be considered in all patients with de novo AHF and in 
those with unknown cardiac function; however, the optimal tim- 
ing is unknown (preferably within 48 h from admission, if the ex- 
pertise is available). Pocket-size echocardiography may be used 
as an extension of the clinical examination in the first instance 
where available. Repeated echocardiography is usually not 
needed unless there is relevant deterioration in clinical status. 
Bedside thoracic ultrasound for signs of interstitial oedema and 
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Figure 12.2 Initial management of a patient with acute heart failure. aAcute mechanical cause: myocardial rupture complicating acute coronary 
syndrome (free wall rupture, ventricular septal defect, acute mitral regurgitation), chest trauma or cardiac intervention, acute native or prosthetic 
valve incompetence secondary to endocarditis, aortic dissection or thrombosis, see above. 
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Cardiac Heart failure 
Acute coronary syndromes 
Pulmonary embolism 
Myocarditis 
Left ventricular hypertrophy 
Hypertrophic or restrictive cardiomyopathy 
Valvular heart disease 
Congenital heart disease 
Atrial and ventricular tachyarrhythmias 
Heart contusion 
Cardioversion, ICD shock 
Surgical procedures involving the heart 
Pulmonary hypertension 
Non-cardiac Advanced age 
Ischaemic stroke 
Subarachnoid haemorrhage 
Renal dysfunction 
Liver dysfunction (mainly liver cirrhosis with ascites) 
Paraneoplastic syndrome 
Chronic obstructive pulmonary disease 
Severe infections (including pneumonia and sepsis) 
Severe burns 
Anaemia 
Severe metabolic and hormone abnormalities 
(e.g. thyrotoxicosis, diabetic ketosis) 
 
 
 
Table 12.3   Causes of elevated concentrations of 
natriuretic peptides522 – 524 
   
   
       HFpEF ¼ heart failure with preserved ejection fraction; HFrEF ¼ heart failure wit reduced ejection fraction; ICD ¼ implantable cardioverter defibrillator. 
h 
 
 
 
 
pleural effusion may be useful in detecting AHF if the expertise is 
available. 
• Laboratory tests: 
– Natriuretic peptides. 
– Upon presentation to the ED or CCU/ICU, a plasma NP level 
(BNP, NT-proBNP or MR-proANP) should be measured in all 
patients with acute dyspnoea and suspected AHF to help in 
the differentiation of AHF from non-cardiac causes of acute 
dyspnoea. NPs have high sensitivity, and normal levels in pa- 
tients with suspected AHF makes the diagnosis unlikely 
(thresholds: BNP ,100 pg/mL, NT-proBNP ,300 pg/mL, 
MR-proANP ,120 pg/mL).57 – 61,77,78,521 However, elevated 
levels of NPs do not automatically confirm the diagnosis of 
AHF, as they may also be associated with a wide variety of car- 
diac and non-cardiac causes (Table 12.3). Unexpectedly low 
levels of NPs can be detected in some patients with decom- 
pensated end-stage HF, flash pulmonary oedema or right sided 
AHF. 
Other laboratory tests at presentation. 
– The following laboratory assessments should be performed at 
admission on the blood of all patients with AHF: cardiac 
troponin, blood urea nitrogen (BUN) (or urea), creatinine, 
electrolytes (sodium, potassium), liver function tests, thyroid- 
stimulating hormone (TSH), glucose and complete blood 
count; D-dimer is indicated in patients with a suspicion of 
acute pulmonary embolism. 
W Routine arterial blood gas is not needed and should be re- 
stricted to patients in whom oxygenation cannot be readily 
assessed by pulse oximetry. However, arterial blood gas may 
be useful when a precise measurement of O2 and CO2 par- 
tial pressures is needed. A venous sample might acceptably 
indicate pH and CO2. 
W   Of note, measurement of cardiac troponins is useful for de- 
tection of ACS as the underlying cause of AHF. However, 
elevated concentrations of circulating cardiac troponins 
are detected in the vast majority of patients with AHF, often 
without obvious myocardial ischaemia or an acute coronary 
event, suggesting ongoing myocyte injury or necrosis in 
these patients.525 Also in patients with acute pulmonary em- 
bolism as the underlying cause of acute decompensation, 
elevated troponins are useful for risk stratification and 
decision-making.526 
W It is recommended to measure creatinine, BUN and electro- 
lytes every 1 – 2 days while in the hospital and before dis- 
charge from the hospital. Of note, more frequent testing 
might be justified according to the severity of the case. Pre- 
discharge assessment of NPs may be considered for prog- 
nostic evaluation. 
W Assessment of procalcitonin levels may be considered in pa- 
tients with AHF with suspected coexisting infection, particu- 
larly for the differential diagnosis of pneumonia and to guide 
antibiotic therapy,527 if considered. 
W Liver function tests are often impaired in patients with AHF 
due to haemodynamic derangements (both reduced output 
and increased venous congestion). Abnormal liver function 
tests identify patients at risk of poor prognosis and may be 
useful for optimal management.528 – 530 
W Since both hypothyroidism and hyperthyroidism may precipi- 
tate AHF, TSH should be assessed in newly diagnosed AHF. 
W Multiple other biomarkers, including those reflecting inflam- 
mation, oxidative stress, neurohormonal disarray and myo- 
cardial and matrix remodelling, have been investigated for 
their diagnostic and prognostic value in AHF; however, 
none has reached the stage of being recommended for rou- 
tine clinical use. 
• Routine invasive haemodynamic evaluation with a pulmonary ar- 
tery catheter is not indicated for the diagnosis of AHF. It may be 
helpful in selected cases of haemodynamically unstable patients 
with an unknown mechanism of deterioration. Also, routine 
use of an arterial line or central venous line for diagnostic pur- 
poses is not indicated. 
 
 
Numerous clinical and laboratory variables are independent pre- 
dictors of in-hospital complications and longer-term outcomes in 
AHF syndromes, but their impact on management has not been ad- 
equately established. 
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Recommendations Class a Level b Ref c 
Upon presentation a measurement of plasma natriuretic peptide level (BNP, NT-proBNP or MR-proANP) is recommended in all 
patients with acute dyspnoea and suspected AHF to help in the differentiation of AHF from non-cardiac causes of acute dyspnoea. 
 
I  A  531–534 
At admission in all patients presenting with suspected AHF, the following diagnostic tests are recommended: 
a. 12-lead ECG; 
b. chest X-ray to assess signs of pulmonary congestion and detect other cardiac or non-cardiac diseases that may 
cause or contribute to the patient’s symptoms; 
c. the following laboratory assessments in the blood: cardiac troponins, BUN (or urea), creatinine, electrolytes 
(sodium, potassium), glucose, complete blood count, liver function tests and TSH. 
   
I 
I 
I 
C 
C 
C 
Echocardiography is recommended immediately in haemodynamically unstable AHF patients and within 48 hours when 
cardiac structure and function are either not known or may have changed since previous studies. 
 
I  C  
 
 
 
 
Recommendations regarding applied diagnostic measurements 
   
   
      A 
p 
a 
b 
c 
HF ¼ acute heart failure; BNP ¼ B-type natriuretic peptide; BUN ¼ blood urea nitrogen; ECG ¼ electrocardiogram; MR-proANP ¼ mid-regional pro A-type natriuretic 
eptide; NT-proBNP ¼ N-terminal pro-B type natriuretic peptide; TSH ¼ thyroid-stimulating hormone 
Class of recommendation. 
Level of evidence. 
Reference(s) supporting recommendations. 
 
 
12.3 Management 
AHF is a life-threatening medical condition, thus rapid transfer to the 
nearest hospital should be pursued, preferably to a site with a cardiology 
department and/or a coronary care/intensive care unit (CCU/ICU). 
Early diagnosis is important in AHF. Therefore, all patients with 
suspected AHF should have a diagnostic workup and appropriate 
pharmacological and non-pharmacological treatment should be 
started promptly and in parallel. 
Initial evaluation and continued non-invasive monitoring of the 
acute pulmonary oedema. A prompt reduction in blood pressure 
should be considered as a primary therapeutic target and initiated 
as soon as possible. Aggressive blood pressure reduction (in the 
range of 25% during the first few hours and cautiously thereafter) 
with i.v. vasodilators in combination with loop diuretics is 
recommended.317,536,537 
• Rapid arrhythmias or severe bradycardia/conduction dis- 
turbance. Severe rhythm disturbances in patients with AHF and 
unstable conditions should be corrected urgently with medical 
260,316,389 
patient’s vital cardiorespiratory functions, including pulse oximetry, 
blood pressure, respiratory rate and a continuous ECG instituted 
within minutes, is essential to evaluate whether ventilation, periph- 
eral perfusion, oxygenation, heart rate and blood pressure are ad- 
equate. Urine output should also be monitored, although routine 
urinary catheterization is not recommended. 
Patients with respiratory distress/failure or haemodynamic com- 
promise should be triaged to a location where immediate respira- 
tory and cardiovascular support can be provided (Figure 12.2). 
 
 
12.3.1 Identification of precipitants/causes leading to 
decompensation that needs urgent management 
The next step should comprise the identification of major precipitants/ 
causes leading to decompensation, which should be managed urgently 
to avoid further deterioration (Figure 12.2). These include the following: 
 
• Acute coronary syndrome. Patients presenting with ACS 
should be managed according to the ESC guidelines on non-ST 
elevation ACS (NSTE-ACS) and STEMI.114,535 Coexistence of 
these two clinical conditions (ACS and AHF) always identifies a 
very-high-risk group where an immediate (i.e. ,2 h from hospital 
admission in patients with NSTEMI, analogous to STEMI manage- 
ment) invasive strategy with intent to perform revascularization is 
recommended, irrespective of ECG or biomarker findings.114,535 
See below for patients presenting with persistent haemodynamic 
therapy, electrical cardioversion or temporary pacing 
(see also Section 10.1 for AF management). 
Electrical cardioversion is recommended if an atrial or ven- 
tricular arrhythmia is thought to be contributing to the patient’s 
haemodynamic compromise in order to restore sinus rhythm and 
improve the patient’s clinical condition. 
Patients with AHF and incessant ventricular arrhythmias pre- 
sent a challenging scenario, as arrhythmias and haemodynamic 
instability operate in a vicious circle, perpetuating each other. In 
selected cases, immediate angiography (with resultant revascular- 
ization, if needed) and electrophysiological testing with radiofre- 
quency ablation may be considered.260 
• Acute mechanical cause underlying AHF. This may present 
as a mechanical complication of ACS (free wall rupture, ventricu- 
lar septal defect, acute mitral regurgitation), chest trauma or car- 
diac intervention, or as acute native or prosthetic valve 
incompetence secondary to endocarditis, aortic dissection or 
thrombosis and comprise rare causes of obstruction (e.g. cardiac 
tumours). Echocardiography is essential for diagnosis, and treat- 
ment typically requires circulatory support with surgical or per- 
cutaneous intervention. 
• Acute pulmonary embolism. When acute pulmonary em- 
bolism is confirmed as the cause of shock or hypotension, im- 
mediate specific treatment is recommended with primary 
reperfusion either with thrombolysis, catheter-based approach 
526 
instability due to mechanical ACS complication. or surgical embolectomy. Patients presenting with acute pul- 
• Hypertensive emergency. AHF precipitated by rapid and ex- monary embolism should be managed according to the appro- 526 
cessive increase in arterial blood pressure typically manifests as priate guidelines. 
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Recommendations Class a Level b Ref c 
Monitoring of transcutaneous arterial oxygen saturation (SpO2) is recommended. I C  
Measurement of blood pH and carbon dioxide tension (possibly including lactate) should be considered, especially in 
patients with acute pulmonary oedema or previous history of COPD using venous blood. In patients with cardiogenic 
shock arterial blood is preferable. 
 
IIa 
 
C  
Oxygen therapy is recommended in patients with AHF and SpO2 <90% or PaO2 <60 mmHg (8.0 kPa) to correct hypoxaemia. I C  
Non-invasive positive pressure ventilation (CPAP, BiPAP) should be considered in patients with respiratory distress 
(respiratory rate >25 breaths/min, SpO2 <90%) and started as soon as possible in order to decrease respiratory distress 
and reduce the rate of mechanical endotracheal intubation. 
Non-invasive positive pressure ventilation can reduce blood pressure and should be used with caution in hypotensive 
patients. Blood pressure should be monitored regularly when this treatment is used. 
 
 
IIa 
 
 
B 
 
 
541–545 
Intubation is recommended, if respiratory failure, leading to hypoxaemia (PaO2 <60 mmHg (8.0 kPa)), hypercapnia 
(PaCO2 >50 mmHg (6.65 kPa)) and acidosis (pH <7.35), cannot be managed non-invasively. 
 
I  C  
 
 
Identification of acute aetiologies/precipitants with subsequent 
initiation of specific treatments should be done within the immedi- 
ate phase of AHF management (initial 60 – 120 min) (Figure 12.2). 
12.3.2 Criteria for hospitalization in ward vs. intensive 
care/coronary care unit 
 
• Patients with persistent, significant dyspnoea or haemodynamic 
instability should be triaged to a location where immediate resus- 
citative support can be provided if needed. 
• For high-risk patients (i.e. with persistent, significant dyspnoea, 
haemodynamic instability, recurrent arrhythmias, AHF and associated 
ACS), initial care should be provided in a high-dependency setting 
(ICU/CCU). Clinical risk algorithms developed to predict in-hospital 
mortality of patients with AHF can assist in determining which patients 
in the ED need the highest level of inpatient care.538,539 
• The criteria for ICU/CCU admission include any of the following: 
– need for intubation (or already intubated) 
– signs/symptoms of hypoperfusion 
– oxygen saturation (SpO2) ,90% (despite supplemental oxygen) 
– use of accessory muscles for breathing, respiratory rate 
.25/min 
– heart rate ,40 or .130 bpm, SBP ,90 mmHg.540 
• The remaining patients with AHF usually need hospitalization on 
an ordinary ward. Only a few patients admitted to the ED with 
AHF (mainly as exacerbation of HF symptoms with subtle signs 
of congestion) after a small dose of diuretics and some adjust- 
ments of oral therapy can be discharged directly home from 
the ED with advice to be clinically followed in an outpatient clinic. 
• Step-down care from the ICU/CCU is dictated by clinical stabil- 
ization and resolution of morbid conditions. Further treatment 
will be continued with the involvement of a multidisciplinary 
team and discharge planning. 
 
12.3.3 Management of the early phase 
Oxygen therapy and/or ventilatory support 
 
  Recommendations for the management of patients with acute heart failure: oxygen therapy and ventilatory support  
   
   
       AHF ¼ acute heart failure; BiPAP ¼ bilevel positive airway pressure; COPD ¼ chronic obstructive pulmonary disease; CPAP ¼ continuous positive airway pressure; PaCO2 ¼ partial pressure of carbon dioxide in arterial blood; PaO2 ¼ partial pressure of oxygen in arterial blood; SpO2 ¼ transcutaneous oxygen saturation. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
 
 
 
In AHF, oxygen should not be used routinely in non-hypoxaemic pa- 
tients, as it causes vasoconstriction and a reduction in cardiac out- 
put.546,547 In COPD, hyperoxygenation may increase ventilation – 
perfusion mismatch, suppressing ventilation and leading to hyper- 
capnia. During oxygen therapy, acid – base balance and transcutane- 
ous SpO2 should be monitored. 
Non-invasive positive pressure ventilation includes both CPAP 
and bi-level positive pressure ventilation (PPV). Bi-level PPV also al- 
lows inspiratory pressure support that improves minute ventilation 
and is especially useful in patients with hypercapnia, most typically 
COPD patients. 
Congestion affects lung function and increases intrapulmonary 
shunting, resulting in hypoxaemia. The fraction of inspired oxygen 
(FiO2) should be increased up to 100% if necessary, according to 
SpO2, unless contraindicated. Hyperoxia, however, should be 
avoided.546,547  Non-invasive positive pressure ventilation reduces 
respiratory  distress541 – 545   and  may  decrease  intubation  and 
mortality rates,543 although data regarding mortality are less 
conclusive. CPAP is a feasible technique in the pre-hospital 
setting, because  it is simpler than pressure  support positive 
end-expiratory pressure (PS-PEEP) and requires minimal training 
and equipment. On hospital arrival, patients who still show signs 
of respiratory distress should continue with non-invasive ventila- 
tion, preferably PS-PEEP, in case of acidosis and hypercapnia, par- 
ticularly in those with a previous history of COPD or signs of 
fatigue.540 
Caution should be exercised with regard to side effects of anaes- 
thetic drugs, among which propofol can induce hypotension and 
have cardiodepressive side effects. In contrast, midazolam may 
have fewer cardiac side effects and thus is preferred in patients 
with AHF or cardiogenic shock. 
A management algorithm for  patients  with  AHF  based  on 
the clinical profile during an early phase is presented  in 
Figure 12.3. 
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Figure 12.3 Management of patients with acute heart failure based on clinical profile during an early phase 
aSymptoms/signs of congestion: orthopnoea, paroxysmal nocturnal dyspnoea, breathlessness, bi-basilar rales, an abnormal blood pressure re- 
sponse to the Valsalva maneuver (left-sided); symptoms of gut congestion, jugular venous distension, hepatojugular reflux, hepatomegaly, ascites, 
and  peripheral  oedema  (right-sided). 
Page 51 of 85 ESC Guidelines  
 
 
 
 
 
 
 
 
 
Pharmacological therapy 
 
 
Recommendations for the management of patients with acute heart failure: pharmacotherapy 
 
Recommendations Class a Level b Ref c 
Diuretics 
 
improve symptoms. It is recommended to regularly monitor symptoms, urine output, renal function and electrolytes during 
use of i.v. diuretics. 
 
I 
 
C  
In patients with new-onset AHF or those with chronic, decompensated HF not receiving oral diuretics the initial 
recommended dose should be 20–40 mg i.v. furosemide (or equivalent); for those on chronic diuretic therapy, initial i.v. 
dose should be at least equivalent to oral dose. 
 
I 
 
B 
 
540, 548 
It is recommended to give diuretics either as intermittent boluses or as a continuous infusion, and the dose and duration 
should be adjusted according to patients’ symptoms and clinical status. 
 
I  B  548 
Combination of loop diuretic with either thiazide-type diuretic or spironolactone may be considered in patients with  IIb  C  549 
Vasodilators 
i.v. vasodilators should be considered for symptomatic relief in AHF with SBP >90 mmHg (and without symptomatic 
hypotension). 
Symptoms and blood pressure should be monitored frequently during administration of i.v. vasodilators. 
 
IIa 
 
B 
 
537, 
550–555 
 
In patients with hypertensive AHF, i.v. vasodilators should be considered as initial therapy to improve symptoms and reduce 
congestion. 
 
IIa 
 
B 
 
537, 
551–554 
Inotropic agents – dobutamine, dopamine, levosimendan, phosphodiesterase III (PDE III) inhibitors 
Short-term, i.v. infusion of inotropic agents may be considered in patients with hypotension (SBP <90 mmHg) and/or signs/ 
 
peripheral perfusion and maintain end-organ function. 
 
IIb 
 
C  
An intravenous infusion of levosimendan or a PDE III inhibitor may be considered to reverse the effect of beta-blockade 
if beta-blockade is thought to be contributing to hypotension with subsequent hypoperfusion. 
 
IIb  C  
Inotropic agents are not recommended unless the patient is symptomatically hypotensive or hypoperfused because of 
safety concern. 
 
III 
 
A 
 
556, 557 
Vasopressors 
A vasopressor (norepinephrine preferably) may be considered in patients who have cardiogenic shock, despite treatment 
with another inotrope, to increase blood pressure and vital organ perfusion. 
 
IIb  B  558 
It is recommended to monitor ECG and blood pressure when using inotropic agents and vasopressors, as they can cause 
arrhythmia, myocardial ischaemia, and in the case of levosimendan and PDE III inhibitors also hypotension. 
In such cases intra-arterial blood pressure measurement may be considered. 
 
I  C 
 
C 
540, 
559–563 
IIb 
Thrombo-embolism prophylaxis 
Thrombo-embolism prophylaxis (e.g. with LMWH) is recommended in patients not already anticoagulated and with no 
contra-indication to anticoagulation, to reduce the risk of deep venous thrombosis and pulmonary embolism. 
 
I  B  564 
Other drugs 
 
 
d 
 
b. amiodarone may be considered. 
 
IIa 
IIb 
 
C 
 
 
 
565–567 B 
Opiates may be considered for cautious use to relieve dyspnoea and anxiety in patients with severe dyspnoea but nausea 
and hypopnea may occur. 
 
IIb  B  568, 569 
 
AHF ¼ acute heart failure; ECG ¼ electrocardiogram; HF ¼ heart failure; i.v. ¼ intravenous; LMWH ¼ low molecular weight heparin; SBP ¼ systolic blood pressure. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting recommendations. 
dBeta-blockers should be used cautiously, if the patient is hypotensive. 
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Vasodilator Bolus Infusion rate 
Dobutaminea No 2–20 µg/kg/min (beta+) 
Dopamine No 3–5 µg/kg/min; inotropic (beta+) 
  >5 µg/kg/min: (beta+), 
vasopressor (alpha+) 
a,b 25–75 µg/kg 
over 10–20 min 
0.375–0.75 µg/kg/min 
Enoximonea 0.5–1.0 mg/kg 
over 5–10 min 
5–20 µg/kg/min 
Levosimendana 12 µg/kg over 
10 min (optional) 
c 
0.1 µg/kg/min, which can be 
decreased to 0.05 or increased 
to 0.2 µg/kg/min 
Norepinephrine No 0.2–1.0 µg/kg/min 
Epinephrine Bolus: 1 mg 
can be given 
i.v. during 
resuscitation, 
repeated every 
3–5 min 
0.05–0.5 µg/kg/min 
 
T 
u 
able 12.5  Positive inotropes and/or vasopressors 
sed to treat acute heart failure 
 
   
   
 
 
 
 
 
Milrinone 
 
      i. 
a 
b 
c 
v. ¼ intravenous. 
Also a vasodilator. 
Not recommended in acutely worsened ischaemic heart failure. 
Bolus not recommended in hypotensive patients. 
 
 
 
Diuretics 
Diuretics are a cornerstone in the treatment of patients with AHF 
and signs of fluid overload and congestion. Diuretics increase renal 
salt and water excretion and have some vasodilatory effect. In pa- 
tients with AHF and signs of hypoperfusion, diuretics should be 
avoided before adequate perfusion is attained. 
The initial approach to congestion management involves i.v. 
diuretics with the addition of vasodilators for dyspnoea relief if 
blood pressure allows. To enhance diuresis or overcome diuretic 
resistance, options include dual nephron blockade by loop diuretics 
(i.e. furosemide or torasemide) with thiazide diuretics or natriuretic 
doses of MRAs.570,571 However, this combination requires careful 
monitoring to avoid hypokalaemia, renal dysfunction and 
hypovolaemia. 
Data defining optimal dosing, timing and method of delivery are in- 
complete. In the ‘high-dose’ arm of the DOSE study, administration of 
furosemide at 2.5 times the previous oral dose resulted in greater im- 
provement in dyspnoea, larger weight change and fluid loss at the cost 
of transient worsening in renal function.548 In AHF, i.v. furosemide is 
the most commonly used first-line diuretic. The dose should be lim- 
ited to the smallest amount to provide adequate clinical effect and 
modified according to previous renal function and previous dose of 
diuretics. The initial i.v. dose should be at least equal to the pre- 
existing oral dose used at home. Consequently, patients with new- 
onset AHF or those with chronic HF without a history of renal failure 
and previous use of diuretics may respond to i.v. boluses of 20 – 
40 mg, whereas those with previous use of diuretics usually require 
higher doses. A bolus of 10– 20 mg i.v. torasemide may be considered 
as an alternative. 
 
Vasodilators 
Intravenous vasodilators (Table 12.4) are the second most often 
used agents in AHF for symptomatic relief; however, there is no ro- 
bust evidence confirming their beneficial effects. 
They have dual benefit by decreasing venous tone (to optimize 
preload) and arterial tone (decrease afterload). Consequently, 
they may also increase stroke volume. Vasodilators are especially 
useful in patients with hypertensive AHF, whereas in those with 
SBP ,90 mmHg (or with symptomatic hypotension) they should 
be avoided. Dosing should be carefully controlled to avoid excessive 
decreases in blood pressure, which is related to poor outcome. Va- 
sodilators should be used with caution in patients with significant 
mitral or aortic stenosis. 
Use of an inotrope (Table 12.5) should be reserved for patients 
with a severe reduction in cardiac output resulting in compromised 
vital organ perfusion, which occurs most often in hypotensive AHF. 
Inotropic agents are not recommended in cases of hypotensive AHF 
where the underlying cause is hypovolaemia or other potentially 
correctable factors before elimination of these causes. Levosimen- 
dan is preferable over dobutamine to reverse the effect of beta- 
blockade if beta-blockade is thought to be contributing to hypoper- 
fusion.572 However, levosimendan is a vasodilator, thus it is not suit- 
able for treatment of patients with hypotension (SBP ,85 mmHg) 
or cardiogenic shock unless in combination with other inotropes or 
vasopressors.559,573,574 Inotropes, especially those with adrenergic 
mechanisms, can cause sinus tachycardia and may induce myocardial 
ischaemia and arrhythmias, thus ECG monitoring is required. There 
is long-standing concern that they may increase mortality, which 
 
 
Table 12.4   Intravenous vasodilators used to treat acute heart failure 
 
Vasodilator Dosing Main side effects Other 
Nitroglycerine Start with10–20 µg/min, increase up to 200 µg/min Hypotension, headache Tolerance on continuous use 
Isosorbide dinitrate Start with 1 mg/h, increase up to 10 mg/h Hypotension, headache Tolerance on continuous use 
Nitroprusside Start with 0.3 µg/kg/min and increase up to 5 µg/kg/min Hypotension, isocyanate toxicity Light sensitive 
Nesiritidea Bolus 2 µg/kg + infusion 0.01 µg/kg/min Hypotension  
 
aNot available in many European countries. 
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Recommendations regarding renal replacement 
therapy in patients with acute heart failure 
   
   
         
b 
c 
Class of recommendation. 
Level of evidence. 
Reference(s) supporting recommendations. 
 
 
 
derives from studies in which intermittent or continuous infusions 
of inotropes were given.559 – 563,575 In any case, inotropes have to 
be used with caution starting from rather low doses and up-titrating 
with close monitoring. 
 
Vasopressors 
Drugs with prominent peripheral arterial vasoconstrictor action 
such as norepinephrine or dopamine in higher doses (.5 mg/kg/ 
min) are given to patients with marked hypotension. These agents 
are given to raise blood pressure and redistribute blood to the vital 
organs. However, this is at the expense of an increase in LV 
afterload. 
Dopamine was compared with norepinephrine in the treatment 
of various shock patients. A subgroup analysis suggested that nor- 
epinephrine would have fewer side effects and lower mortality.558 
Epinephrine (adrenaline) should be restricted to patients with per- 
sistent hypotension despite adequate cardiac filling pressures and 
the use of other vasoactive agents, as well as for resuscitation 
protocols.576 
 
Thromboembolism prophylaxis 
Thromboembolism prophylaxis with heparin or another anticoagu- 
lant is recommended unless contraindicated or unnecessary (be- 
cause of existing treatment with oral anticoagulants). 
 
Digoxin 
Digoxin is mostly indicated in patients with AF and rapid ventricular 
rate (.110 bpm) and given in boluses of 0.25 – 0.5 mg i.v. if not used 
previously (0.0625 – 0.125 mg may be an adequate dose in patients 
with moderate to severe renal dysfunction). However, in patients 
with co-morbidities or other factors affecting digoxin metabolism 
(including other drugs) and/or the elderly, the maintenance dose 
may be difficult to estimate theoretically, and in this situation it 
should be established empirically, based on the measurements of di- 
goxin concentration in peripheral blood. 
 
Vasopressin antagonists 
Vasopressin antagonists such as tolvaptan block the action of argin- 
ine vasopressin (AVP) at the V2 receptor in renal tubules and pro- 
mote aquaresis. Tolvaptan may be used to treat patients with 
volume overload and resistant hyponatraemia (thirst and dehydra- 
tion are recognized adverse effects).577 
 
Opiates 
Opiates relieve dyspnoea and anxiety. In AHF, routine use of 
opiates is not recommended and they may only be cautiously con- 
sidered in patients with severe dyspnoea, mostly with pulmonary 
oedema. Dose-dependent side effects include nausea, hypotension, 
bradycardia and respiratory depression (potentially increasing the 
need for invasive ventilation). There are controversies regarding 
the  potentially  elevated  mortality  risk  in  patients  receiving 
morphine.568,569 
 
Anxiolytics and sedatives 
Anxiolytics or sedatives may be needed in a patient with agitation or 
delirium. Cautious use of benzodiazepines (diazepam or lorazepam) 
may be the safest approach. 
Device therapy 
 
 
 
 
 
Recommendations Class a Level b Ref C 
 
patients with refractory congestion, 
who failed to respond to diuretic- 
based strategies. 
 
 
IIb 
 
 
B 
 
 
578–580 
Renal replacement therapy should 
be considered in patients with 
refractory volume overload and 
acute kidney injury. 
 
 
IIa 
 
 
C 
 
 
a 
 
 
 
 
Renal replacement therapy 
Ultrafiltration involves the removal of plasma water across a 
semipermeable membrane in response to a transmembrane pres- 
sure gradient. There is no evidence favouring ultrafiltration over 
loop diuretics as first-line therapy in patients with AHF.571,578 At 
the present time, routine use of ultrafiltration is not recommended 
and should be confined to patients who fail to respond to diuretic- 
based strategies. 
The following criteria may indicate the need for initiation of renal 
replacement therapy in patients with refractory volume overload: 
oliguria unresponsive to fluid resuscitation measures, severe hyper- 
kalaemia (K+ .6.5 mmol/L), severe acidaemia (pH ,7.2), serum 
urea level .25 mmol/L (150 mg/dL) and serum creatinine .300 
mmol/L (.3.4 mg/dL). 
 
Mechanical assist devices Intra-
aortic  balloon  pump 
The conventional indications for an intra-aortic balloon pump 
(IABP) are to support the circulation before surgical correction of 
specific acute mechanical problems (e.g. interventricular septal rup- 
ture and acute mitral regurgitation), during severe acute myocarditis 
and in selected patients with acute myocardial ischaemia or infarc- 
tion before, during and after percutaneous or surgical revasculariza- 
tion. There is no good evidence that an IABP is of benefit in other 
causes of cardiogenic shock (for details see below). 
Ventricular assist devices 
Ventricular assist devices and other forms of mechanical circulatory 
support (MCS) may be used as a ‘bridge to decision’ or longer term 
in selected patients (see Section 13). 
 
Other interventions 
In patients with AHF and pleural effusion, pleurocentesis with fluid 
evacuation may be considered if feasible in order to alleviate 
dyspnoea. 
In patients with ascites, ascitic paracentesis with fluid evacuation 
may be considered in order to alleviate symptoms. This procedure, 
through reduction in intra-abdominal pressure, may also partially 
normalize the transrenal pressure gradient, thus improving renal 
filtration.581 
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Recommendations Class a Level b Ref c 
In all patients with suspected cardiogenic shock, immediate ECG and echocardiography are recommended. I C  
All patients with cardiogenic shock should be rapidly transferred to a tertiary care center which has a 24/7 service of cardiac 
catheterization, and a dedicated ICU/CCU with availability of short-term mechanical circulatory support. 
 
I 
 
C  
In patients with cardiogenic shock complicating ACS an immediate coronary angiography is recommended (within 2 hours 
from hospital admission) with an intent to perform coronary revascularization. 
 
I 
 
C  
Continous ECG and blood pressure monitoring are recommended. I C  
Invasive monitoring with an arterial line is recommended. I C  
  I 
 
C  
Intravenous inotropic agents (dobutamine) may be considered to increase cardiac output. IIb C  
Vasopressors (norepinephrine preferable over dopamine) may be considered if there is a need to maintain SBP in the 
presence of persistent hypoperfusion. 
 
IIb  B  558 
IABP is not routinely recommended in cardiogenic shock. III B 585, 586 
Short-term mechanical circulatory support may be considered in refractory cardiogenic shock depending on patient age, 
comorbidities and neurological function. 
 
IIb  C  
 
 
12.3.4 Management   of   patients   with   cardiogenic   shock 
Cardiogenic shock is defined as hypotension (SBP ,90 mmHg) des- 
pite adequate filling status with signs of hypoperfusion (Table 12.2). 
The pathogenetic scenarios of cardiogenic shock range from low- 
output advanced end-stage chronic HF to acute-onset de novo 
cardiogenic shock most often caused by STEMI, but also by various 
aetiologies other than ACS. A patient in cardiogenic shock should 
undergo immediate comprehensive assessment. ECG and echocar- 
diography are required immediately in all patients with suspected 
cardiogenic shock. In patients with cardiogenic shock complicating 
ACS, an immediate coronary angiography is recommended (within 
2 h from hospital admission) with an intent to perform coronary 
revascularization.114,535  Invasive monitoring with an arterial line 
should be also considered. 
There is no agreement on the optimal method of haemodynamic 
monitoring in assessing and treating patients in cardiogenic shock, 
including pulmonary artery catheterization. 
Pharmacologic therapy aims to improve organ perfusion by increas- 
ing cardiac output and blood pressure. After fluid challenge, pharmaco- 
logic management consists of an inotropic agent and a vasopressor as 
needed. Treatment is guided by the continuous monitoring of organ 
perfusion and haemodynamics. Pulmonary artery catheterization may 
be considered. As a vasopressor, norepinephrine is recommended 
when mean arterial pressure needs pharmacologic support. Dobuta- 
mine is the most commonly used adrenergic inotrope. Levosimendan 
may also be used in combination with a vasopressor.582,583 Levosimen- 
dan infusion in cardiogenic shock following AMI on top of dobutamine 
and norepinephrine improved cardiovascular haemodynamics without 
leading to hypotension.582,583 PDE3 inhibitors may be another option, 
especially in non-ischaemic patients.561,584 
However, rather than combining several inotropes, device therapy has 
to be considered when there is an inadequate response. Recently the 
IABP-SHOCK II trial showed that the use of an IABP did not improve 
outcomes in patients suffering from AMI and cardiogenic shock.585,586 
Therefore, routine use of an IABP cannot be recommended. 
12.4 Management of evidence-based oral 
therapies 
 
Recommendations regarding oral evidence-based 
disease-modifying therapies in patients with acute heart 
failure 
 
Recommendations Class a Level b 
In case of worsening of chronic HFrEF, every 
attempt should be made to continue evidence- 
based, disease-modifying therapies, in the 
absence of haemodynamic instability or contra- 
indications. 
 
 
I 
 
 
C 
In the case of de novo HFrEF, every attempt 
should be made to initiate these therapies after 
haemodynamic stabilization. 
 
I 
 
C 
 
AHF ¼ acute heart failure; HFrEF ¼ heart failure with reduced ejection 
fraction. 
aClass of recommendation. 
bLevel of evidence. 
 
 
 
 
Oral disease-modifying HF therapy should be continued on ad- 
mission with AHF, except in the presence of haemodynamic in- 
stability (symptomatic hypotension, hypoperfusion, bradycardia), 
hyperkalaemia or severely impaired renal function. In these cases, 
the daily dosage of oral therapy may be reduced or stopped tem- 
porarily until the patient is stabilized. In particular, beta-blockers 
can be safely continued during AHF presentations except in car- 
diogenic shock. A recent meta-analysis demonstrated that discon- 
tinuation of beta-blockers in patients hospitalized with AHF was 
associated with significantly increased in-hospital mortality, short- 
term mortality and the combined endpoint of short-term rehos- 
pitalization or mortality.587 
 
R  ecommendations regarding management of patients with cardiogenic shock  
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      A 
p 
a 
b 
c 
CS ¼ acute coronary syndrome; CCU ¼ coronary care unit; ECG ¼ electrocardiogram; IABP ¼ intra-aortic balloon pump; ICU ¼ intensive care unit; SBP ¼ systolic blood 
ressure. 
Class of recommendation. 
Level of evidence. 
Reference(s) supporting recommendations. 
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Recommendations Class a Level b 
Standard non-invasive monitoring of heart rate, 
rhythm, respiratory rate, oxygen saturation and 
blood pressure is recommended. 
 
I 
 
C 
It is recommended that patients should be 
 
chart completed. 
 
I 
 
C 
It is recommended to evaluate signs and 
symptoms relevant to HF (e.g. dyspnoea, 
pulmonary rales, peripheral oedema, weight) 
 
 
 
I 
 
 
C 
Frequent, often daily,measurement of 
renal function (blood urea, creatinine) and 
electrolytes (potassium, sodium) during 
i.v. therapy and when renin-angiotensin- 
aldosterone system antagonists are initiated is 
recommended. 
 
 
 
I 
 
 
 
C 
Intra-arterial line should be considered in 
patients with hypotension and persistent 
symptoms despite treatment. 
 
IIa 
 
C 
Pulmonary artery catheter may be considered 
in patients who, despite pharmacological 
treatment present refractory symptoms 
(particularly with hypotension and 
hypoperfusion). 
 
 
IIb 
 
 
C 
 
 Recommendations regarding monitoring of clinical 
status of patients hospitalized due to acute heart failur 
 
 
e 
   
   
       HF ¼ heart failure; i.v. ¼ intravenous. aClass of recommendation. 
bLevel of evidence. 
 
 
Immediate (ED/ICU/CCU) 
Improve haemodynamics and organ perfusion. 
Restore oxygenation. 
Alleviate symptoms. 
Limit cardiac and renal damage. 
Prevent thrombo-embolism. 
Minimize ICU length of stay. 
Intermediate (in hospital) 
Identify aetiology and relevant co-morbidities. 
Titrate therapy to control symptoms and congestion and optimize blood 
pressure. 
Initiate and up-titrate disease-modifying pharmacological therapy. 
Consider device therapy in appropriate patients. 
Pre-discharge and long-term management 
Develop a careplan that provides: 
o A schedule for up-titration and monitoring of pharmacological therapy. 
o Need and timing for review for device therapy. 
o Who will see the patient for follow-up and when. 
Enrol  in  disease  management  programme,  educate,  and  initiate 
appropriate lifestyle adjustments. 
Prevent early readmission. 
Improve symptoms, quality of life, and survival. 
 
 
12.5 Monitoring of clinical status of 
patients hospitalized due to acute heart 
failure 
• once provided with tailored education and advice about self-care. 
Patients should preferably be 
• enrolled in a disease management programme; follow-up plans 
must be in place prior to discharge and clearly communicated 
to the primary care team; 
• reviewed by their general practitioner within 1 week of 
discharge; 
• seen by the hospital cardiology team within 2 weeks of discharge 
if feasible. 
 
Patients with chronic HF should be followed up within a multipro- 
fessional HF service. Pre- and post-discharge management should 
follow the standards of care of the HFA.540,591,592 
 
12.7 Goals of treatment during the 
different stages of management of acute 
heart failure 
During the treatment of patients with AHF, one can distinguish 
subsequent stages that require different therapeutic approaches 
(described in the previous sections of this chapter). Importantly, 
the goals of treatment during the different stages of management 
of patients with AHF also differ, and are  summarized  in 
Table 12.6. 
 
 
 
 
Table 12.6   Goals of treatment in acute heart failure 
 
 
 
 
 
 
 
 
 
Patients should be weighed daily and an accurate fluid balance chart 
should be maintained. Renal function should preferably be moni- 
tored with daily measurement of BUN/urea, creatinine and electro- 
lytes. Routine use of a urinary catheter is not recommended. 
Renal function is commonly impaired at admission, but may im- 
prove or deteriorate with diuresis. Routine monitoring of pulse, re- 
spiratory rate and blood pressure should continue. There is no 
study showing the usefulness of invasive haemodynamic monitoring 
in patients with AHF excluding those with cardiogenic shock. There 
is evidence that measuring NPs during the hospital admission may 
help with discharge planning. Patients whose NP concentrations 
fall during admission have lower cardiovascular mortality and re- 
admission rates at 6 months.588 – 590 
 
12.6 Criteria for discharge from hospital 
and follow-up in high-risk period 
Patients admitted with AHF are medically fit for discharge552 
 
• when haemodynamically stable, euvolaemic, established on 
evidence-based oral medication and with stable renal function 
for at least 24 hours before discharge; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCU ¼ 
unit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
coronary care unit; ED ¼ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
emergency department; ICU 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
¼ intensive care 
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13. Mechanical circulatory support 
and heart transplantation 
 
13.1 Mechanical circulatory support 
For patients with either chronic or acute HF who cannot be stabi- 
lized with medical therapy, MCS systems can be used to unload the 
failing ventricle and maintain sufficient end-organ perfusion. Patients 
in acute cardiogenic shock are initially treated with short-term as- 
sistance using extracorporeal, non-durable life support systems so 
that more definitive therapy may be planned. Patients with chronic, 
refractory HF despite medical therapy can be treated with a per- 
manent implantable left ventricular assist device (LVAD). Table 13.1 
lists the current indications for the use of mechanical circulatory as- 
sist devices.593 
 
 
13.1.1 Mechanical circulatory support in acute heart 
failure 
To manage patients with AHF or cardiogenic shock (INTERMACS 
level 1), short-term mechanical support systems, including percu- 
taneous cardiac support devices, extracorporeal life support 
(ECLS) and extracorporeal membrane oxygenation (ECMO) may 
be used to support patients with left or biventricular failure until 
cardiac and other organ function have recovered. Typically the 
use of these devices is restricted to a few days to weeks. The Survival 
After Veno-arterial ECMO (SAVE) score can help to predict survival 
 
 
 
Table 13.1   Terms describing various indications for 
mechanical circulatory support 
 
Bridge to 
decision (BTD)/ 
Bridge to 
bridge (BTB) 
Use of short-term MCS (e.g. ECLS or ECMO) 
in patients with cardiogenic shock until 
haemodynamics and end-organ perfusion are 
stabilized, contra-indications for long-term MCS 
are excluded (brain damage after resuscitation) 
and additional therapeutic options including 
long-term VAD therapy or heart transplant can 
be evaluated. 
Bridge to 
candidacy 
(BTC) 
Use of MCS (usually LVAD) to improve end-organ 
function in order to make an ineligible patient 
eligible for heart transplantation. 
Bridge to 
transplantation 
(BTT) 
Use of MCS (LVAD or BiVAD) to keep patient 
alive who is otherwise at high risk of death before 
transplantation until a donor organ becomes 
available. 
Bridge to 
recovery (BTR) 
Use of MCS (typically LVAD) to keep patient 
 
remove MCS. 
Destination 
therapy (DT) 
Long-term use of MCS (LVAD) as an alternative 
to transplantation in patients with end-stage HF 
ineligible for transplantation or long-term waiting 
for heart transplantation. 
 
BiVAD ¼ biventricular assist device; BTB ¼ bridge to bridge; BTC ¼ bridge to 
candidacy; BTD ¼ bridge to decision; BTR ¼ bridge to recovery; BTT ¼ bridge to 
transplantation; DT ¼ destination therapy; ECLS ¼ extracorporeal life support; 
ECMO ¼ extracorporeal membrane oxygenation; HF ¼ heart failure; LVAD ¼ 
left ventricular assist device; MCS ¼ mechanical circulatory support; VAD ¼ 
ventricular assist device. 
for patients receiving ECMO for refractory cardiogenic shock 
(online calculator at http://www.save-score.com).594 
In addition, MCS systems, particularly ECLS and ECMO, can be 
used as a ‘bridge to decision’ (BTD) in patients with acute and rap- 
idly deteriorating HF or cardiogenic shock to stabilize haemo- 
dynamics, recover end-organ function and allow for a full clinical 
evaluation for the possibility of either heart transplant or a more 
durable MCS device.595 
Evidence regarding the benefits of temporary percutaneous MCS 
in patients not responding to standard therapy, including inotropes, 
is limited. In a meta-analysis of three randomized clinical trials 
comparing a percutaneous MCS vs. IABP in a total of 100 patients 
in cardiogenic shock, percutaneous MCS appeared safe and demon- 
strated better haemodynamics, but did not improve 30-day mortal- 
ity and was associated with more bleeding complications.596 In a 
randomized trial on high-risk PCI in patients with impaired LV func- 
tion (PROTECT II trial), the 30-day incidence of major adverse 
events was not different for patients with IABP or a haemodynamic 
support device.597 Based on these results, temporary percutaneous 
MCS cannot be recommended as a proven or efficacious treatment 
for acute cardiogenic shock. In selected patients it may serve as a 
bridge to definite therapy. A difficult decision to withdraw MCS 
may need to be made when the patient has no potential for cardiac 
recovery and is not eligible for longer-term MCS support or heart 
transplant. 
 
13.1.2 Mechanical circulatory support in end-stage chronic 
heart failure 
Heart transplantation has always been a limited therapeutic option 
for patients with end-stage chronic HF. The increasing number of 
patients with refractory, chronic HF and the declining willingness 
for organ donation have resulted in expanded waiting lists and pro- 
longed waiting times for patients listed for heart transplantation 
(median 16 months in the region covered by Eurotransplant).598 
More than 60% of patients are transplanted in high-urgency status, 
leaving little chance for patients listed for less urgent transplantation. 
Three times more patients are listed for heart transplantation annu- 
ally than are actually transplanted, and the mortality rate on the 
Eurotransplant waiting list in 2013 was 21.7%.598 
More recent data suggest that patients with ongoing LVAD sup- 
port may have an improved survival on the transplant waiting 
list.599 Accordingly, MCS devices, particularly continuous-flow 
LVADs, are increasingly seen as an alternative to heart transplant- 
ation. Initially LVADs were developed for use as a short-term BTT 
approach (Table 13.1),600 but they are now being used for months 
to years in patients who will either face a long-term wait on the 
transplant list (currently only 10% of patients with an MCS device 
implanted with a BTT indication will receive an organ within 1 
year of listing) or in patients who are not eligible for transplantation 
as permanent therapy or destination therapy. The number of pa- 
tients with a permanent LVAD who are considered neither too 
old nor ineligible for transplantation is constantly growing. For a ma- 
jority of these patients, lifelong LVAD therapy, despite eligibility for 
transplantation, has become a clinical reality. Current 2 – 3-year sur- 
vival rates in carefully selected patients receiving the latest continu- 
ous flow devices are excellent, and comparable to early survival 
after heart transplantation.595  However, fewer data are available 
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Table 13.2   INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) stages for classifying 
patients with advanced heart failure 
   
   
       ECLS ¼ extracorporeal life support; ECMO ¼ extracorporeal membrane oxygenation; INTERMACS ¼ Interagency Registry for Mechanically Assisted Circulatory Support; LVAD ¼ left ventricular assist device; NYHA ¼ New York Heart Association. 
aKaplan-Meier estimates with standard error of the mean for 1 year survival with LVAD therapy. Patients were censored at time of last contact, recovery or heart transplantatio 
Due to small numbers outcomes for INTERMACS levels 5, 6, 7 were combined610. 
 
 
. 
 
 
 
 
 
 
 
INTERMACS level NYHA 
Class 
Description Device 1y survival with 
LVAD therapy 
1. Cardiogenic shock 
“Crash and burn” 
IV Haemodynamic instability in spite of increasing doses of catecholamines 
and/or mechanical circulatory support with critical hypoperfusion of target 
organs (severe cardiogenic shock). 
ECLS, ECMO, 
percutaneous 
support devices 
52.6±5.6% 
2. Progressive decline 
despite inotropic 
support “Sliding on 
inotropes” 
IV Intravenous inotropic support with acceptable blood pressure but rapid 
deterioration of renal function, nutritional state, or signs of congestion. 
ECLS, ECMO, 
LVAD 
63.1±3.1% 
3. Stable but inotrope 
dependent “Dependent 
stability” 
IV Haemodynamic stability with low or intermediate doses of inotropics, but 
necessary due to hypotension, worsening of symptoms, or progressive 
renal failure. 
LVAD 78.4±2.5% 
4. Resting symptoms 
 
IV 
ambulatory 
Temporary cessation of inotropic treatment is possible, but patient presents 
 
LVAD 78.7±3.0% 
5. Exertion intolerant 
“Housebound” 
IV 
ambulatory 
Complete cessation of physical activity, stable at rest, but frequently with 
 
LVAD 93.0±3.9%a 
6. Exertion limited 
“Walking wounded” 
III Minor limitation on physical activity and absence of congestion while at 
rest. Easily fatigued by light activity. 
LVAD / Discuss 
LVAD as option 
- 
7.“Placeholder” III  
 
Discuss LVAD 
as option 
- 
 
 
 
n 
 
 
 
 
for longer-term outcomes. Among patients with continuous-flow 
LVADs, actuarial survival is 80% at 1 year and 70% at 2 years in pre- 
dominantly non-transplant-eligible patients. Notably, survival of 
85% at 2 years was recorded for patients up to 70 years of age with- 
out diabetes, renal impairment or cardiogenic shock.601,602 Patients 
receiving LVAD devices as BTT have a post-transplant survival rate 
similar or better than those not requiring or receiving bridging.599 
Despite technological improvements, bleeding, thromboembolism 
(both of which can cause stroke), pump thrombosis, driveline infec- 
tions and device failure remain significant problems and affect the 
long-term outcome of patients on MCS.599,603 – 606  It is recom- 
mended that such devices should only be implanted and managed 
at centres with appropriately trained specialist HF physicians and 
surgeons and an outpatient LVAD clinic with trained nursing staff.607 
In some patients, LV reverse remodelling and functional improve- 
ment during MCS may permit removal of the LVAD [‘bridge to re- 
covery’ (BTR)]. This outcome is more likely in younger patients with 
an acute fulminant but reversible cause of HF, such as acute myocar- 
ditis or peripartum cardiomyopathy.608,609 LVADs may also be used 
as a ‘bridge to candidacy’ (BTC) in order to permit recovery of 
end-organ dysfunction, improve RV function and relieve pulmonary 
hypertension, which may allow initially ineligible patients to become 
eligible for heart transplantation. 
Earlier ventricular assist device (VAD) implantation in less severe- 
ly ill patients, e.g. those not yet on inotropic support, was tested in a 
recent trial that revealed better outcomes than in those patients 
continuing on medical therapy.605 The INTERMACS registry like- 
wise shows better outcomes in patients implanted with a higher 
INTERMACS class, although the majority of VAD implants are 
done at INTERMACS levels 1 – 3.604,610 Additionally, it needs to 
be remembered that no RCTs exist comparing medical therapy 
vs. MCS devices in these transplant-eligible patients (Table 13.2). 
Typically, patients with end-stage HF considered for MCS exhibit 
many clinical hallmarks of declining cardiovascular function593 and 
may already be on continuous inotropic support or manifest a de- 
cline in end-organ function. Markers of liver and renal dysfunction, 
haematologic and coagulation abnormalities and lower serum albu- 
min levels are associated with worse outcome.611,612 
Evaluation of RV function is crucial since postoperative RV failure 
greatly increases perioperative mortality and reduces survival to, 
and after, transplantation. There are, however, multiple approaches 
to assessment of the RV (see Section 5.2.3). If RV failure is expected 
to be potentially reversible, temporary (days to weeks) extracor- 
poreal right ventricular assist device (RVAD) support using a centri- 
fugal pump in addition to LVAD implantation may be considered. 
For patients with chronic biventricular failure or a high risk for per- 
sisting RV failure after LVAD implantation, implantation of a biven- 
tricular assist device (BiVAD) may be necessary. Patients requiring 
long-term BiVAD support must be transplant-eligible, as BiVAD 
therapy is not suitable for destination therapy. The outcomes of Bi- 
VAD therapy are inferior to those for LVAD therapy and therefore 
the indication for VAD therapy should be discussed before RV func- 
tion deteriorates. The implantation of a total artificial heart with re- 
moval of the native heart should be restricted to selected patients 
who cannot be treated with an LVAD (unrepairable ventricular sep- 
tal defect, cardiac rupture). 
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Patients with >2 months of severe symptoms despite optimal 
medical and device therapy and more than one of the following: 
LVEF <25% and, if measured, peak VO2 <12 mL/kg/min. 
≥3 HF hospitalizations in previous 12 months without an obvious 
precipitating cause. 
Dependence on i.v. inotropic therapy. 
Progressive  end-organ  dysfunction  (worsening  renal  and/or  hepatic 
 
pressure (PCWP ≥20 mmHg and SBP ≤80–90 mmHg or CI ≤2 L/min/m2). 
Absence of severe right ventricular dysfunction together with severe 
tricuspid regurgitation. 
 
Patients to 
consider 
End-stage HF with severe symptoms, a poor prognosis, 
and no remaining alternative treatment options. 
Motivated, well informed, and emotionally stable. 
Capable of complying with the intensive treatment 
required postoperatively. 
Contra- 
indications 
Active infection. 
Severe peripheral arterial or cerebrovascular disease. 
Pharmacologically irreversible pulmonary hypertension 
(LVAD should be considered with a subsequent re- 
evaluation to establish candidacy). 
Cancer (a collaboration with oncology specialists 
should occur to stratify each patient as to their risk of 
tumour recurrence). 
Irreversible renal dysfunction (e.g. creatinine clearance 
<30 mL/min). 
Systemic disease with multi-organ involvement. 
Other serious co-morbidity with poor prognosis. 
Pre-transplant BMI >35 kg/m2 (weight loss is 
recommended to achieve a BMI <35 kg/m2). 
Current alcohol or drug abuse. 
Any patient for whom social supports are deemed 
setting. 
 
Table 13.4    Heart transplantation: indications and 
contra-indications 
   
   
      B MI ¼ body mass index; HF ¼ heart failure; LVAD ¼ left ventricular assist device . 
 
 
 
Table 13.3    Patients potentially eligible for 
implantation of a left ventricular assist device 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        C 
e 
b 
I ¼ cardiac index; HF ¼ heart failure; i.v. ¼ intravenous; LVEF ¼ left ventricular 
jection fraction; PCWP ¼ pulmonary capillary wedge pressure; SBP ¼ systolic 
lood pressure; VO2 ¼ oxygen consumption. 
 
 
 
Patients with active infection, severe renal, pulmonary or hepatic 
dysfunction or uncertain neurological status after cardiac arrest or 
due to cardiogenic shock are not usually candidates for BTT or 
DT but may be candidates for BTC (Table 13.3). 
 
 
Recommendations for implantation of mechanical 
circulatory support in patients with refractory heart 
failure 
 
Recommendations Class a Level b Ref c 
An LVAD should be considered in 
patients who have end- stage HFrEF 
despite optimal medical and device 
therapy and who are eligible for 
heart transplantation in order 
to improve symptoms, reduce the 
risk of HF hospitalization and the 
risk of premature death (Bridge to 
transplant indication). 
 
 
 
 
IIa 
 
 
 
 
C 
 
An LVAD should be considered in 
patients who have end-stage HFrEF 
despite optimal medical and device 
therapy and who are not eligible for 
heart transplantation to, reduce the 
risk of premature death. 
 
 
 
IIa 
 
 
 
B 
 
 
605, 612, 
613 
 
HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection fraction; LVAD ¼ 
left ventricular assist device. 
aClass of recommendation. 
bLevel of evidence. 
cReference(s) supporting levels of evidence. 
 
 
13.2  Heart transplantation 
Heart transplantation is an accepted treatment for end-stage 
HF.614,615 Although controlled trials have never been conducted, 
there is a consensus that transplantation—provided that proper se- 
lection criteria are applied—significantly increases survival, exercise 
capacity, quality of life and return to work compared with conven- 
tional treatment. 
Apart from the shortage of donor hearts, the main challenges in 
transplantation are the consequences of the limited effectiveness 
and complications of immunosuppressive therapy in the long term 
(i.e. antibody-mediated rejection, infection, hypertension, renal fail- 
ure, malignancy and coronary artery vasculopathy). The indications 
for and contraindications to heart transplantation have recently 
been updated and are summarized in Table 13.4.616 It needs to be 
considered that some contraindications are transient and treatable. 
While an active infection remains a relative contraindication to heart 
transplantation, patients with HIV, hepatitis, Chagas disease and tu- 
berculosis can be considered as suitable candidates provided certain 
strict management principles are adhered to by the teams. In pa- 
tients with cancer requiring heart transplantation, a close collabor- 
ation with oncology specialists should occur to stratify each patient 
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Table 14.1   Characteristics and components of 
management programmes for patients with heart 
failure 
   
  
 
 
 
 
 
 
educated staff. 
 
   
 
 
 
 
 
 
 
 
Characteristics Should employ a multidisciplinary approach 
(cardiologists, primary care physicians, nurses, 
pharmacists, physiotherapists, dieticians, social 
workers, surgeons, psychologists, etc.). 
Should target high-risk symptomatic patients. 
Should include competent and professionally 
617 
Components Optimized medical and device management. 
Adequate patient education, with special emphasis 
on adherence and self-care. 
Patient involvement in symptom monitoring and 
 
Follow-up after discharge (regular clinic and/or 
home-based visits; possibly telephone support or 
remote monitoring). 
Increased access to healthcare (through in-person 
follow-up and by telephone contact; possibly 
through remote monitoring). 
Facilitated access to care during episodes of 
decompensation. 
Assessment of (and appropriate intervention in 
response to) an unexplained change in weight, 
nutritional status, functional status, quality of life, 
 
Access to advanced treatment options. 
Provision of psychosocial support to patients and 
family and/or caregivers. 
 
 
 
 
 
 
 
The use of mechanical circulatory support, particularly LVAD, 
should be considered for patients with potentially reversible or 
treatable co-morbidities, such as cancer, obesity, renal failure, 
tobacco use and pharmacologically irreversible pulmonary 
hypertension, with a subsequent re-evaluation to establish 
candidacy. 
 
 
14. Multidisciplinary team 
management 
 
Non-pharmacological non-device/surgical interventions used in the 
management of HF (both HFrEF and HFpEF) are summarized in 
Tables 14.1 and 14.2 and detailed practical recommendations on 
their use have been published by the HFA of the ESC.591,592 There 
is no evidence that these on their own improve mortality, morbidity 
or quality of life. For this reason, these interventions have not been 
given a recommendation with an evidence level. The exceptions are 
implementation of care in a multidisciplinary framework, monitoring 
and exercise training (see recommendations table), all of which are 
discussed below. 
Recommendations for exercise, multidisciplinary 
management and monitoring of patients with heart 
failure 
 
Recommendations Class a Level b Ref c 
It is recommended that regular 
aerobic exercise is encouraged 
in patients with HF to improve 
functional capacity and symptoms. 
 
 
I 
 
 
A 
 
321, 
618–621 
It is recommended that regular 
aerobic exercise is encouraged in 
stable patients with HFrEF to reduce 
the risk of HF hospitalization. 
 
 
I 
 
 
A 
 
 
618, 619 
It is recommended that patients with 
HF are enrolled in a multidisciplinary 
care management programme to 
reduce the risk of HF hospitalization 
and mortality. 
 
 
I 
 
 
A 
 
 
622–625 
Referral to primary care for long- 
term follow-up may be considered 
for stable HF patients who are on 
optimal therapy to monitor for 
effectiveness of treatment, disease 
progression and patient adherence. 
 
 
 
IIb 
 
 
 
B 
 
 
 
626, 627 
Monitoring of pulmonary artery 
pressures using a wireless 
implantable haemodynamic 
monitoring system (CardioMems) 
may be considered in symptomatic 
patients with HF with previous 
HF hospitalization in order to 
reduce the risk of recurrent HF 
hospitalization. 
 
 
 
 
IIb 
 
 
 
 
B 
 
 
 
 
628, 629 
Multiparameter monitoring based 
on ICD (IN-TIME approach) may be 
considered in symptomatic patients 
with HFrEF (LVEF ≤35%) in order to 
improve clinical outcomes. 
 
 
IIb 
 
 
B 
 
 
630 
 
HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection fraction; ICD ¼ 
implantable cardioverter-defibrillator; LVEF ¼ left ventricular ejection fraction, IN-
TIME ¼ Implant-based multiparameter telemonitoring of patients with heart failure. aClass 
of recommendation. 
bLevel of evidence. 
cReference(s) supporting levels of evidence. 
 
 
14.1 Organization of care 
The goal of management of HF is to provide a ‘seamless’ system of 
care that embraces both the community and hospital throughout 
the health care journey. The standards of care that patients with HF 
should expect have been published by the ESC HFA.591 To achieve 
this goal, other services, such as cardiac rehabilitation and palliative 
care, must be integrated into the overall provision for patients with 
HF. Fundamental to the delivery of this complete package of care 
are multidisciplinary management programmes designed to improve 
outcomes through structured follow-up with patient education, opti- 
mization of medical treatment, psychosocial support and improved 
access to care (Table 14.1). Such strategies reduce HF hospitalization 
and mortality in patients discharged from the hospital.624,625 
Key to the success of these programmes is coordination of care 
along the continuum of HF and throughout the chain of care 
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Education topic Patient skills Professional behaviours 
 
aetiology and 
trajectory of 
HF (including 
prognosis). 
• Understand the cause of HF, symptoms and disease 
trajectory. 
• Make realistic decisions including decisions about 
treatment at end-of-life. 
• Provide oral and written information that takes account of educational 
grade and health literacy. 
• Recognize HF disease barriers to communication and provide 
information at regular time intervals. 
• Sensitively communicate information on prognosis at time of diagnosis, 
during decision making about treatment options, when there is a  
change in the clinical condition and whenever the patient requests. 
Symptom 
monitoring and 
self-care. 
• Monitor and recognize change in signs and symptoms. 
• Know how and when to contact a healthcare professional. 
• In line with professional advice, know when to self- 
• Provide individualized information to support self-management such as: 
c:> In the case of increasing dyspnoea or oedema or a sudden 
unexpected weight gain of >2 kg in 3 days, patients may increase 
their diuretic dose and/or alert their healthcare team. 
c:> 
c:> Self-care support aids such as dosette box when appropriate. 
Pharmacological 
treatment. 
• Understand the indications, dosing and side effects of drugs. 
• Recognize the common side effects and know 
when to notify a healthcare professional. 
• 
• Provide written and oral information on dosing, effects and side 
effects (see web tables 7.4–7.8 – practical guidance on use of 
pharmacological agents). 
Implanted devices 
and percutaneous/ 
surgical 
interventions. 
• Understand the indications and aims of procedures/ 
implanted devices. 
• Recognize the common complications and know when to 
notify a healthcare professional. 
• 
implanted devices. 
• 
• Provide written and oral information on regular control of device 
functioning, along with documentation of regular check-up. 
Immunization • 
disease 
• Advise on local guidance and immunization practice. 
Diet and alcohol • 
• 
c:>     Increase intake during periods of high heat and 
humidity, nausea/vomiting 
c:>     Fluid restriction of 1.5–2 L/day may be considered in 
patients with severe HF to relieve symptoms and 
congestion. 
• Monitor body weight and prevent malnutrition. 
• Eat healthily, avoid excessive salt intake (>6 g/day) and 
maintain a healthy body weight. 
• Abstain from or avoid excessive alcohol intake, especially 
for alcohol induced cardiomyopathy. 
•   
weight and periods of high heat and humidity.Adjust advice during 
periods of acute decompensation and consider altering these 
restrictions towards end-of-life. 
• Tailor alcohol advice to aetiology of HF; e.g. abstinence in 
alcoholic cardiomyopathy. 
• Normal alcohol guidelines apply (2 units per day in men or 1 unit per 
day in women). 1 unit is 10 mL of pure alcohol (e.g. 1 glass of wine, 1/2 
pint of beer, 1 measure of spirit). 
• For management of obesity (see Section 11.15). 
Smoking and 
recreational 
substance use. 
• Stop smoking and taking recreational substances. • Refer for specialist advice for smoking cessation and drug withdrawal 
and replacement therapy. 
• Consider referral for cognitive behavioural theory and psychological 
support if patient wishes support to stop smoking. 
Exercise • 
moderate breathlessness. 
• Advice on exercise that recognizes physical and functional limitations, 
such as frailty, comorbidities. 
• Referral to exercise programme when appropriate. 
Travel and leisure • Prepare travel and leisure activities according to physical 
capacity. 
• 
 
• Be aware of adverse reactions to sun exposure with 
certain medication (such as amiodarone). 
• Consider effect of high altitude on oxygenation. 
• take medicine in cabin luggage in the plane, have a list with 
you of treatments and the dosage with the generic name. 
• 
• 
Sleep and 
breathing (see 
co-morbidities 
Section 11.16). 
• Recognize problems with sleeping, their relationship with 
HF and how to optimize sleep. 
• Provide advice such as timing of diuretics, environment for sleep, device 
support. 
• In presence of sleep-disordered breathing provide advice on weight 
reduction/control. 
Sexual activity (see 
co-morbidities 
Section 11.7). 
• Be reassured about engaging in sex, provided sexual 
activity does not provoke undue symptoms. 
• Recognize problems with sexual activity, their relationship 
with HF and applied treatment and how to treat erectile 
dysfunction. 
• Provide advice on eliminating factors predisposing to erectile 
dysfunction and available pharmacological treatment of erectile 
dysfunction. 
• Refer to specialist for sexual counselling when necessary. 
 
 
 
Table 14.2    Key topics and self-care skills to include in patient education and the professional behaviours to optimize 
learning and facilitate shared decision making 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
continued 
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Education topic Patient skills Professional behaviours 
Psychosocial 
aspects 
• Understand that depressive symptoms and cognitive 
dysfunction are found more frequently in people with HF, 
and that they may affect adherence. 
• Recognize psychological problems which may occur 
in the course of disease, in relation to changed lifestyle, 
pharmacotherapy, implanted devices and other 
procedures (including mechanical support and heart 
transplantation). 
• Regularly communicate information on disease, treatment options and 
self-management. 
• Involve family and carers in HF management and self-care. 
• Refer to specialist for psychological support when necessary. 
 
 
 
Table 14.2   Key topics and self-care skills to include in patient education and the professional behaviours to optimize 
learning and facilitate shared decision making (continued) 
   
   
       HF ¼ heart failure; ICD ¼ implantable cardioverter defibrillator.  
 
delivered by the various services within the health care system. This 
necessitates close collaboration between HF practitioners (primar- 
ily cardiologists, HF nurses and general practitioners) and other ex- 
perts, including pharmacists, dieticians, physiotherapists, 
psychologists, palliative care providers and social workers. The con- 
tent and structure of HF management programmes may vary in dif- 
ferent countries and health care settings. The components shown in 
Table 14.1 are recommended. HF services should be easily access- 
ible to the patient and his/her family and care providers. A telephone 
helpline may facilitate access to professional advice. 
The website http://ww.heartfailurematters.org is an option for 
professional information for those patients and families with Inter- 
net access. 
14.2 Discharge planning 
Early readmission after hospital discharge is common and may be ad- 
dressed through coordinated discharge planning. The standards of 
care that patients should expect have been published by the HFA 
and the Acute Cardiac Care Association.540,631 Discharge planning 
should commence as soon as the patient’s condition is stable. During 
hospital admission, providing patients with information and education 
for self-care improves outcome. Discharge should be arranged for 
when the patient is euvolaemic and any precipitants of the admission 
have been treated. Hospitals with early physician follow-up after dis- 
charge show reduced 30-day readmission, and those that initiated 
programmes to discharge patients with an outpatient follow-up ap- 
pointment already scheduled experienced a greater reduction in 
readmissions than those not taking up this strategy.632 
 
14.3 Lifestyle advice 
There is little evidence that specific lifestyle advice improves quality 
of life or prognosis; however, providing this information has become 
a key component of education for self-care. Patients should be pro- 
vided with sufficient up-to-date information to make decisions on 
lifestyle adjustment and self-care. Ideally for those patients admitted 
to the hospital, lifestyle advice should begin prior to discharge. Infor- 
mation should be individually tailored to need and take into account 
relevant co-morbidities that may influence retention of information 
(such as cognitive impairment and depression). Practical recommen- 
dations have been published by the HFA.591 Key topics to include 
are recommended in Table 14.2. 
 
14.4 Exercise training 
Several systematic reviews and meta-analyses of small studies have 
shown  that  physical  conditioning  by  exercise  training  improves 
exercise tolerance, health-related quality of life and HF hospitaliza- 
tion rates in patients with HF. A single large RCT618 showed a modest 
and non-significant reduction in the primary composite outcome of 
all-cause mortality or all-cause hospitalization. There was no reduc- 
tion in mortality and no safety concerns were raised.618,633 The 
most recent Cochrane review of exercise training619 included 33 
trials with 4740 patients with HF (predominantly HFrEF). There 
was a trend towards a reduction in mortality with exercise in trials 
with .1 year of follow-up. Compared with the control group, exer- 
cise training reduced the rate of overall and HF-specific hospitaliza- 
tion and improved quality of life. Practical recommendations on 
exercise training have been published by the HFA.120 
There is evidence that in patients with HFpEF, exercise training has 
several benefits, including improvements in exercise capacity, as mea- 
sured objectively using peak oxygen consumption, quality of life and 
diastolic function, assessed by echocardiography.321,620,621,634 
Patients with HF, regardless of LVEF, are recommended to perform 
properly designed exercise training (see the recommendations table). 
 
14.5 Follow-up and monitoring 
Patients with HF benefit from regular follow-up and monitoring of 
biomedical parameters to ensure the safety and optimal dosing of 
medicines and detect the development of complications or disease 
progression that may require a change in management (e.g. the onset 
of AF or development of anaemia). Monitoring may be undertaken by 
the patients themselves during home visits, in community or hospital 
clinics, by remote monitoring with or without implanted devices or 
by structured telephone support (STS). The optimal method of mon- 
itoring will depend on local organizations and resources and will vary 
among patients. For example, more frequent monitoring will be re- 
quired during periods of instability or optimization of medication. 
Older adults may also benefit from more frequent monitoring. 
Some patients will be keen and able to participate in self-monitoring. 
High circulating NPs predict unfavourable outcomes in patients 
with HF, and a decrease in NP levels during recovery from circula- 
tory decompensation is associated with a better prognosis.588 – 590 
Although it is plausible to monitor clinical status and tailor treatment 
based on changes in circulating NPs in patients with HF, published 
studies have provided differing results.635 – 638 This does not enable 
us to recommend a broad application of such an approach. 
Telemedicine in HF, which is also termed remote patient manage- 
ment, has variable clinical trial results.639 Several meta-analyses sug- 
gest clinical benefits, but numerous prospectively initiated clinical 
trials including .3700 patients have not confirmed this. These clin- 
ical trials include Tele-HF,640 TIM-HF,641 INH,642 WISH643 and 
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Monitor frailty and seek and address reversible causes (cardiovascular 
and non-cardiovascular) of deterioration in frailty score. 
Medication review: optimize doses of heart failure medication slowly and 
with frequent monitoring of clinical status. Reduce polypharmacy; number, 
doses and complexity of regime. Consider stopping medication without an 
immediate effect on symptom relief or quality of life (such as statin).Review 
the timing and dose of diuretic therapy to reduce risk of incontinence. 
Consider need to refer to specialist care of the elderly team and to 
general practitioner and social worker, etc. for follow-up and support for 
the patient and his/her family. 
 
Progressive functional decline (physical and mental) and dependence in 
most activities of daily living. 
Severe heart failure symptoms with poor quality of life despite optimal 
pharmacological and non-pharmacological therapies. 
Frequent  admissions  to  hospital  or  other  serious  episodes  of 
decompensation despite optimal treatment. 
Heart transplantation and mechanical circulatory support ruled out. 
Cardiac cachexia. 
Clinically judged to be close to end of life. 
 
Focus on improving or maintaining the quality of life of a patient and his/ 
her family as well as possible until he/she dies. 
Frequent assessment of symptoms (including dyspnoea and pain) 
resulting from advanced heart failure and other co-morbidities and focus 
on symptom relief. 
Access for the patient and his/her family to psychological support and 
spiritual care according to need. 
Advanced care planning, taking account of preferences for place of 
death and resuscitation (which may include deactivating devices, such as 
 
 
TEHAF.644 It is clear that there is not just one type of telemedicine, 
and each approach needs to be assessed on its individual merit. 
Recently, two individual approaches were shown to be successful 
in improving clinical outcome when used in patients with HFpEF or 
HFrEF. These approaches include the CardioMems system (tested 
in 550 patients with both HFrEF and HFpEF)628 and the IN-TIME 
approach (tested in 664 HFrEF patients)630, which may be considered 
for use in selected patients with HF (see the recommendations table). 
 
14.6 The older adult, frailty and cognitive 
impairment 
HF management and self-care behaviour are complicated by ageing, 
co-morbid conditions, cognitive impairment, frailty and limited so- 
cial support. HF is also a leading cause of hospital admission in the 
older adult, where it is associated with increased hospital length of 
stay and risk of mortality.645 
Frailty is common in older adults with HF, with a recent study sug- 
gesting it may be present in .70% of patients with HF and .80 
years of age.645 Frailty scoring systems provide an objective assess- 
ment and identify the presence of or change in the level of frailty. 
Patients with a high frailty score will benefit from closer contact 
with the HF specialist team, more frequent follow-up and monitor- 
ing and individualized self-care support. 
Frailty scores include646 walking speed (gait speed test), timed 
up-and-go test, PRISMA 7 questionnaire, Frail Score,647 Fried 
Score647,648 and Short Physical Performance Battery (SPPB). 
Cognitive impairment and HF frequently coexist. Acute delirium 
is also associated with decompensated HF and may be present on 
hospital admission. Cognitive function can be assessed using the 
Mini-Mental State Examination649 or the Montreal cognitive assess- 
ment.650 The presence of delirium and HF is found more commonly 
in older adults and is associated with increased mortality and poorer 
self-care ability and increases any hospital length of stay.651 There is 
currently no clinical evidence that HF medication worsens or im- 
proves cognitive function. However, its effect on HF outcome 
suggests such medication should be used. Support from a multidis- 
ciplinary HF team in collaboration with specialist dementia support 
teams, alongside medication compliance aids, tailored self-care 
advice and involvement of family and caregivers, may improve 
adherence with complex HF medication and self-care regimens 
(see Table 14.2 on patient education) (Table 14.3). 
 
14.7 Palliative and end-of-life 
care 
Palliative care approaches include a focus on symptom management, 
emotional support and communication between the patient and his/ 
her family. Ideally this should be introduced early in the disease trajec- 
tory and increased as the disease progresses. A decision to alter the 
focus of care from modifying disease progression to optimising quality 
of life should be made in discussion with the patient, cardiologist, 
nurse and general practitioner. The patient’s family should be involved 
in such discussions if requested by the patient652,653 (Table 14.4). 
Key components of a palliative care service are recommended in 
Table 14.5. Palliative care has been discussed in detail in a position 
paper from the ESC HFA.654 
Liaison between the specialist palliative care services and the HF 
team and/or the primary care physician, using a shared care 
 
Table 14.3   Specific recommendations regarding 
monitoring and follow-up of the older adult with heart 
failure 
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approach, is required in order to address and optimally coordinate 
the patient’s care. Recent pilot studies have suggested an improve- 
ment in symptom burden and quality of life,653,655 but these data are 
too limited to provide a recommendation. 
Specific therapies and actions may provide palliation of symptoms 
and improve quality of life but have a limited evidence base: 
 
• Morphine (with an antiemetic when high doses are needed) can 
be used to reduce breathlessness, pain and anxiety.656 
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• Increasing the inspired oxygen concentration may provide relief 
of dyspnoea. 
• Diuretic management can be used to relieve severe congestion 
or optimize symptom control (congestion and thirst). 
• Reduce HF drugs that reduce blood pressure to maintain suffi- 
cient oxygenation and reduce the risk of falls. 
 
Ideally these therapies should be delivered in the patient’s home. In the 
majority of cases the whole family should receive social support.652 
A management plan should be developed through discussion with 
the patient and family. It should include 
 
• A discussion about stopping medication that does not have an im- 
mediate effect on symptom management or health-related quality 
of life, such as agents to lower cholesterol or treat osteoporosis 
• Documentation of the patient’s decision regarding resuscitation 
attempts 
• Deactivation of an ICD at end-of-life (according to local legal 
regulations) 
• Preferred place for care and death 
• Emotional support to the patient and family/caregiver with ap- 
propriate referral for psychological or spiritual support 
 
Clearly, symptoms and quality of life change over time and regular 
reassessment is recommended. Palliative scores provide an object- 
ive assessment of the patient’s symptoms and needs and may help 
establish the effectiveness of therapy. 
Palliative outcome scores include the Palliative Care Outcome 
Scale,657 Karnofsky Performance Status658 and Functional Assess- 
ment of Chronic Illness Therapy – Palliative Care (FACIT-Pal).659 
 
 
 
15. Gaps in evidence 
 
Clinicians responsible for managing patients with HF must frequently 
make treatment decisions without adequate evidence or a consensus 
of expert opinion. The following is a short list of selected, common 
issues that deserve to be addressed in future clinical research. 
 
1. Definition, diagnosis, epidemiology 
 
• For HFmrEF/HFpEF, research into the underlying characteris- 
tics, pathophysiology and diagnosis (with new modalities) 
• Updated epidemiology on HF incidence and prevalence includ- 
ing patients from all continents 
• For imaging and biomarkers, studies on effects of specific im- 
aging modalities and biomarkers to improve clinical outcome 
(e.g. biomarker-guided therapies, detection of CAD/myocardial 
ischaemia, late-gadolinium enhancement CMR, echocardio- 
graphic strain measurements, stress echocardiography, etc.) 
• Increasing awareness of HF in the medical community, lay pub- 
lic and among policy makers. 
 
2. Strategies aimed at prevention and screening of HF 
 
• Evaluate the comparative clinical effectiveness and cost- 
effectiveness of different strategies to screen for HF. 
 
3. Pharmacological therapy 
 
• Identification of non-responders to current guideline-advised 
medical treatment 
• Targeted therapies for specific aetiologies of HFrEF (e.g. myo- 
carditis, peripartum cardiomyopathy) 
• Therapies directly improving cardiomyocyte function (e.g. 
acto-myosin cross-bridge activation, sarco/endoplasmic re- 
ticulum Ca2+-ATPase activation, ryanodine receptor stabiliza- 
tion, energetic  modulation) or targeting non-myocytic 
compartment (e.g. anti-fibrosis/matrix remodelling) 
• Therapies for HFmrEF/HFpEF (ARNIs, beta-blockers, soluble 
guanyl cyclase inhibitors, i.v. iron) 
 
4. Devices and interventions 
 
• Indications  for  ICDs in specific  subgroups (e.g.  ARVC and 
HFmrEF/HFpEF) and optimal selection of ICD candidates 
• QRS morphology or duration as a predictor of response to CRT 
• CRT in patients with AF 
• Efficacy of PV ablation as a rhythm-control strategy in patients 
with AF 
• Interventional approach to recurrent, life-threatening ven- 
tricular tachyarrhythmias 
• The role of remote monitoring strategies in HF 
• Non-surgical (percutaneous) correction of functional mitral 
and tricuspid regurgitations 
• Identification of indications for coronary angiography/revascu- 
larization in patients with HF and chronic stable CAD 
• Effects of novel LVADs as destination therapy and bridge to 
transplantation 
 
5. Co-morbidities 
 
• A better understanding of pathophysiology and potential 
treatments in specific HF populations, including the 
• very elderly, 
• young patients, 
• eGFR ,30 mL/min, 
• diabetic patients, 
• cardiotoxic chemotherapy-induced HF, 
• muscular dystrophies, 
• cachexia and depression. 
• Therapies for HF-related sleep-disordered breathing in HFrEF/ 
HFpEF/HFmrEF. 
 
6. Acute heart failure 
 
• Prospective evaluation of the ‘time-to-treatment’ concept in AHF 
• Evaluation of whether inadequate phenotyping is responsible 
for the failure of treatments to improve outcome in AHF 
• Better definition and treatment of diuretic resistance 
• Role of nitrates in the management of AHF 
• Treatments improving mortality and morbidity 
• Strategies and therapies to prevent early rehospitalization after 
discharge for a hospital admission for AHF. 
 
7. Other/remaining aspects 
 
• Treatment algorithms for patients with HF excluded by pivotal 
clinical trials 
• Palliative and end-of-life care management and assessment of 
outcome 
• Optimal integration of multidisciplinary care, self-management 
of patients and their adherence. 
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Recommendations for cardiac imaging in patients with suspected or established heart failure Class a Level b 
TTE is recommended for the assessment of myocardial structure and function in subjects with suspected HF in order to establish a 
diagnosis of either HFrEF, HFmrEF or HFpEF. 
 
I 
 
C 
TTE is recommended for the assessment of LVEF in order to identify patients with HF who would be suitable for evidence-based 
pharmacological and device (ICD, CRT) treatment recommended for HFrEF. 
 
I 
 
C 
Recommendations aiming to prevent or delay the development of overt heart failure or prevent death 
before the onset of symptoms 
Class a Level b 
Treatment of hypertension is recommended to prevent or delay the onset of HF and prolong life. I A 
ACE-I is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction in order to 
prevent or delay the onset of HF and prolong life. 
 
I 
 
A 
Beta-blocker is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction, in order 
to prevent or delay the onset of HF and prolong life. 
 
I 
 
B 
Pharmacological treatments indicated in patients with symptomatic heart failure with reduced ejection 
fraction 
Class a Level b 
An ACE-Ic is recommended, in addition to a beta-blocker, for symptomatic patients with HFrEF to reduce the risk of HF 
hospitalization and death. 
 
I 
 
A 
A beta-blocker is recommended, in addition to an ACE-Ic, for patients with stable, symptomatic HFrEF to reduce the risk of HF 
hospitalization and death. 
 
I 
 
A 
An MRA is recommended for patients with HFrEF, who remain symptomatic despite treatment with an ACE-Ic and a beta-blocker, to 
reduce the risk of HF hospitalization and death. 
 
I 
 
A 
Other pharmacological treatments recommended in selected patients with symptomatic heart failure with 
reduced ejection fraction 
Class a Level b 
Diuretics are recommended in order to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion. I B 
Sacubitril/valsartan is recommended as a replacement for an ACE-I to further reduce the risk of HF hospitalization and death in 
ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE-I, a beta-blocker and an MRA. 
 
I 
 
B 
Treatments (or combinations of treatments) that may cause harm in patients with symptomatic (New York 
Heart Association Class II–IV) heart failure with reduced ejection fraction 
Class a Level b 
Diltiazem or verapamil are not recommended in patients with HFrEF, as they increase the risk of HF worsening and HF hospitalization. III C 
The addition of an ARB (or a renin inhibitor) to the combination of an ACE-I and an MRA is not recommended in patients with HF, 
because of the increased risk of renal dysfunction and hyperkalaemia. 
 
III 
 
C 
 Class a Level b 
Secondary prevention 
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular 
arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status. 
 
I 
 
A 
Primary prevention 
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA Class II–
III), and an LVEF ≤35% despite ≥3 months of OMT, provided they are expected to survive substantially longer than 1 year with good 
functional status, and they have: 
• IHD (unless they have had an MI in the prior 40 days) 
• DCM 
 
 
 
 
I 
I 
 
 
 
 
A 
B 
ICD implantation is not recommended within 40 days of an MI as implantation at this time does not improve prognosis. III A 
Recommendations for cardiac resynchronization therapy  implantation in patients with heart failure Class a Level b 
CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration ≥150 msec and LBBB QRS morphology and 
with LVEF ≤35% despite OMT in order to improve symptoms and reduce morbidity and mortality. 
 
I 
 
A 
CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration of 130–149 msec and LBBB QRS 
morphology and with LVEF ≤35% despite OMT in order to improve symptoms and reduce morbidity and mortality. 
 
I 
 
B 
CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA Class who have an indication for ventricular  I 
 
A 
CRT is contra-indicated in patients with a QRS duration <130 msec III A 
 
 
16. To do and not to do messages from the Guidelines 
 
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   continued 
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To do and not to do messages from the Guidelines (continued) 
 
Not-recommended treatments of co-morbidities in patients with heart failure Class a Level b 
Adaptive servo-ventilation is not recommended in patients with HFrEF and a predominant central sleep apnoea because of an 
increased all-cause and cardiovascular mortality. 
 
III 
 
B 
Thiazolidinediones (glitazones) are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization. III A 
NSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization. III B 
Recommendations regarding diagnostic measurements in patients with suspected acute heart failure Class a Level b 
Upon presentation a measurement of plasma natriuretic peptide level (BNP, NT-proBNP or MR-proANP) is recommended in all 
patients with acute dyspnoea and suspected AHF to help in the differentiation of AHF from non-cardiac causes of acute dyspnoea. 
 
I 
 
A 
Recommendations for the management of patients with acute heart failure – pharmacotherapy Class a Level b 
 
symptoms. It is recommended to regularly monitor symptoms, urine output, renal function and electrolytes during use of i.v. diuretics. 
 
I 
 
C 
In patients with new-onset AHF or those with chronic, decompensated HF not receiving oral diuretics the initial recommended dose 
should be 20–40 mg i.v. furosemide (or equivalent); for those on chronic diuretic therapy, initial i.v. dose should be at least equivalent to 
oral dose. 
 
I 
 
B 
It is recommended to give diuretics either as intermittent boluses or a continuous infusion, and the dose and duration should be 
adjusted according to the patients’ symptoms and clinical status. 
 
I 
 
B 
Inotropic agents are not recommended unless the patient is symptomatically hypotensive or hypoperfused because of safety concern. III A 
Recommendations regarding management of patients with cardiogenic shock Class a Level b 
In all patients with suspected cardiogenic shock, immediate ECG and echocardiography are recommended. I C 
All patients with cardiogenic shock should be rapidly transferred to a tertiary care centre which has a 24/7 service of cardiac 
catheterization, and a dedicated ICU/CCU with availability of short-term mechanical circulatory support. 
 
I 
 
C 
Recommendations regarding oral evidence-based disease-modifying therapies in patients with acute heart failure Class a Level b 
In case of worsening of chronic HFrEF, every attempt should be made to continue evidence-based, disease-modifying therapies, in the 
absence of haemodynamic instability or contra-indications. 
 
I 
 
C 
Recommendations for exercise, multidisciplinary management, and monitoring of patients with heart failure Class a Level b 
It is recommended that regular aerobic exercise is encouraged in patients with HF to improve functional capacity and symptoms. I A 
It is recommended that regular aerobic exercise is encouraged in stable patients with HFrEF to reduce the risk of HF hospitalization. I A 
It is recommended that patients with HF are enrolled in a multidisciplinary care management programme to reduce the risk of HF 
hospitalization and mortality. 
 
I 
 
A 
 
ACE-I ¼ angiotensin-converting enzyme inhibitor; AHF ¼ acute heart failure;; ARB ¼ angiotensin receptor blocker; AST ¼ aspartate aminotransferase; AV ¼ atrio-ventricular; 
BNP ¼ B-type natriuretic peptide; CCU ¼ coronary care unit; COX-2 ¼ cyclooxygenase 2; CRT ¼ cardiac resynchronization therapy; CT ¼ computed tomography; DCM ¼ 
dilated cardiomyopathy; ECG ¼ electrocardiogram; HF ¼ heart failure; HFmrEF ¼ heart failure with mid-range ejection fraction; HFpEF ¼ heart failure with preserved ejection 
fraction; HFrEF ¼ heart failure with reduced ejection fraction; ICD ¼ implantable cardioverter-defibrillator; ICU ¼ intensive care unit; i.v. ¼ intravenous; LBBB ¼ left bundle 
branch block; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; MRA ¼ mineralocorticoid receptor antagonist; MR-proANP ¼ mid- 
regional pro A-type natriuretic peptide; NSAIDs ¼ non-steroidal anti-inflammatory drugs; NT-proBNP ¼ N-terminal pro-B type natriuretic peptide; NYHA ¼ New York Heart 
Association; OMT ¼ optimal medical therapy; QRS ¼ Q, R, and S waves (combination of three of the graphical deflections); RV ¼ right ventricular; TTE ¼ transthoracic 
echocardiography. 
aClass of recommendation. 
bLevel of evidence 
cOr ARB if ACEI is not tolerated/contra-indicated. 
 
 
 
 
 
 
17. Web Addenda 
 
All Web figures and Web tables are available in the Web addenda, available at European Heart Journal online and also via the ESC website. 
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18. Appendix 
 
ESC Committee for Practice Guidelines (CPG): Jose Luis Za- 
morano (Chairperson) (Spain), Victor Aboyans (France), Stephan 
Achenbach (Germany), Stefan Agewall (Norway), Lina Badimon 
(Spain), Gonzalo Baro´ n-Esquivias (Spain), Helmut Baumgartner 
(Germany), Jeroen J. Bax (The Netherlands), He´ctor Bueno (Spain), 
Scipione Carerj (Italy), Veronica Dean (France), Çetin Erol (Turkey), 
Donna Fitzsimons (UK), Oliver Gaemperli (Switzerland), Paulus 
Kirchhof (UK/Germany), Philippe Kolh (Belgium), Patrizio Lancellot- 
ti (Belgium), Gregory Y. H. Lip (UK), Petros Nihoyannopoulos (UK), 
Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marco Roffi 
(Switzerland), Adam Torbicki (Poland), Anto´ nio Vaz Carneiro (Por- 
tugal), Stephan Windecker (Switzerland). 
ESC National Cardiac Societies actively involved in  the  re- 
view process of the 2016 ESC Guidelines for the diagnosis and treat- 
ment of acute and chronic heart failure 
Armenia:   Armenian   Cardiologists   Association,   Hamayak 
S. Sisakian; Azerbaijan: Azerbaijan Society of Cardiology, Elnur 
Isayev; Belarus: Belorussian Scientific Society of Cardiologists, Ale- 
na Kurlianskaya; Belgium: Belgian Society of Cardiology, Wilfried 
Mullens; Bulgaria: Bulgarian Society of Cardiology, Mariya Tokma- 
kova; Cyprus: Cyprus Society of Cardiology, Petros Agathangelou; 
Czech Republic: Czech Society of Cardiology, Vojtech Melenovs- 
ky; Denmark: Danish Society of Cardiology, Henrik Wiggers; 
Egypt: Egyptian Society of Cardiology, Mahmoud Hassanein; Es- 
tonia: Estonian Society of Cardiology, Tiina Uuetoa; Finland: Finn- 
ish Cardiac Society, Jyri Lommi; Former Yugoslav Republic of 
Macedonia: Macedonian FYR Society of Cardiology, Elizabeta Srbi- 
novska Kostovska; France: French Society of Cardiology, Yves Juil- 
lie` re;  Georgia:  Georgian  Society  of  Cardiology,  Alexander 
Aladashvili; Germany: German Cardiac Society, Andreas Luchner; 
Greece: Hellenic Cardiological Society, Christina Chrysohoou; 
Hungary: Hungarian Society of Cardiology, Noe´mi Nyolczas; Ice- 
land: Icelandic Society of Cardiology, Gestur Thorgeirsson; Israel: 
Israel Heart Society, Jean Marc Weinstein; Italy: Italian Federation 
of Cardiology, Andrea Di Lenarda; Kazakhstan: Association of 
Cardiologists of Kazakhstan, Nazipa Aidargaliyeva; Kosovo: Kosovo 
Society of Cardiology, Gani Bajraktari; Kyrgyzstan: Kyrgyz Society 
of Cardiology, Medet Beishenkulov; Latvia: Latvian Society of Car- 
diology, Ginta Kamzola; Lebanon: Lebanese Society of Cardiology, 
Tony Abdel-Massih; Lithuania: Lithuanian Society of Cardiology, 
Jelena Cˇ elutkiene˙; Luxembourg: Luxembourg Society of Cardi- 
ology, Ste´phanie Noppe; Malta: Maltese Cardiac Society, Andrew 
Cassar; Moldova: Moldavian Society of Cardiology, Eleonora Vata- 
man; Morocco: Moroccan Society of Cardiology, Saadia Abir- 
Khalil; The Netherlands: Netherlands Society of Cardiology, Pet- 
ra van Pol; Norway: Norwegian Society of Cardiology, Rune Mo; 
Poland: Polish Cardiac Society, Ewa Straburzyn´ska-Migaj; Portu- 
gal: Portuguese Society of Cardiology, Caˆndida Fonseca; Romania: 
Romanian Society of Cardiology, Ovidiu Chioncel; Russian Feder- 
ation: Russian Society of Cardiology, Evgeny Shlyakhto; San Mar- 
ino: San Marino Society of Cardiology, Marco Zavatta; Serbia: 
Cardiology Society of Serbia, Petar Otasevic; Slovakia: Slovak So- 
ciety of Cardiology, Eva Goncalvesova´; Slovenia: Slovenian Society 
of Cardiology, Mitja Lainscak; Spain: Spanish Society of Cardiology, 
Beatriz Dı´az Molina; Sweden: Swedish Society of Cardiology, Maria 
Schaufelberger; Switzerland: Swiss Society of Cardiology, Thomas 
Suter; Turkey: Turkish Society of Cardiology, Mehmet Birhan 
Yılmaz; Ukraine: Ukrainian Association of Cardiology, Leonid Vor- 
onkov; United Kingdom: British Cardiovascular Society, Ceri 
Davies. 
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